Document:

Indenture

 Exhibit 4.1 
 SALIX PHARMACEUTICALS, LTD. 
 as Issuer 
 AND 
 U.S. BANK NATIONAL ASSOCIATION 
 as Trustee 
 INDENTURE 
 Dated as of August 22, 2008 
 5.5%
Convertible Senior Notes due 2028 

 TABLE OF CONTENTS 
  

					
	 ARTICLE I
 DEFINITIONS

	 	  	Page
			
	Section 1.01.	  	Definitions	  	1
	
	 ARTICLE II
 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES

			
	Section 2.01.	  	Designation and Amount	  	19
			
	Section 2.02.	  	Form of Notes	  	19
			
	Section 2.03.	  	Date and Denomination of Notes; Payments of Interest	  	20
			
	Section 2.04.	  	[Reserved]	  	21
			
	Section 2.05.	  	Execution, Authentication and Delivery of Notes	  	21
			
	Section 2.06.	  	Exchange and Registration of Transfer of Notes; Restrictions on Transfer; Depositary	  	22
			
	Section 2.07.	  	Mutilated, Destroyed, Lost or Stolen Notes	  	28
			
	Section 2.08.	  	Temporary Notes	  	29
			
	Section 2.09.	  	Cancellation of Notes Paid, Etc.	  	30
			
	Section 2.10.	  	CUSIP Numbers	  	30
			
	Section 2.11.	  	Additional Notes; Repurchases	  	30
	
	 ARTICLE III
 REDEMPTION

			
	Section 3.01.	  	Company’s Right to Redeem; Notices to Trustee	  	31
			
	Section 3.02.	  	Selection of Notes to Be Redeemed	  	31
			
	Section 3.03.	  	Notice of Redemption	  	32
			
	Section 3.04.	  	Effect of Notice of Redemption	  	33
			
	Section 3.05.	  	Notes Redeemed in Part	  	33
	
	 ARTICLE IV
 SATISFACTION AND DISCHARGE

			
	Section 4.01.	  	Satisfaction and Discharge	  	34
	
	 ARTICLE V
 PARTICULAR COVENANTS OF THE COMPANY

			
	Section 5.01.	  	Payment of Principal, Interest and Additional Interest	  	34
			
	Section 5.02.	  	Maintenance of Office or Agency	  	34
			
	Section 5.03.	  	Appointments to Fill Vacancies in Trustee’s Office	  	35
			
	Section 5.04.	  	Provisions as to Paying Agent	  	35

  

 i 

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	Page
	Section 5.05.	  	Existence	  	37
			
	Section 5.06.	  	Rule 144A Information Requirement and Annual Reports	  	37
			
	Section 5.07.	  	Stay, Extension and Usury Laws	  	38
			
	Section 5.08.	  	Compliance Certificate; Statements as to Defaults	  	38
			
	Section 5.09.	  	Limitation on Incurrence of Additional Debt	  	38
			
	Section 5.10.	  	Further Instruments and Acts	  	39
	
	 ARTICLE VI
 LISTS OF NOTEHOLDERS AND REPORTS BY THE COMPANY AND THE TRUSTEE

			
	Section 6.01.	  	Lists of Noteholders	  	39
			
	Section 6.02.	  	Preservation and Disclosure of Lists	  	39
			
	Section 6.03.	  	Reports by Trustee	  	40
	
	 ARTICLE VII
 DEFAULTS AND REMEDIES

			
	Section 7.01.	  	Events of Default	  	40
			
	Section 7.02.	  	Acceleration	  	42
			
	Section 7.03.	  	Additional Interest	  	43
			
	Section 7.04.	  	Payments of Notes on Default; Suit Therefor	  	43
			
	Section 7.05.	  	Application of Monies Collected by Trustee	  	45
			
	Section 7.06.	  	Proceedings by Noteholders	  	46
			
	Section 7.07.	  	Proceedings by Trustee	  	46
			
	Section 7.08.	  	Remedies Cumulative and Continuing	  	47
			
	Section 7.09.	  	Direction of Proceedings and Waiver of Defaults by Majority of Noteholders	  	47
			
	Section 7.10.	  	Notice of Defaults	  	48
			
	Section 7.11.	  	Undertaking to Pay Costs	  	48
	
	 ARTICLE VIII
 CONCERNING THE TRUSTEE

			
	Section 8.01.	  	Duties and Responsibilities of Trustee	  	48
			
	Section 8.02.	  	Reliance on Documents, Opinions, Etc.	  	50
			
	Section 8.03.	  	No Responsibility for Recitals, Etc.	  	51
			
	Section 8.04.	  	Trustee, Paying Agents, Conversion Agents or Registrar May Own Notes	  	51

  

 ii 

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	Page
			
	Section 8.05.	  	Monies to Be Held in Trust	  	51
			
	Section 8.06.	  	Compensation and Expenses of Trustee	  	51
			
	Section 8.07.	  	Officers’ Certificate as Evidence	  	52
			
	Section 8.08.	  	Conflicting Interests of Trustee	  	52
			
	Section 8.09.	  	Eligibility of Trustee	  	53
			
	Section 8.10.	  	Resignation or Removal of Trustee	  	53
			
	Section 8.11.	  	Acceptance by Successor Trustee	  	54
			
	Section 8.12.	  	Succession by Merger, Etc.	  	55
			
	Section 8.13.	  	Limitation on Rights of Trustee as Creditor	  	55
			
	Section 8.14.	  	Trustee’s Application for Instructions from the Company	  	55
	
	 ARTICLE IX
 CONCERNING THE NOTEHOLDERS

			
	Section 9.01.	  	Action by Noteholders	  	56
			
	Section 9.02.	  	Proof of Execution by Noteholders	  	56
			
	Section 9.03.	  	Who Are Deemed Absolute Owners	  	56
			
	Section 9.04.	  	Company-Owned Notes Disregarded	  	57
			
	Section 9.05.	  	Revocation of Consents; Future Noteholders Bound	  	57
	
	 ARTICLE X
 NOTEHOLDERS’ MEETINGS

			
	Section 10.01.	  	Purpose of Meetings	  	57
			
	Section 10.02.	  	Call of Meetings by Trustee	  	58
			
	Section 10.03.	  	Call of Meetings by Company or Noteholders	  	58
			
	Section 10.04.	  	Qualifications for Voting	  	58
			
	Section 10.05.	  	Regulations	  	58
			
	Section 10.06.	  	Voting	  	59
			
	Section 10.07.	  	No Delay of Rights by Meeting	  	59
	
	 ARTICLE XI
 SUPPLEMENTAL INDENTURES

			
	Section 11.01.	  	Supplemental Indentures Without Consent of Noteholders	  	60
			
	Section 11.02.	  	Supplemental Indentures With Consent of Noteholders	  	60
			
	Section 11.03.	  	Effect of Supplemental Indentures	  	62

  

 iii 

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	Page
	Section 11.04.	  	Notation on Notes	  	62
			
	Section 11.05.	  	Evidence of Compliance of Supplemental Indenture to Be Furnished to Trustee	  	62
	
	 ARTICLE XII
 CONSOLIDATION, MERGER, SALE, CONVEYANCE AND LEASE

			
	Section 12.01.	  	Company May Consolidate, Etc. on Certain Terms	  	62
			
	Section 12.02.	  	Successor Corporation to Be Substituted	  	63
			
	Section 12.03.	  	Opinion of Counsel to Be Given to Trustee	  	64
	
	 ARTICLE XIII
 IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS

			
	Section 13.01.	  	Indenture and Notes Solely Corporate Obligations	  	64
	
	 ARTICLE XIV
 [INTENTIONALLY OMITTED]

	
	 ARTICLE XV
 CONVERSION OF NOTES

			
	Section 15.01.	  	Conversion Privilege	  	65
			
	Section 15.02.	  	Conversion Procedure	  	67
			
	Section 15.03.	  	Increased Conversion Rate Applicable to Certain Notes Surrendered in Connection with Make-Whole Fundamental Changes	  	71
			
	Section 15.04.	  	Adjustment of Conversion Rate	  	73
			
	Section 15.05.	  	Shares to Be Fully Paid	  	84
			
	Section 15.06.	  	Effect of Reclassification, Consolidation, Merger or Sale	  	84
			
	Section 15.07.	  	Certain Covenants	  	87
			
	Section 15.08.	  	Responsibility of Trustee	  	87
			
	Section 15.09.	  	Notice to Noteholders Prior to Certain Actions	  	88
			
	Section 15.10.	  	Stockholder Rights Plans	  	89
			
	Section 15.11.	  	Exchange in Lieu of Conversion	  	89
	
	 ARTICLE XVI
 REPURCHASE OF NOTES AT OPTION OF HOLDERS

			
	Section 16.01.	  	Repurchase of Notes by the Company at Option of the Holder	  	90
			
	Section 16.02.	  	Withdrawal of Repurchase Notice	  	93
			
	Section 16.03.	  	Deposit of Repurchase Price	  	93

  

 iv 

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	Page
	Section 16.04.	  	Repurchase at Option of Noteholders upon a Fundamental Change	  	94
			
	Section 16.05.	  	Withdrawal of Fundamental Change Repurchase Notice	  	97
			
	Section 16.06.	  	Deposit of Fundamental Change Repurchase Price	  	97
	
	 ARTICLE XVII
 MISCELLANEOUS PROVISIONS

			
	Section 17.01.	  	Provisions Binding on Company’s Successors	  	98
			
	Section 17.02.	  	Official Acts by Successor Corporation	  	98
			
	Section 17.03.	  	Addresses for Notices, Etc.	  	98
			
	Section 17.04.	  	Governing Law	  	99
			
	Section 17.05.	  	Evidence of Compliance with Conditions Precedent; Certificates and Opinions of Counsel to Trustee	  	99
			
	Section 17.06.	  	Legal Holidays	  	100
			
	Section 17.07.	  	No Security Interest Created	  	100
			
	Section 17.08.	  	Benefits of Indenture	  	100
			
	Section 17.09.	  	Table of Contents, Headings, Etc.	  	100
			
	Section 17.10.	  	Authenticating Agent	  	100
			
	Section 17.11.	  	Execution in Counterparts	  	101
			
	Section 17.12.	  	Severability	  	101
			
	Section 17.13.	  	Waiver of Jury Trial	  	101
			
	Section 17.14.	  	Force Majeure	  	102
			
	Section 17.15.	  	Calculations in Respect of the Notes	  	102

  

 v 

 EXHIBITS 
  

					
	Exhibit A	  	Form of Note	  	A-1
			
	Exhibit B	  	Form of Notice of Conversion	  	B-1
			
	Exhibit C	  	Form of Repurchase Notice	  	C-1
			
	Exhibit D	  	Form of Fundamental Change Repurchase Notice	  	D-1
			
	Exhibit E	  	Form of Assignment and Transfer	  	E-1
			
	Exhibit F	  	Form of Certificate of Free Transferability	  	F-1

  

 vi 

 INDENTURE dated as of August 22, 2008 between Salix Pharmaceuticals, Ltd., a Delaware corporation,
as issuer (the “Company”) and U.S. Bank National Association, as trustee (the “Trustee”). 
 W I T N ES S E T H :

 WHEREAS, for its lawful corporate purposes, the Company has duly authorized the issue of its 5.5% Convertible Senior Notes due 2028
(hereinafter sometimes called the “Notes”), initially in an aggregate principal amount not to exceed $60,000,000, and in order to provide the terms and conditions upon which the Notes are to be authenticated, issued and delivered, the
Company has duly authorized the execution and delivery of this Indenture; 
 WHEREAS, the Form of Note, the certificate of authentication to
be borne by each Note, the Form of Notice of Conversion, the Form of Repurchase Notice, the Form of Fundamental Change Repurchase Notice, the Form of Assignment and Transfer and the Form of Certificate of Free Transferability to be borne by the
Notes are to be substantially in the forms hereinafter provided for; and 
 WHEREAS, all acts and things necessary to make the Notes, when
executed by the Company and authenticated and delivered by the Trustee or a duly authorized authenticating agent, the valid, binding and legal obligations of the Company, and to constitute a valid agreement according to its terms, have been done and
performed, and the execution of this Indenture and the issue hereunder of the Notes have in all respects been duly authorized. 
 NOW,
THEREFORE, THIS INDENTURE WITNESSETH: 
 That in order to declare the terms and conditions upon which the Notes are, and are to be,
authenticated, issued and delivered, and in consideration of the premises and of the purchase and acceptance of the Notes by the holders thereof, the Company covenants and agrees with the Trustee for the equal and proportionate benefit of the
respective holders from time to time of the Notes (except as otherwise provided below), as follows: 
 ARTICLE I 
 DEFINITIONS 
 SECTION 1.01.
Definitions. The terms defined in this Section 1.01 (except as herein otherwise expressly provided) for all purposes of this Indenture and of any indenture supplemental hereto shall have the respective meanings specified in this
Section 1.01. All other terms used in this Indenture that are defined in the Trust Indenture Act or that are by reference therein defined in the Securities Act (except as herein otherwise expressly provided) shall have the meanings assigned to
such terms in said Trust Indenture Act and in said Securities Act as in force at the date of the execution of this Indenture. The words “herein,” “hereof,” “hereunder,” and words of similar import refer to this
Indenture as a whole and not to any particular Article, Section or other subdivision. The terms defined in this Article include the plural as well as the singular. 
 “Additional Interest” means all amounts, if any, payable pursuant to Sections 5.06(d), 5.06(e) and 7.03, as applicable, hereof. 

 “Affiliate” of any specified Person means any other Person directly or indirectly
controlling or controlled by or under direct or indirect common control with such specified Person. For the purposes of this definition, “control,” when used with respect to any specified Person means the power to direct or cause the
direction of the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; and the terms “controlling” and “controlled” have meanings correlative
to the foregoing. 
 “Attributable Indebtedness” means, for purposes of Section 5.09, on any date, (a) in respect
of any capital lease of any Person, the capitalized amount thereof that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP, and (b) in respect of any Synthetic Lease Obligation, the capitalized
amount of the remaining lease payments under the relevant lease that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP if such lease were accounted for as a capital lease. 
 “Bankruptcy Law” means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors. 
 “Board of Directors” means the board of directors of the Company or a committee of such board duly authorized to act for it hereunder.

 “Board Resolution” means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to
have been duly adopted by the Board of Directors, and to be in full force and effect on the date of such certification, and delivered to the Trustee. 
 “Business Day” means each Monday, Tuesday, Wednesday, Thursday and Friday that is not a day on which the banking institutions in The City of New York are authorized or obligated by law or executive
order to close or be closed. 
 “Capital Stock” means, for any entity, any and all shares, interests, rights to purchase,
warrants, options, participations or other equivalents of or interests in (however designated) stock issued by that entity. 
 “Cash
Settlement Averaging Period” means, with respect to any Note surrendered for conversion, the forty consecutive Trading Day period beginning on, and including, the third Trading Day immediately following the Conversion Date for such Note;
provided that, the “Cash Settlement Averaging Period” means (1) with respect to any Conversion Date occurring during the period beginning on, and including, March 15, 2028 and ending at the close of business on the
Business Day immediately prior to the Maturity Date, the forty consecutive Trading Day period beginning on, and including, the forty-second Scheduled Trading Day prior to the Maturity Date; and (2) with respect to any Conversion Date for Notes
called for redemption, the forty consecutive Trading Day period beginning on, and including, the forty-second Scheduled Trading Day prior to the Redemption Date. 
 “Certificate of Free Transferability” means a certificate in substantially the form set forth as Exhibit F hereto. 
 “close of business” means 5:00 p.m. (New York City time). 
  

 2 

 “Commission” means the Securities and Exchange Commission. 
 “Common Equity” of any Person means Capital Stock of such Person that is generally entitled (a) to vote in the election of
directors of such Person or (b) if such Person is not a corporation, to vote or otherwise participate in the selection of the governing body, partners, managers or others that will control the management or policies of such Person. 

“Common Stock” means, subject to Section 15.06, shares of common stock of the Company, par value $0.001 per share, at the date
of this Indenture or shares of any class or classes resulting from any reclassification or reclassifications thereof and that have no preference in respect of dividends or of amounts payable in the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Company and that are not subject to redemption by the Company; provided that if at any time there shall be more than one such resulting class, the shares of each such class then so issuable shall be
substantially in the proportion that the total number of shares of such class resulting from all such reclassifications bears to the total number of shares of all such classes resulting from all such reclassifications. 
 “Company” means Salix Pharmaceuticals, Ltd., a Delaware corporation, and subject to the provisions of Article 12, shall include its
successors and assigns. 
 “Company Order” means a written request or order signed in the name of the Company (i) by
its Chairman, its President, Chief Executive Officer or a Vice President and (ii) by its Chief Financial Officer, its Treasurer or an Assistant Treasurer, its Associate Vice President, Finance, its Secretary or an Assistant Secretary and
delivered to the Trustee; provided, however, that such written request or order may be signed by any two of the officers or directors listed in clause (i) above in lieu of being signed by one of such officers or directors listed
in such clause (i) and one of the officers listed in clause (ii) above. 
 “Consolidated EBITDA” means, for
purposes of Section 5.09, for any period, for the Company’s and its Subsidiaries on a consolidated basis, an amount equal to Consolidated Net Income for such period plus: 
 (a) the following to the extent deducted in calculating such Consolidated Net Income: 
 (i) Consolidated Interest Charges for such period; 
 (ii) the provision for Federal, state, local and foreign income taxes payable by the Company and its Subsidiaries for such period;

 (iii) depreciation and amortization expense; 
 (iv) non-cash expenses and amortization related to the granting of stock options and restricted stock grants to employees and directors of
the Company and its Subsidiaries in the ordinary course of business under the Company’s compensation and incentive plans; and 
  

 3 

 (v) other non-recurring expenses of the Company and its Subsidiaries reducing such
Consolidated Net Income which do not represent a cash item in such period or any future period; and minus  
 (b) the following to the
extent included in calculating such Consolidated Net Income: 
 (i) Federal, state, local and foreign income tax credits of
the Company and its Subsidiaries for such period; and 
 (ii) all non-cash items increasing Consolidated Net Income for such
period. 
 In addition, Consolidated EBITDA shall be adjusted on a pro forma basis, as of the first day of any applicable period, for any acquisitions and
Dispositions of assets, including, without limitation, adjustments reflecting any non-recurring costs and any extraordinary expenses of any such acquisitions and asset dispositions consummated during such period calculated consistent with GAAP and
Regulation S-X promulgated under the Exchange Act. 
 “Consolidated Fixed Charge Coverage Ratio” means, for purposes of
Section 5.09, as of any date of determination, the ratio of (a) Consolidated EBITDA minus capital expenditures to (b) Consolidated Fixed Charges, in each case, for the four consecutive fiscal quarters most recently ended. 

“Consolidated Fixed Charges” means, for purposes of Section 5.09, for any period, the sum of the following determined on a
consolidated basis, for the Company and its Subsidiaries in accordance with GAAP: 
  

	 	(a)	Consolidated Interest Charges for such period; 

  

	 	(b)	cash taxes paid during such period; 

  

	 	(c)	the amount of scheduled and mandatory principal payments with respect to Indebtedness for such period; and 

  

	 	(d)	cash dividends and distributions made with respect to the Company’s Equity Interest during such period. 

 “Consolidated Funded Indebtedness” means, for purposes of Section 5.09, as of any date of determination, for the Company and its
Subsidiaries on a consolidated basis, the sum of: 
  

	 	(a)	the outstanding principal amount of all obligations, whether current or long-term, for borrowed money and all obligations evidenced by bonds, debentures, notes, loan agreements or
other similar instruments; 

  

	 	(b)	all purchase money Indebtedness; 

  

 4 

	 	(c)	all direct obligations arising under letters of credit (including standby and commercial), bankers’ acceptances, bank guaranties, surety bonds and similar instruments;

  

	 	(d)	all obligations in respect of the deferred purchase price of property or services (other than trade accounts payable in the ordinary course of business); 

 

	 	(e)	Attributable Indebtedness in respect of capital leases and Synthetic Lease Obligations; 

  

	 	(f)	to the extent not included in clauses (a) through (e) above, all Permitted Debt; 

  

	 	(g)	without duplication, all Guarantees with respect to outstanding Indebtedness of the types specified in clauses (a) through (f) above of persons other than the Company or
any of its Subsidiaries; and 

  

	 	(h)	all Indebtedness of the types referred to in clauses (a) through (g) above of any partnership or joint venture (other than a joint venture that is itself a corporation or
limited liability company) in which the Company or any of its Subsidiaries is a general partner or joint venturer, unless such Indebtedness is expressly made non-recourse to the Company or such Subsidiary; 

 provided, however, that Consolidated Funded Indebtedness shall not include any Indebtedness of the types referred to in clauses (a) through
(h) above that is Subordinated Indebtedness. 
 “Consolidated Interest Charges” means, for purposes of
Section 5.09, for any period, for the Company and its Subsidiaries on a consolidated basis, the sum of (a) all interest, premium payments, debt discount, fees, charges and related expenses of the Company and its Subsidiaries in connection
with borrowed money (including capitalized interest) or in connection with the deferred purchase price of assets, in each case to the extent treated as interest in accordance with GAAP, and (b) the portion of rent expense of the Company and its
Subsidiaries with respect to such period under capital leases that is treated as interest in accordance with GAAP. 
 “Consolidated
Leverage Ratio” means, for purposes of Section 5.09, as of any date of determination, the ratio of: (a) Consolidated Funded Indebtedness as of such date to (b) Consolidated EBITDA for the period of the four consecutive fiscal
quarters most recently ended. 
 “Consolidated Net Income” means, for purposes of Section 5.09, for any period,
for the Company and its Subsidiaries on a consolidated basis, the net income of the Company and its Subsidiaries from continuing operations (excluding extraordinary gains or extraordinary losses) for that period. 
 “Continuing Director” means a director who either was a member of the Board of Directors on August 22, 2008 or who becomes a member
of the Board of Directors subsequent to that date and whose election, appointment or nomination for election by the stockholders of the Company is duly approved by a majority of the Continuing Directors on the Board of Directors at the time of such
approval, either by a specific vote or by approval of the proxy statement issued by the Company on behalf of the entire Board of Directors in which such individual is named as nominee for director. 
  

 5 

 “Conversion Agent” shall have the meaning specified in Section 5.02. 
 “Conversion Date” shall have the meaning specified in Section 15.02(e). 
 “Conversion Obligation” shall have the meaning specified in Section 15.01(a). 
 “Conversion Price” means as of any date, $1,000, divided by the Conversion Rate as of such date. 
 “Conversion Rate” shall have the meaning specified in Section 15.01(a). 
 “Conversion Trigger Price” shall have the meaning specified in Section 15.01(b)(iv). 
 “Corporate Trust Office” means the office of the Trustee at which at any time its corporate trust business shall be administered, which
office at the dated hereof is located at Hearst Tower - 214 N. Tryon Street, 27th Floor, Charlotte, NC 28202, Attention: Corporate Trust Department, or such other address as the Trustee may designate from time to time by notice to the Noteholders
and the Company, or the principal corporate trust office of any successor Trustee (or such other address as such successor Trustee may designate from time to time by notice to the Noteholders and the Company). 
 “Credit Facility” means the Company’s Credit Agreement, originally dated as of February 22, 2007, by and among the
Company, Bank of America, N.A. and the other parties thereto, and as further amended by the first amendment thereto, dated as of August 4, 2008, and by the second amendment thereto, dated as of August 22, 2008. 
 “Custodian” means the Trustee, as custodian for The Depositary, with respect to the Global Notes, or any successor entity thereto.

 “Daily Conversion Value” means, for each of the forty consecutive Trading Days during the Cash Settlement Averaging
Period, one-fortieth (1/40th) of the product of (a) the then-applicable Conversion Rate on such Trading Day and (b) the Daily VWAP of the Common Stock on such Trading Day. 
 “Daily Measurement Value” is equal to the Specified Dollar Amount, divided by forty. 
 “Daily Settlement Amount” for each of the forty consecutive Trading Days during the Cash Settlement Averaging Period, shall consist of:

  

	 	(a)	cash equal to the lesser of the Daily Measurement Value and the Daily Conversion Value for such Trading Day; and 

  

 6 

	 	(b)	to the extent the Daily Conversion Value for such Trading Day exceeds the Daily Measurement Value, a number of shares of Common Stock equal to the Daily Share Amount.

 “Daily Share Amount” means, to the extent the Daily Conversion Value exceeds the Daily Measurement Value,
(i) the difference between the Daily Conversion Value and the Daily Measurement Value, divided by (ii) the Daily VWAP of the Common Stock for such Trading Day. 
 “Daily VWAP” for the Common Stock, in respect of any Trading Day, means the per share volume-weighted average price on the Nasdaq Global Select Market as displayed under the heading “Bloomberg
VWAP” on Bloomberg page “SLXP.Q <equity> AQR” (or its equivalent successor if such page is not available) in respect of the period from the scheduled opening of trading until the scheduled close of trading of the primary trading
session on such Trading Day (or if such volume-weighted average price is unavailable, the market value of one share of the Common Stock on such Trading Day as determined by the Board of Directors in a commercially reasonable manner, using a
volume-weighted average price method) and will be determined without regard to after-hours trading or any other trading outside of the regular trading session. 
 “Default” means any event that is, or after notice or passage of time, or both, would be, an Event of Default. 
 “Defaulted Interest” means any interest on any Note that is payable, but is not punctually paid or duly provided for, on any February 15 or August 15 of each year, beginning
February 15, 2009. 
 “Depositary” means, with respect to the Global Notes, the Person specified in Section 2.06
as the Depositary with respect to such Notes, until a successor shall have been appointed and become such pursuant to the applicable provisions of this Indenture, and thereafter, “Depositary” shall mean or include such successor.

 “Designated Institution” shall have the meaning specified in Section 15.11. 
 “Disposition” means, for purposes of Section 5.09, the sale, transfer, license, lease or other disposition (including any sale and
leaseback transaction) of any property by any Person, including any sale, assignment, transfer or other disposal, with or without recourse, of any notes or accounts receivable or any rights and claims associated therewith. 
 “Distributed Property” shall have the meaning specified in Section 15.04(c). 
 “Effective Date” shall have the meaning specified in Section 15.03(a). 
 “Equity Interests” means, for purposes of Section 5.09, with respect to any Person, all of the shares of capital stock of (or other
ownership or profit interests in) such Person, all of the warrants, options or other rights for the purchase or acquisition from such Person of shares of capital stock of (or other ownership or profit interests in) such Person, all of the securities
convertible into or exchangeable for shares of capital stock of (or other ownership or 

  

 7 

 
profit interests in) such Person or warrants, rights or options for the purchase or acquisition from such Person of such shares (or such other interests),
and all of the other ownership or profit interests in such Person (including partnership, member or trust interests therein), whether voting or nonvoting, and whether or not such shares, warrants, options, rights or other interests are outstanding
on any date of determination. 
 “Event of Default” shall have the meaning specified in Section 7.01. 
 “Ex-Dividend Date” means, with respect to any issuance, dividend or distribution in which the holders of Common Stock (or other
security) have the right to receive any cash, securities or other property, the first date on which the shares of the Common Stock (or other security) trade on the applicable exchange or in the applicable market, regular way, without the right to
receive the issuance, dividend or distribution in question. 
 “Exchange Act” means the Securities Exchange Act of 1934, as
amended, and the rules and regulations promulgated thereunder. 
 “Expiration Date” shall have the meaning specified in
Section 15.04(e). 
 “Expiration Time” shall have the meaning specified in Section 15.04(e). 
 “Fiscal Quarter” means a fiscal quarter of any Fiscal Year. 
 “Fiscal Year” means a fiscal year of the Company. 
 “Fundamental Change” means the occurrence after the original issuance of the Notes of any of the following events: 
  

	 	(a)	any “person” or “group” (within the meaning of Section 13(d) of the Exchange Act) other than the Company or its Subsidiaries files a Schedule TO or any
schedule, form or report under the Exchange Act disclosing that such person or group has become the direct or indirect ultimate “beneficial owner,” as defined in Rule 13d-3 under the Exchange Act, of the Company’s Common Equity
representing more than 50% of the voting power of the Company’s Common Equity; 

  

	 	(b)	consummation of any binding share exchange, exchange offer, tender offer, consolidation or merger of the Company pursuant to which the Common Stock will be converted into cash,
securities or other property or any sale, lease or other transfer in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its Subsidiaries, taken as a whole, to any Person other than
one or more of the Company’s Subsidiaries (any such exchange, offer, consolidation, merger, transaction or series of transactions being referred to herein as an “event”); provided, however, that any such event where the
holders of more than 50% of shares of Common Stock immediately prior to such event, own, directly or indirectly, more than 50% of all classes of Common Equity of the continuing or surviving person or transferee or the parent thereof immediately
after such event shall not be a Fundamental Change; 

  

 8 

	 	(c)	the first day on which Continuing Directors cease to constitute at least a majority of the Board of Directors; 

  

	 	(d)	the stockholders of the Company approve any plan or proposal for the liquidation or dissolution of the Company; or 

  

	 	(e)	the Common Stock (or other common stock into which the Notes are then convertible) ceases to be listed on at least one U. S. national securities exchange, 

provided, however, in the case of an event described in clause (a) or (b) above, if at least 90% of the consideration, excluding cash payments
for fractional shares, in the event constituting the Fundamental Change consists of shares of Publicly Traded Securities, and as a result of the event, the Notes become convertible into such Publicly Traded Securities, excluding cash payments for
fractional shares (subject to the provisions of Section 15.02(b)), such event shall not be a Fundamental Change. 
 For purposes of this
definition, whether a “person” is a “beneficial owner” shall be determined in accordance with Rule 13d-3 under the Exchange Act and “person” includes any syndicate or group that would be deemed to be a
“person” under Section 13(d)(3) of the Exchange Act. 
 “Fundamental Change Company Notice” shall have the
meaning specified in Section 16.04(b). 
 “Fundamental Change Expiration Time” shall have the meaning specified in
Section 16.04(b)(ix). 
 “Fundamental Change Repurchase Date” shall have the meaning specified in
Section 16.04(a). 
 “Fundamental Change Repurchase Notice” shall have the meaning specified in
Section 16.04(a)(i). 
 “Fundamental Change Repurchase Price” shall have the meaning specified in
Section 16.04(a). 
 “GAAP” means, for purposes of Section 5.09, generally accepted accounting principles in the
United States set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or such other
principles as may be approved by a significant segment of the accounting profession in the United States, that are applicable to the circumstances as of the date of determination, consistently applied. 
 “Guarantee” means, for purposes of Section 5.09, as to any Person, 
  

 9 

	 	(a)	any obligation, contingent or otherwise, of such Person guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation payable or performable by
another Person (the “primary obligor”) in any manner, whether directly or indirectly, and including any obligation of such Person, direct or indirect, 

  

	 	(i)	to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation, 

  

	 	(ii)	to purchase or lease property, securities or services for the purpose of assuring the obligee in respect of such Indebtedness or other obligation of the payment or performance of
such Indebtedness or other obligation, 

  

	 	(iii)	to maintain working capital, equity capital or any other financial statement condition or liquidity or level of income or cash flow of the primary obligor so as to enable the
primary obligor to pay such Indebtedness or other obligation, or 

  

	 	(iv)	entered into for the purpose of assuring in any other manner the obligee in respect of such Indebtedness or other obligation of the payment or performance thereof or to protect such
obligee against loss in respect thereof (in whole or in part), or 

  

	 	(b)	any Lien on any assets of such Person securing any Indebtedness or other obligation of any other Person, whether or not such Indebtedness or other obligation is assumed by such
Person (or any right, contingent or otherwise, of any holder of such Indebtedness to obtain any such Lien). 

 The amount of
any Guarantee shall be deemed to be an amount equal to the stated or determinable amount of the related primary obligation, or portion thereof, in respect of which such Guarantee is made or, if not stated or determinable, the maximum reasonably
anticipated liability in respect thereof as determined by the guaranteeing Person in good faith. The term “Guarantee” as a verb has a corresponding meaning. 
 “Global Note” shall have the meaning specified in Section 2.06(b). 
 “Indebtedness” means, for purposes of Section 5.09, as to any Person at a particular time, without duplication, all of the following, whether or not included as indebtedness or liabilities in accordance with GAAP:

  

	 	(a)	all obligations of such Person for borrowed money and all obligations of such Person evidenced by bonds, debentures, notes, loan agreements or other similar instruments;

  

	 	(b)	all direct or contingent obligations of such Person arising under letters of credit (including standby and commercial), bankers’ acceptances, bank guaranties, surety bonds and
similar instruments; 

  

 10 

	 	(c)	net obligations of such Person under any Swap Contract; 

  

	 	(d)	all obligations of such Person to pay the deferred purchase price of property or services (other than trade accounts payable in the ordinary course of business and, in each case,
not past due for more than sixty (60) days after the date on which such trade account payable was created); 

  

	 	(e)	indebtedness (excluding prepaid interest thereon) secured by a Lien on property owned or being purchased by such Person (including indebtedness arising under conditional sales or
other title retention agreements), whether or not such indebtedness shall have been assumed by such Person or is limited in recourse; 

  

	 	(f)	all Attributable Indebtedness in respect of capital leases and Synthetic Lease Obligations; 

  

	 	(g)	all obligations of such Person to purchase, redeem, retire, defease or otherwise make any payment in respect of any Equity Interest in such Person or any other Person, valued, in
the case of a redeemable preferred interest, at the greater of its voluntary or involuntary liquidation preference plus accrued and unpaid dividends; and 

  

	 	(h)	all Guarantees of such Person in respect of any of the foregoing. 

 For all purposes hereof, the Indebtedness of any Person shall include the Indebtedness of any partnership or joint venture (other than a joint venture that is itself a corporation or limited liability company) in which such Person is a
general partner or a joint venturer, unless such Indebtedness is expressly made non-recourse to such Person. The amount of any net obligation under any Swap Contract on any date shall be deemed to be the Swap Termination Value thereof as of such
date. The amount of any capital lease or Synthetic Lease Obligation as of any date shall be deemed to be the amount of Attributable Indebtedness in respect thereof as of such date. 
 “Indenture” means this instrument as originally executed or, if amended or supplemented as herein provided, as so amended or
supplemented. 
 “Initial Purchasers” means Banc of America Securities LLC and Roth Capital Partners, LLC. 
 “Interest Payment Date” means each February 15 and August 15 of each year, beginning on February 15, 2009;
provided, however, that if any Interest Payment Date falls on a date that is not a Business Day, such payment of interest (or principal in the case of the Maturity Date) will be postponed until the next succeeding Business Day, and no
interest or other amount will be paid as a result of such postponement. 
 “Interest Record Date,” with respect to any
Interest Payment Date, shall mean the February 1 or August 1 (whether or not such day is a Business Day) immediately preceding the relevant Interest Payment Date, respectively. 
  

 11 

 “Last Reported Sale Price” of the Common Stock on any date means the closing sale price
per share (or if no closing sale price is reported, the average of the bid and ask prices or, if more than one in either case, the average of the average bid and the average ask prices) on that date as reported in composite transactions for the
principal U.S. national or regional securities exchange on which the Common Stock is listed for trading. The Last Reported Sale Price will be determined without reference to after-hours or extended market trading. If the Common Stock is not listed
for trading on a U.S. national securities exchange on the relevant date, then the “Last Reported Sale Price” of the Common Stock will be the last quoted bid price for the Common Stock in the over-the-counter market on the relevant date as
reported by the Pink OTC Markets Inc. or similar organization. If the Common Stock is not so quoted, the “Last Reported Sale Price” of the Common Stock will be determined by a U.S. nationally recognized independent investment banking firm
selected by the Company for this purpose. 
 “Lien” means, for purposes of Section 5.09, any mortgage, pledge,
hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or other), charge, or preference, priority or other security interest or preferential arrangement in the nature of a security interest of any kind or nature whatsoever
(including any conditional sale or other title retention agreement, any easement, right of way or other encumbrance on title to real property, and any financing lease having substantially the same economic effect as any of the foregoing).

 “Make-Whole Conversion Rate Adjustment” shall have the meaning specified in Section 15.03(a). 
 “Make-Whole Fundamental Change” means any transaction or event that constitutes a Fundamental Change under clause (a) or
(b) of the definition thereof (in the case of any Fundamental Change described in clause (b) of the definition thereof, determined without regard to the proviso in such clause (b), but subject to the paragraph immediately following clause
(e) of the definition thereof). For the avoidance of doubt, a transaction or event does not constitute a Fundamental Change if at least 90% of the consideration, excluding cash payments for fractional shares, in the event constituting the
Fundamental Change consists of shares of Publicly Traded Securities, and as a result of the event, the Notes become convertible into such Publicly Traded Securities, excluding cash payments for fractional shares (subject to the provisions of
Section 15.02(b)). 
 “Make-Whole Fundamental Change Period” shall have the meaning specified in Section 15.03(a).

 “Market Disruption Event” means (a) a failure by the primary exchange or quotation system on which the Common Stock
trades or is quoted, as the case may be, to open for trading during its regular trading session or (b) the occurrence or existence, prior to 1:00 p.m., New York City time, on any Trading Day for the Common Stock, of an aggregate one-half hour
period, of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the stock exchange or otherwise) in the Common Stock or in any options contracts or futures contracts relating to the Common
Stock. 
 “Maturity Date” means August 15, 2028. 
  

 12 

 “Measurement Period” shall have the meaning specified in Section 15.01(b)(i).

 “Merger Event” shall have the meaning specified in Section 15.06. 
 “Note” or “Notes” shall mean any note or notes, as the case may be, authenticated and delivered under this Indenture.

 “Noteholder” or “holder,” as applied to any Note, or other similar terms (but excluding the term
“beneficial holder”), shall mean any person in whose name at the time a particular Note is registered on the Note Register. 
 “Note Register” shall have the meaning specified in Section 2.06(a). 
 “Note Registrar”
shall have the meaning specified in Section 2.06(a). 
 “Notice of Conversion” shall have the meaning specified in
Section 15.02(d). 
 “Offering Memorandum” means the final offering memorandum dated August 18, 2008 relating to
the offering and sale of the Notes. 
 “Officer” means, with respect to the Company, (i) the Chairman of the Board, the
Chief Executive Officer, the President, any Vice President or the Chief Financial Officer, and (ii) the Treasurer or any Assistant Treasurer, the Associate Vice President, Finance, or the Secretary or any Assistant Secretary. 
 “Officers’ Certificate” means a certificate signed by two officers of the Company, one of whom must be the principal executive
officer, the principal financial officer or the principal accounting officer of the Company. Each Officers’ Certificate (other than certificates provided pursuant to TIA Section 314(a)(4)) shall include the statements provided for in TIA
Section 314(e). 
 “open of business” or “opening of business” means 9:00 a.m. (New York City time).

 “Opinion of Counsel” means an opinion in writing signed by legal counsel, who may be an employee of or counsel to the
Company, or other counsel acceptable to the Trustee, that is delivered to the Trustee. Each such opinion shall include the statements provided for in Section 17.05 if and to the extent required by the provisions of such Section. 
 “outstanding,” when used with reference to Notes, shall, subject to the provisions of Section 9.04, mean, as of any particular
time, all Notes authenticated and delivered by the Trustee under this Indenture, except: 
 (a) Notes theretofore canceled by the Trustee or
accepted by the Trustee for cancellation; 
 (b) Notes that have been paid pursuant to Section 2.09 or Notes in lieu of which, or in
substitution for which, other Notes shall have been authenticated and delivered pursuant to the terms of Section 2.07 unless proof satisfactory to the Trustee is presented that any such Notes are held by protected purchasers in due course;

  

 13 

 (c) Notes that have become due and payable, whether at the Maturity Date, Repurchase Date, any
Fundamental Change Repurchase Date, upon conversion or otherwise, for which the Company has deposited with the Trustee or delivered to Noteholders, as applicable, cash or cash and shares of Common Stock, if any (solely to satisfy the Company’s
Conversion Obligation, if applicable), sufficient to pay all of the outstanding Notes and all other sums due payable under this Indenture by the Company; and 
 (d) Notes converted pursuant to Article 15. 
 “Paying Agent” shall have the meaning
specified in Section 5.02. 
 “Permitted Debt” means, for purposes of Section 5.09, without duplication, each of
the following: 
  

	 	(a)	Indebtedness in respect of the Notes; 

  

	 	(b)	Indebtedness in respect of any future unsecured convertible notes (regardless of the amount incurred thereunder) issued or Guaranteed by the Company or any of its Subsidiaries, if
and only if at the time any such Indebtedness is incurred neither the Company nor its Subsidiaries has any secured debt outstanding; 

  

	 	(c)	Indebtedness incurred by the Company or any of its Subsidiaries pursuant to the Credit Facility, both (i) as outstanding on the date hereof and (ii) any future draws on
the Credit Facility as it exists on the date hereof but excluding any existing amendments to Section 7.12 thereof; 

  

	 	(d)	Subordinated Indebtedness incurred by the Company or any of its Subsidiaries; 

  

	 	(e)	other Indebtedness of the Company and its Subsidiaries outstanding on the closing date other than the Indebtedness under the Credit Facility or otherwise specified under any of the
other clauses of this definition of Permitted Debt; 

  

	 	(f)	hedging obligations entered into in the ordinary course of business by the Company or its Subsidiaries and not for speculative purposes; 

  

	 	(g)	intercompany Indebtedness among the Company and any of its Subsidiaries; 

  

	 	(h)	Indebtedness of the Company or any of its Subsidiaries arising from the honoring by a bank or other financial institution of a check, draft or similar instrument inadvertently
(except in the case of daylight overdrafts) drawn against insufficient funds in the ordinary course of business; provided that such Indebtedness is extinguished within two Business Days of incurrence; 

  

 14 

	 	(i)	Indebtedness of the Company or any of its Subsidiaries represented by letters of credit for the account of the Company or any of its Subsidiaries in order to provide security for
workers’ compensation claims, payment obligations in connection with self-insurance or similar requirements in the ordinary course of business; 

  

	 	(j)	capital leases, Synthetic Lease Obligations and purchase money obligations for fixed or capital assets; provided that the aggregate amount of all such Indebtedness at any one
time outstanding shall not exceed $20,000,000; 

  

	 	(k)	Indebtedness arising from agreements of the Company or any of its Subsidiaries providing for the indemnification, adjustment of purchase price, earn-out or similar obligations, in
each case assumed with the acquisition or disposition of any business; and 

  

	 	(l)	additional Indebtedness of the Company or any of its Subsidiaries in an aggregate principal amount not to exceed $5 million at any one time outstanding. 

 “Person” means an individual, a corporation, a limited liability company, an association, a partnership, a joint venture, a joint stock
company, a trust, an unincorporated organization or a government or an agency or a political subdivision thereof. 
 “PORTAL
Market” means the PORTAL Market operated by The Nasdaq Stock Market, Inc. or any successor thereto. 
 “Predecessor Note” of any particular Note means every previous Note evidencing all or a portion of the same debt as that evidenced by such particular Note; and, for the purposes of this definition,
any Note authenticated and delivered under Section 2.07 in lieu of or in exchange for a mutilated, lost, destroyed or stolen Note shall be deemed to evidence the same debt as the mutilated, lost, destroyed or stolen Note that it replaces.

 “Publicly Traded Securities” means shares of common stock that are traded on a U.S. national securities exchange or that
will be so traded when issued or exchanged in connection with a Fundamental Change described in clause (a) or (b) of the definition thereof. 
 “Purchase Agreement” means that certain Purchase Agreement, dated as of August 18, 2008, between the Company and Banc of America Securities LLC, as representative of the several Initial
Purchasers named therein. 
 “Record Date” shall have the meaning specified in Section 15.04(f). 
 “Redemption Date” means the date specified in a notice of redemption on which the Notes may be redeemed in accordance with the terms of
the Notes and the Indenture. 
 “Redemption Price” shall have the meaning specified in Section 3.01. 
 “Reference Property” shall have the meaning specified in Section 15.06. 
  

 15 

 “Refinance” means, for purposes of Section 5.09, in respect of any security or
Indebtedness, to refinance, extend, renew, refund, repay, prepay, redeem, defease or retire, or to issue a security or Indebtedness in exchange or replacement for, such security or Indebtedness in whole or in part. “Refinanced” and
“refinancing” shall have correlative meanings. 
 “Repurchase Company Notice” shall have the meaning specified in
Section 16.01(a). 
 “Repurchase Date” shall have the meaning specified in Section 16.01(a). 
 “Repurchase Expiration Time” shall have the meaning specified in Section 16.01(a)(vii). 
 “Repurchase Notice” shall have the meaning specified in Section 16.01(b). 
 “Repurchase Price” shall have the meaning specified in Section 16.01(a). 
 “Resale Restriction Termination Date” shall have the meaning specified in Section 2.06(d). 
 “Responsible Officer” means, when used with respect to the Trustee, any officer within the corporate trust department of the Trustee,
including any vice president, assistant vice president, assistant secretary, assistant treasurer, trust officer or any other officer of the Trustee, who shall have direct responsibility for the administration of this Indenture or to whom any
corporate trust matter is referred because of such person’s knowledge of and familiarity with the particular subject. 
 “Restricted Global Note” means a Global Note that is subject to restrictions set out in Section 2.06(d) (including the legend set forth in Section 2.06(d)). 
 “Restricted Securities” shall have the meaning specified in Section 2.06(d). 
 “Rule 144A” means Rule 144A as promulgated under the Securities Act. 
 “Scheduled Trading Day” means any day that is scheduled to be a Trading Day. 
 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. 
 “Settlement Amount” has the meaning specified in Section 15.02(b). 
 “Settlement Method” means, with respect to a conversion of Notes, the relative proportions of cash and/or shares of Common Stock with
which such conversion is settled under this Indenture, as elected (or deemed elected) by the Company. 
 “Settlement Notice”
has the meaning specified in Section 15.02(b)(iii). 
  

 16 

 “Significant Subsidiary” means, at any date of determination, any Subsidiary that would
constitute a “significant subsidiary” within the meaning of Article 1 of Regulation S-X promulgated under the Securities Act as in effect on August 22, 2008. 
 “Specified Dollar Amount” means an amount of cash per $1,000 principal amount of a converted Note specified by the Company in the
Settlement Notice related to such converted Note. 
 “Spin-Off” shall have the meaning specified in Section 15.04(c).

 “Stock Price” means (a) in the case of a Make-Whole Fundamental Change described in clause (b) of the
definition of Fundamental Change in which holders of Common Stock receive solely cash consideration in connection with such Make-Whole Fundamental Change, the amount of cash paid per share of the Common Stock and (b) in the case of all other
Make-Whole Fundamental Changes, the average of the Last Reported Sale Prices per share of Common Stock over the period of five consecutive Trading Days ending on, and including, the Trading Day immediately preceding the Effective Date of such
Make-Whole Fundamental Change. The Board of Directors will make appropriate adjustments, in its good faith determination, to account for any adjustment to the Conversion Rate that becomes effective, or any event requiring an adjustment to the
Conversion Rate where the Ex-Dividend Date of the event occurs, during such five consecutive Trading Day period. 
 “Subordinated
Indebtedness” means, for purposes of Section 5.09, 
  

	 	(a)	any Indebtedness of the Company that is by its terms expressly subordinated in right of payment to the Notes; and 

  

	 	(b)	any Indebtedness of any of the Company’s Subsidiaries that has Guaranteed any of the Company’s Indebtedness that is by its terms expressly subordinated in right of payment
to such Guarantee. 

 “Subsidiary” means, with respect to any Person, any corporation, association,
partnership or other business entity of which more than 50% of the total voting power of shares of Capital Stock or other interests (including partnership interests) entitled (without regard to the occurrence of any contingency) to vote in the
election of directors, managers, general partners or trustees thereof is at the time owned or controlled, directly or indirectly, by (i) such Person; (ii) such Person and one or more Subsidiaries of such Person; or (iii) one or more
Subsidiaries of such Person. 
 “Successor Company” shall have the meaning specified in Section 12.01(a). 

“Swap Contract” means, for purposes of Section 5.09, (a) any and all rate swap transactions, basis swaps, credit derivative
transactions, forward rate transactions, commodity swaps, commodity options, forward commodity contracts, equity or equity index swaps or options, bond or bond price or bond index swaps or options or forward bond or forward bond price or forward
bond index transactions, interest rate options, forward foreign exchange transactions, cap transactions, floor transactions, collar transactions, currency swap transactions, cross-currency rate swap transactions, currency options, spot contracts, or
any other similar 

  

 17 

 
transactions or any combination of any of the foregoing (including any options to enter into any of the foregoing), whether or not any such transaction is
governed by or subject to any master agreement, and (b) any and all transactions of any kind, and the related confirmations, which are subject to the terms and conditions of, or governed by, any form of master agreement published by the
International Swaps and Derivatives Association, Inc., any International Foreign Exchange Master Agreement, or any other master agreement (any such master agreement, together with any related schedules, a “Master Agreement”),
including any such obligations or liabilities under any Master Agreement. 
 “Swap Termination Value” means, for purposes of
Section 5.09, in respect of any one or more Swap Contracts, after taking into account the effect of any legally enforceable netting agreement relating to such Swap Contracts, (a) for any date on or after the date such Swap Contracts have
been closed out and termination value(s) determined in accordance therewith, such termination value(s), and (b) for any date prior to the date referenced in clause (a), the amount(s) determined as the mark-to-market value(s) for such Swap
Contracts, as determined based upon one or more mid-market or other readily available quotations provided by any recognized dealer in such Swap Contracts. 
 “Synthetic Lease Obligation” means, for purposes of Section 5.09, the monetary obligation of a Person under (a) a so-called synthetic, off-balance sheet or tax retention lease, or
(b) an agreement for the use or possession of property creating obligations that do not appear on the balance sheet of such Person but which, upon the insolvency or bankruptcy of such Person, would be characterized as the Indebtedness of such
Person (without regard to accounting treatment). 
 “Trading Day” means a day during which trading in the Common Stock
generally occurs on the primary exchange or quotation system on which Common Stock then trades or is quoted and there is no Market Disruption Event. If the Common Stock (or other security for which a Last Reported Sale Price or Daily VWAP must be
determined) is not so traded or quoted, “Trading Day” means “Business Day.” 
 “Trading Price” of the
Notes on any date of determination means the average of the bona fide secondary market bid quotations obtained by the Company for $5.0 million principal amount of Notes (expressed as a price per $1,000 principal amount) at approximately 3:30 p.m.,
New York City time, on such determination date from three independent U.S. nationally recognized securities dealers selected by the Company; provided that if three such bids cannot reasonably be obtained by the Company, but two such bids are
obtained, then the average of the two bids shall be used, and if only one such bid can reasonably be obtained by the Company, that one bid shall be used. If the Company cannot reasonably obtain at least one bid for $5.0 million principal amount of
Notes from a U.S. nationally recognized securities dealer, then the Trading Price per $1,000 principal amount of Notes will be deemed to be less than 98% of the product of the Last Reported Sale Price of the Common Stock and the applicable
Conversion Rate. 
 “transfer” shall have the meaning specified in Section 2.06(d). 
 “Trigger Event” shall have the meaning specified in Section 15.04(c). 
  

 18 

 “Trust Indenture Act” means the Trust Indenture Act of 1939, as amended, as it was in
force at the date of execution of this Indenture, except as provided in Section 11.03 and Section 15.06; provided, however, that in the event the Trust Indenture Act of 1939 is amended after the date hereof, the term
“Trust Indenture Act” shall mean, to the extent required by such amendment, the Trust Indenture Act of 1939, as so amended. 
 “Trustee” means the Person named as the “Trustee” in the first paragraph of this Indenture until a successor Trustee shall have become such pursuant to the applicable provisions of this Indenture, and thereafter
“Trustee” shall mean or include each Person who is then a Trustee hereunder. 
 “Unrestricted Global Note” means
an unrestricted Global Note that is not subject to the restrictions set out in Section 2.06(d) (and does not bear the legend set forth in Section 2.06(d)). 
 “Valuation Period” shall have the meaning specified in Section 15.04(c). 
 “Weighted Average Consideration” shall have the meaning specified in Section 15.06(c)(iv). 
 ARTICLE II

 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION 
 AND EXCHANGE OF NOTES 
 SECTION 2.01. Designation and Amount. The Notes shall be
designated as the “5.5% Convertible Senior Notes due 2028.” The aggregate principal amount of Notes that may be authenticated and delivered under this Indenture is initially limited to $60,000,000, subject to Section 2.11 and except
for Notes authenticated and delivered upon registration or transfer of, or in exchange for, or in lieu of other Notes pursuant to Section 2.06, Section 2.07, Section 2.08, Section 3.05, Section 11.04, Section 15.02,
Section 16.03 and Section 16.06 hereof. 
 SECTION 2.02. Form of Notes. The Notes and the Trustee’s certificate of
authentication to be borne by such Notes shall be substantially in the respective forms set forth in Exhibit A, which are incorporated in and made a part of this Indenture. 
 Any Global Note may be endorsed with or have incorporated in the text thereof such legends or recitals or changes not inconsistent with the provisions of
this Indenture as may be required by the Custodian, the Depositary, any regulatory body or by The Nasdaq Stock Market, Inc. in order for the Notes to be tradable in The PORTAL Market or as may be required for the Notes to be tradable on any other
market developed for trading of securities pursuant to Rule 144A or required to comply with any applicable law or any regulation thereunder or with the rules and regulations of any securities exchange or automated quotation system upon which the
Notes may be listed or traded or designated for issuance or to conform with any usage with respect thereto, or to indicate any special limitations or restrictions to which any particular Notes are subject. 
  

 19 

 Any of the Notes may have such letters, numbers or other marks of identification and such notations,
legends or endorsements as the Officers executing the same may approve (execution thereof to be conclusive evidence of such approval) and as are not inconsistent with the provisions of this Indenture, or as may be required to comply with any law or
with any rule or regulation made pursuant thereto or with any rule or regulation of any securities exchange or automated quotation system on which the Notes may be listed or designated for issuance, or to conform to usage or to indicate any special
limitations or restrictions to which any particular Notes are subject. 
 A Global Note shall represent such principal amount of the
outstanding Notes as shall be specified therein and shall provide that it shall represent the aggregate principal amount of outstanding Notes from time to time endorsed thereon and that the aggregate principal amount of outstanding Notes represented
thereby may from time to time be increased or reduced to reflect repurchases, conversions, transfers or exchanges permitted hereby. Any endorsement of a Global Note to reflect the amount of any increase or decrease in the amount of outstanding Notes
represented thereby shall be made by the Trustee or the Custodian, at the direction of the Trustee, in such manner and upon instructions given by the holder of such Notes in accordance with this Indenture. Payment of principal (including the
Redemption Price, Repurchase Price or Fundamental Change Repurchase Price, as applicable), accrued and unpaid interest, and Additional Interest, if any, on a Global Note shall be made to the holder of such Note on the date of payment, unless a
record date or other means of determining holders eligible to receive payment is provided for herein. 
 The terms and provisions contained
in the form of Note attached as Exhibit A hereto shall constitute, and are hereby expressly made, a part of this Indenture and, to the extent applicable, the Company and the Trustee, by their execution and delivery of this Indenture, expressly agree
to such terms and provisions and to be bound thereby. 
 SECTION 2.03. Date and Denomination of Notes; Payments of Interest. The
Notes shall be issuable in registered form without coupons in minimum denominations of $1,000 principal amount and in integral multiples of $1,000 in excess thereof. Each Note shall be dated the date of its authentication and shall bear interest
from the date specified on the face of the form of Note attached as Exhibit A hereto. Interest (including Additional Interest, if any) on the Notes shall be computed on the basis of a 360-day year comprised of twelve 30-day months. 
 The Person in whose name any Note (or its Predecessor Note) is registered on the Note Register at the close of business on any Interest Record Date with
respect to any Interest Payment Date shall be entitled to receive the interest payable on such Interest Payment Date. Interest (including Additional Interest, if any) shall be payable at the office or agency of the Company maintained by the Company
for such purposes in The Borough of Manhattan, City of New York, which shall initially be the office of the Paying Agent. The Company shall pay interest (including Additional Interest, if any) (a) on any Notes in certificated form by check
mailed to the address of the Person entitled thereto as it appears in the Note Register or (b) on any Global Note by wire transfer of immediately available funds to the account of the Depositary or its nominee. 
  

 20 

 Any Defaulted Interest shall forthwith cease to be payable to the Noteholder on the relevant Interest
Record Date by virtue of its having been such Noteholder, and such Defaulted Interest shall be paid by the Company, at its election in each case, as provided in clause (1) or (2) below: 
 (1) The Company may elect to make payment of any Defaulted Interest to the Persons in whose names the Notes (or their respective
Predecessor Notes) are registered at the close of business on a special record date for the payment of such Defaulted Interest, which shall be fixed in the following manner. The Company shall notify the Trustee in writing of the amount of Defaulted
Interest proposed to be paid on each Note and the date of the proposed payment (which shall be not less than twenty-five days after the receipt by the Trustee of such notice, unless the Trustee shall consent to an earlier date), and at the same time
the Company shall deposit with the Trustee an amount of money equal to the aggregate amount to be paid in respect of such Defaulted Interest or shall make arrangements satisfactory to the Trustee for such deposit on or prior to the date of the
proposed payment, such money when deposited to be held in trust for the benefit of the Persons entitled to such Defaulted Interest as in this clause provided. Thereupon the Company shall fix a special record date for the payment of such Defaulted
Interest which shall be not more than fifteen days and not less than ten days prior to the date of the proposed payment, and not less than ten days after the receipt by the Trustee of the notice of the proposed payment (unless the Trustee shall
consent to an earlier date). The Company shall promptly notify the Trustee of such special record date and the Trustee, in the name and at the expense of the Company, shall cause notice of the proposed payment of such Defaulted Interest and the
special record date therefor to be mailed, first-class postage prepaid, to each holder at its address as it appears in the Note Register, not less than seven days prior to such special record date. Notice of the proposed payment of such Defaulted
Interest and the special record date therefor having been so mailed, such Defaulted Interest shall be paid to the Persons in whose names the Notes (or their respective Predecessor Notes) are registered at the close of business on such special record
date and shall no longer be payable pursuant to the following clause (2) of this Section 2.03. 
 (2) The Company
may make payment of any Defaulted Interest in any other lawful manner not inconsistent with the requirements of any securities exchange or automated quotation system on which the Notes may be listed or designated for issuance, and upon such notice
as may be required by such exchange or automated quotation system. 
 SECTION 2.04. [Reserved] 
 SECTION 2.05. Execution, Authentication and Delivery of Notes. The Notes shall be signed in the name and on behalf of the Company by the
manual or facsimile signature of its Officers. 
 At any time and from time to time after the execution and delivery of this Indenture, the
Company may deliver Notes executed by the Company to the Trustee for authentication, together with a Company Order for the authentication and delivery of such Notes, which order shall set forth the number of separate Note certificates, the principal
amount of each 

  

 21 

 
of the Notes to be authenticated, the date on which the original issue of Notes is to be authenticated, the registered holders of the said Notes and delivery
instructions, and the Trustee in accordance with such Company Order shall authenticate and deliver such Notes, without any further action by the Company hereunder. 
 Only such Notes as shall bear thereon a certificate of authentication substantially in the form set forth on the form of Note attached as Exhibit A hereto, executed manually or by facsimile by an authorized officer of
the Trustee (or an authenticating agent appointed by the Trustee as provided by Section 17.10), shall be entitled to the benefits of this Indenture or be valid or obligatory for any purpose. Such certificate upon any Note executed by the
Company shall be conclusive evidence that the Note so authenticated has been duly authenticated and delivered hereunder and that the holder is entitled to the benefits of this Indenture. 
 In case any Officer who shall have signed any of the Notes shall cease to be such Officer before the Notes so signed shall have been authenticated and
delivered by the Trustee, or disposed of by the Company, such Notes nevertheless may be authenticated and delivered or disposed of as though the person who signed such Notes had not ceased to be such Officer; and any Note may be signed on behalf of
the Company by such persons as, at the actual date of the execution of such Note, shall be the proper Officers, although at the date of the execution of this Indenture any such person was not such an officer. 
 SECTION 2.06. Exchange and Registration of Transfer of Notes; Restrictions on Transfer; Depositary. 
 (a) The Company shall cause to be kept at the Corporate Trust Office a register (the register maintained in such office or in any other office or agency
of the Company designated pursuant to Section 5.02 being herein sometimes collectively referred to as the “Note Register”) in which, subject to such reasonable regulations as it may prescribe, the Company shall provide for the
registration of Notes and of transfers of Notes. Such register shall be in written form or in any form capable of being converted into written form within a reasonable period of time. The Trustee is hereby appointed “Note Registrar” for
the purpose of registering Notes and transfers of Notes as herein provided. The Company may appoint one or more co-registrars in accordance with Section 5.02. 
 Upon surrender for registration of transfer of any Note to the Note Registrar or any co-registrar, and satisfaction of the requirements for such transfer set forth in this Section 2.06, the Company shall execute,
and the Trustee shall authenticate and deliver, in the name of the designated transferee or transferees, one or more new Notes of any authorized denominations and of a like aggregate principal amount and bearing such restrictive legends as may be
required by this Indenture. 
 Notes may be exchanged for other Notes of any authorized denominations and of a like aggregate principal
amount, upon surrender of the Notes to be exchanged at any such office or agency maintained by the Company pursuant to Section 5.02. Whenever any Notes are so surrendered for exchange, the Company shall execute, and the Trustee shall
authenticate and deliver, the Notes that the holder making the exchange is entitled to receive, bearing registration numbers not contemporaneously outstanding. 
  

 22 

 All Notes presented or surrendered for registration of transfer or for exchange, repurchase or conversion
shall (if so required by the Company, the Trustee, the Note Registrar or any co-registrar) be duly endorsed, or be accompanied by a written instrument or instruments of transfer in form satisfactory to the Company and duly executed by the holder
thereof or its attorney-in-fact duly authorized in writing. 
 No service charge shall be charged to the Noteholder for any exchange or
registration of transfer of Notes, but the Company or the Trustee may require payment of a sum sufficient to cover any tax, assessments or other governmental charges that may be imposed in connection therewith as a result of the name of the holder
of the new Notes issued upon such exchange or registration of transfer of Notes being different from the name of the holder of the old Notes presented or surrendered for such exchange or registration of transfer. 
 None of the Company, the Trustee, the Note Registrar or any co-registrar shall be required to exchange or register a transfer of (i) any Notes
surrendered for conversion or, if a portion of any Note is surrendered for conversion, such portion thereof surrendered for conversion, (ii) any Note selected for redemption or, if a portion of any Note is selected for redemption, such portion
thereof selected for redemption or (iii) any Notes, or a portion of any Note, surrendered for repurchase (and not withdrawn) in accordance with Article 16 hereof. 
 All Notes issued upon any registration of transfer or exchange of Notes in accordance with this Indenture shall be the valid obligations of the Company, evidencing the same debt, and entitled to the same benefits
under this Indenture as the Notes surrendered upon such registration of transfer or exchange. 
 (b) So long as the Notes are eligible for
book-entry settlement with the Depositary, unless otherwise required by law, all Notes shall be represented by one or more Notes in global form (each, a “Global Note”) registered in the name of the Depositary or the nominee of the
Depositary. The transfer and exchange of beneficial interests in a Global Note that does not involve the issuance of a definitive Note shall be effected through the Depositary (but not the Trustee or the Custodian) in accordance with this Indenture
(including the restrictions on transfer set forth herein) and the procedures of the Depositary therefor. 
 (c) [Reserved] 
 (d) Every Note that bears or is required under this Section 2.06(d) to bear the legend set forth in this Section 2.06(d) (together with any
Common Stock issued upon conversion of the Notes and required to bear the legend set forth in Section 2.06(e), collectively, the “Restricted Securities”) shall be subject to the restrictions on transfer set forth in this
Section 2.06(d) (including the legend set forth below), unless such restrictions on transfer shall be eliminated or otherwise waived by written consent of the Company, and the holder of each such Restricted Security, by such holder’s
acceptance thereof, agrees to be bound by all such restrictions on transfer. As used in Section 2.06(d) and Section 2.06(e), the term “transfer” encompasses any sale, pledge, transfer or other disposition whatsoever of any
Restricted Security. 
  

 23 

 Until the date (the “Resale Restriction Termination Date”), which is the date
(1) that is at least one year after the last date of original issuance of the Notes (or such other date as permitted by Rule 144 under the Securities Act or any successor provision thereto), and (2) on which the Company instructs the
Trustee that the legend (as described below) on the Notes shall be deemed removed from the Notes in accordance with the procedures described herein, any certificate evidencing such Note (and all securities issued in exchange therefor or substitution
thereof, other than Common Stock, if any, issued upon conversion thereof which shall bear the legend set forth in Section 2.06(e), if applicable) shall bear a legend in substantially the following form (unless such Notes have been transferred
pursuant to a registration statement that has become or been declared effective under the Securities Act and that continues to be effective at the time of such transfer, pursuant to the exemption from registration provided by Rule 144 or any similar
provision then in force under the Securities Act, or unless otherwise agreed by the Company in writing, with notice thereof to the Trustee): 
 THIS SECURITY AND THE COMMON STOCK, IF ANY, ISSUABLE UPON CONVERSION OF THIS SECURITY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD, PLEDGED, OR
OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF OR OF A BENEFICIAL INTEREST HEREIN, THE ACQUIRER: 
 (1) REPRESENTS THAT IT, AND ANY ACCOUNT FOR WHICH IT IS ACTING, IS A “QUALIFIED INSTITUTIONAL BUYER” (WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT) AND THAT IT EXERCISES SOLE INVESTMENT DISCRETION WITH RESPECT TO EACH
SUCH ACCOUNT; AND 
 (2) AGREES FOR THE BENEFIT OF THE COMPANY THAT IT WILL NOT OFFER, SELL, PLEDGE, OR OTHERWISE TRANSFER THIS SECURITY OR
ANY BENEFICIAL INTEREST HEREIN PRIOR TO THE RESALE RESTRICTION TERMINATION DATE (AS DEFINED IN THE NEXT PARAGRAPH), EXCEPT: 
 (A) TO THE
COMPANY OR ANY SUBSIDIARY THEREOF; OR 
 (B) PURSUANT TO A REGISTRATION STATEMENT THAT HAS BECOME EFFECTIVE UNDER THE SECURITIES ACT; OR

 (C) TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT; OR 
 (D) PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT OR 

  

 24 

 
ANY OTHER AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. 
 THE RESALE RESTRICTION TERMINATION DATE WILL BE THE DATE (1) THAT IS AT LEAST ONE YEAR AFTER THE LAST ORIGINAL ISSUE DATE HEREOF; AND (2) ON
WHICH THE COMPANY INSTRUCTS THE TRUSTEE THAT THIS LEGEND SHALL BE DEEMED REMOVED FROM THIS SECURITY, IN ACCORDANCE WITH THE PROCEDURES DESCRIBED IN THE INDENTURE RELATING TO THIS SECURITY. 
 PRIOR TO THE REGISTRATION OF ANY TRANSFER IN ACCORDANCE WITH PARAGRAPH 2(D) ABOVE, THE COMPANY AND THE TRUSTEE RESERVE THE RIGHT TO REQUIRE THE DELIVERY
OF SUCH LEGAL OPINIONS, CERTIFICATIONS, OR OTHER EVIDENCE AS MAY REASONABLY BE REQUIRED IN ORDER TO DETERMINE THAT THE PROPOSED TRANSFER IS BEING MADE IN COMPLIANCE WITH THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. NO REPRESENTATION IS
MADE AS TO THE AVAILABILITY OF ANY EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. 
 No transfer of any Note prior to
the Resale Restriction Termination Date will be registered by the Note Registrar unless the applicable box on the completed Form of Assignment and Transfer has been checked. 
 Any Note (or security issued in exchange or substitution therefor) as to which such restrictions on transfer shall have expired in accordance with their
terms may, upon surrender of such Note for exchange to the Note Registrar in accordance with the provisions of this Section 2.06, be exchanged for a new Note or Notes, of like tenor and aggregate principal amount, which shall not bear the
restrictive legend required by this Section 2.06(d). The Company shall notify the Trustee (i) upon the occurrence of the Resale Restriction Termination Date by providing the Trustee with a Certificate of Free Transferability and
(ii) promptly after a registration statement with respect to the Notes or any Common Stock issued upon conversion of the Notes has been declared or become effective under the Securities Act. 
 Notwithstanding the foregoing, in lieu of the restrictive legend being deemed removed from the Notes and the unrestricted CUSIP specified therein being
substituted for the restricted CUSIP thereon, the Company may provide the Trustee with a new Global Note to serve as the Unrestricted Global Note and to bear such unrestricted CUSIP, and the Trustee shall continue to reflect such portion of the
Notes as the Company may direct on the Restricted Global Note. 
 Notwithstanding any other provisions of this Indenture (other than the
provisions set forth in this Section 2.06(d)), a Global Note may not be transferred as a whole or in part except by the Depositary to a nominee of the Depositary or by a nominee of the Depositary to the Depositary or another nominee of the
Depositary or by the Depositary or any such nominee to a successor Depositary or a nominee of such successor Depositary. 
  

 25 

 The Depositary shall be a clearing agency registered under the Exchange Act. The Company initially
appoints The Depository Trust Company to act as Depositary with respect to the Global Notes. Initially, the Global Notes shall be issued to the Depositary, registered in the name of Cede & Co., as the nominee of the Depositary, and
initially deposited with the Trustee as custodian for the Depositary. 
 If (i) the Depositary notifies the Company at any time that the
Depositary is unwilling or unable to continue as depositary for the Global Notes and a successor depositary is not appointed within 90 days, (ii) the Depositary ceases to be registered as a clearing agency under the Exchange Act and a successor
depositary is not appointed within 90 days or (iii) an Event of Default in respect of the Notes has occurred and is continuing, upon the request of the beneficial owner of the Notes, the Company will execute, and the Trustee, upon receipt of an
Officers’ Certificate and a Company Order for the authentication and delivery of Notes, will authenticate and deliver Notes in definitive form to each such beneficial owner of the related Notes (or a portion thereof) in an aggregate principal
amount equal to the principal amount of such Global Note, in exchange for such Global Note, and upon delivery of the Global Note to the Trustee, such Global Note shall be canceled. 
 Definitive Notes issued in exchange for all or a part of the Global Notes pursuant to this Section 2.06(d) shall be registered in such names and in
such authorized denominations as the Depositary, pursuant to instructions from its direct or indirect participants or otherwise, shall instruct the Trustee. Upon execution and authentication, the Trustee shall deliver such definitive Notes to the
Persons in whose names such definitive Notes are so registered. 
 At such time as all interests in a Global Note have been converted,
canceled, repurchased or transferred, such Global Note shall be, upon receipt thereof, canceled by the Trustee in accordance with its standing procedures. At any time prior to such cancellation, if any interest in a Global Note is exchanged for
definitive Notes, converted, canceled, redeemed, repurchased or transferred to a transferee who receives definitive Notes therefor or any definitive Note is exchanged or transferred for part of such Global Note, the principal amount of such Global
Note shall be appropriately reduced or increased, as the case may be, and an endorsement shall be made on such Global Note, by the Trustee or the Custodian, at the direction of the Trustee, to reflect such reduction or increase. 
 None of the Company, the Trustee nor any agent of the Company or the Trustee will have any responsibility or liability for any aspect of the records
relating to or payments made on account of beneficial ownership interests of a Global Note or maintaining, supervising or reviewing any records relating to such beneficial ownership interests. 
 (e) Until the Resale Restriction Termination Date, any stock certificate representing Common Stock issued upon conversion of such Note shall bear a
legend in substantially the following form (unless the Note or such Common Stock has been transferred pursuant to a registration statement that has become or been declared effective under the Securities Act and that continues to be effective at the
time of such transfer or pursuant to the 

  

 26 

 
exemption from registration provided by Rule 144 under the Securities Act or any similar provision then in force under the Securities Act, or such Common
Stock has been issued upon conversion of Notes that have been transferred pursuant to a registration statement that has become or been declared effective under the Securities Act and that continues to be effective at the time of such transfer or
pursuant to the exemption from registration provided by Rule 144 under the Securities Act, or unless otherwise agreed by the Company with written notice thereof to the Trustee and any transfer agent for the Common Stock): 
 THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD,
PLEDGED, OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF OR OF A BENEFICIAL INTEREST HEREIN, THE ACQUIRER: 
 (1) REPRESENTS THAT IT, AND ANY ACCOUNT FOR WHICH IT IS ACTING, IS A “QUALIFIED INSTITUTIONAL BUYER” (WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT) AND THAT IT EXERCISES SOLE INVESTMENT
DISCRETION WITH RESPECT TO EACH SUCH ACCOUNT; AND 
 (2) AGREES FOR THE BENEFIT OF THE COMPANY THAT IT WILL NOT OFFER, SELL, PLEDGE, OR
OTHERWISE TRANSFER THIS SECURITY OR ANY BENEFICIAL INTEREST HEREIN PRIOR TO THE RESALE RESTRICTION TERMINATION DATE (AS DEFINED IN THE NEXT PARAGRAPH), EXCEPT: 
 (A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF; OR 
 (B) PURSUANT TO A REGISTRATION STATEMENT THAT HAS BECOME
EFFECTIVE UNDER THE SECURITIES ACT; OR 
 (C) TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT; OR

 (D) PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT OR ANY OTHER AVAILABLE EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. 
 THE RESALE RESTRICTION TERMINATION DATE WILL BE THE DATE (1) THAT IS AT LEAST ONE
YEAR AFTER THE LAST ORIGINAL ISSUE DATE HEREOF; AND (2) ON WHICH THE COMPANY INSTRUCTS THE TRUSTEE THAT THIS LEGEND SHALL BE DEEMED REMOVED FROM THIS SECURITY, IN ACCORDANCE WITH THE PROCEDURES DESCRIBED IN THE INDENTURE RELATING TO THIS
SECURITY. 
 PRIOR TO THE REGISTRATION OF ANY TRANSFER IN ACCORDANCE WITH PARAGRAPH 2(D) ABOVE, THE COMPANY AND THE TRUSTEE RESERVE THE

  

 27 

 
RIGHT TO REQUIRE THE DELIVERY OF SUCH LEGAL OPINIONS, CERTIFICATIONS, OR OTHER EVIDENCE AS MAY REASONABLY BE REQUIRED IN ORDER TO DETERMINE THAT THE PROPOSED
TRANSFER IS BEING MADE IN COMPLIANCE WITH THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. NO REPRESENTATION IS MADE AS TO THE AVAILABILITY OF ANY EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. 
 Any such Common Stock as to which such restrictions on transfer shall have expired in accordance with their terms may, upon surrender of the certificates
representing such shares of Common Stock for exchange in accordance with the procedures of the transfer agent for the Common Stock, be exchanged for a new certificate or certificates for a like aggregate number of shares of Common Stock, which shall
not bear the restrictive legend required by this Section 2.06(e). 
 (f) Any Note or Common Stock issued upon the conversion or exchange
of a Note that is purchased or owned by the Company or any Affiliate thereof may not be resold by the Company or such Affiliate unless registered under the Securities Act or resold pursuant to an exemption from the registration requirements of the
Securities Act in a transaction that results in such Notes or Common Stock, as the case may be, no longer being “restricted securities” (as defined under Rule 144). During the period of one year after the last original issuance of the
Notes, the Company shall not, and shall not permit any of its “affiliates” (as defined under Rule 144) to, resell any of the Notes that have been reacquired by any of them. 
 (g) Notwithstanding any provision of this Section 2.06 to the contrary, in the event Rule 144 as promulgated under the Securities Act (or any
successor rule) is amended to change the one-year holding period thereunder (or the corresponding period under any successor rule), from and after receipt by the Trustee of the Officers’ Certificate and Opinion of Counsel provided for in this
Section 2.06(g), (i) each reference in Section 2.06(d) to “one year” and in the restrictive legend set forth in such paragraph to “ONE YEAR” shall be deemed for all purposes hereof to be references to such changed
period, (ii) each reference in Section 2.06(e) to “one year” and in the restrictive legend set forth in such paragraph to “ONE YEAR” shall be deemed for all purposes hereof to be references to such changed period and
(iii) all corresponding references in the Notes (including the definition of Resale Restriction Termination Date) and the restrictive legends thereon shall be deemed for all purposes hereof to be references to such changed period, provided
that such changes shall not become effective if they are otherwise prohibited by, or would otherwise cause a violation of, the then-applicable federal securities laws, or are not applicable to the Notes or Common Stock. The provisions of this
Section 2.06(g) will not be effective until such time as the Opinion of Counsel and Officers’ Certificate have been received by the Trustee hereunder. This Section 2.06(g) shall apply to successive amendments to Rule 144 (or any
successor rule) changing the holding period thereunder. 
 SECTION 2.07. Mutilated, Destroyed, Lost or Stolen Notes. In case any
Note shall become mutilated or be destroyed, lost or stolen, the Company in its discretion may execute, and upon its written request the Trustee or an authenticating agent appointed by the Trustee shall authenticate and deliver, a new Note, bearing
a number not contemporaneously outstanding, in exchange and substitution for the mutilated Note, or in lieu of and in substitution 

  

 28 

 
for the Note so destroyed, lost or stolen. In every case the applicant for a substituted Note shall furnish to the Company, to the Trustee and, if
applicable, to such authenticating agent such security or indemnity as may be required by them to save each of them harmless from any loss, liability, cost or expense caused by or connected with such substitution, and, in every case of destruction,
loss or theft, the applicant shall also furnish to the Company, to the Trustee and, if applicable, to such authenticating agent evidence to their satisfaction of the destruction, loss or theft of such Note and of the ownership thereof. 

The Trustee or such authenticating agent may authenticate any such substituted Note and deliver the same upon the receipt of such security or
indemnity as the Trustee, the Company and, if applicable, such authenticating agent may require. Upon the issuance of any substitute Note, the Company or the Trustee may require the payment by the holder of a sum sufficient to cover any tax,
assessment or other governmental charge that may be imposed in relation thereto and any other expenses connected therewith. In case any Note that has matured or is about to mature or is about to be redeemed or has been tendered for repurchase
pursuant to Article 16 hereof or is about to be converted into cash, shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, shall become mutilated or be destroyed, lost or stolen, the Company may, in its sole
discretion, instead of issuing a substitute Note, pay or authorize the payment of or convert or authorize the conversion of the same (without surrender thereof except in the case of a mutilated Note), as the case may be, if the applicant for such
payment or conversion shall furnish to the Company, to the Trustee and, if applicable, to such authenticating agent such security or indemnity as may be required by them to save each of them harmless for any loss, liability, cost or expense caused
by or connected with such substitution, including without limitation if a Note is replaced and subsequently presented or claimed for payment and, in every case of destruction, loss or theft, evidence satisfactory to the Company, the Trustee and, if
applicable, any Paying Agent or Conversion Agent evidence of their satisfaction of the destruction, loss or theft of such Note and of the ownership thereof. 
 Every substitute Note issued pursuant to the provisions of this Section 2.07 by virtue of the fact that any Note is destroyed, lost or stolen shall constitute an additional contractual obligation of the Company,
whether or not the destroyed, lost or stolen Note shall be found at any time, and shall be entitled to all the benefits of (but shall be subject to all the limitations set forth in) this Indenture equally and proportionately with any and all other
Notes duly issued hereunder. To the extent permitted by law, all Notes shall be held and owned upon the express condition that the foregoing provisions are exclusive with respect to the replacement or payment or conversion or repurchase of
mutilated, destroyed, lost or stolen Notes and shall preclude any and all other rights or remedies notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to the replacement or payment or conversion of
negotiable instruments or other securities without their surrender. 
 SECTION 2.08. Temporary Notes. Pending the preparation of
Notes in certificated form, the Company may execute and the Trustee or an authenticating agent appointed by the Trustee shall, upon written request of the Company, authenticate and deliver temporary Notes (printed or lithographed). Temporary Notes
shall be issuable in any authorized denomination, and substantially in the form of the Notes in certificated form but with such omissions, insertions and variations as may be appropriate for temporary Notes, all as may be determined by the Company.
Every such temporary Note shall be executed by the Company and 

  

 29 

 
authenticated by the Trustee or such authenticating agent upon the same conditions and in substantially the same manner, and with the same effect, as the
Notes in certificated form. Without unreasonable delay the Company will execute and deliver to the Trustee or such authenticating agent Notes in certificated form (other than any Global Note) and thereupon any or all temporary Notes (other than any
Global Note) may be surrendered in exchange therefor, at each office or agency maintained by the Company pursuant to Section 5.02 and the Trustee or such authenticating agent shall authenticate and deliver in exchange for such temporary Notes
an equal aggregate principal amount of Notes in certificated form. Such exchange shall be made by the Company at its own expense and without any charge therefor. Until so exchanged, the temporary Notes shall in all respects be entitled to the same
benefits and subject to the same limitations under this Indenture as Notes in certificated form authenticated and delivered hereunder. 
 SECTION 2.09. Cancellation of Notes Paid, Etc. All Notes surrendered for the purpose of payment, redemption, repurchase, conversion, exchange or registration of transfer, shall, if surrendered to the Company or any Paying Agent
or any Note Registrar or any Conversion Agent, be surrendered to the Trustee and promptly canceled by it, or, if surrendered to the Trustee, shall be promptly canceled by it, and no Notes shall be issued in lieu thereof except as expressly permitted
by any of the provisions of this Indenture. The Trustee shall dispose of canceled Notes in accordance with its customary procedures and, after such disposition, shall deliver a certificate of such disposition to the Company, at the Company’s
written request. If the Company shall acquire any of the Notes, such acquisition shall not operate as satisfaction of the indebtedness represented by such Notes unless and until the same are delivered to the Trustee for cancellation. 
 SECTION 2.10. CUSIP Numbers. The Company in issuing the Notes may use “CUSIP” numbers (if then generally in use), and, if so, the
Trustee shall use “CUSIP” numbers in all notices issued to Noteholders as a convenience to them; provided, that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the
Notes or on such notice and that reliance may be placed only on the other identification numbers printed on the Notes. The Company will promptly notify the Trustee in writing of any change in the “CUSIP” numbers. Until such time as the
Company notifies the Trustee to remove the restrictive legend as set forth in Section 2.06(d) from the Notes or a transfer of Notes from a Restricted Global Note to an Unrestricted Global Note is otherwise made pursuant to the terms hereof, the
restricted CUSIP will be the CUSIP number for the Notes. At such time as the Company notifies the Trustee to remove the restrictive legend as set forth in Section 2.06(d) from the Notes, such legend shall be deemed removed from any Global Notes
and an unrestricted CUSIP number for the Notes, as provided therein, shall be deemed to be the CUSIP number for the Notes. 
 SECTION 2.11. Additional Notes; Repurchases. The Company may, without the consent of the Noteholders and notwithstanding Section 2.01, reopen this Indenture and increase the principal amount of the Notes by issuing
additional Notes in the future pursuant to this Indenture with the same terms and with the same CUSIP number as the Notes initially issued hereunder in an unlimited aggregate principal amount, which will form the same series with the Notes initially
issued hereunder, provided that no such additional Notes may be issued unless they will be fungible with the original Notes for U.S. federal income tax and securities law 

  

 30 

 
purposes. Prior to the issuance of any such additional Notes, the Company shall deliver to the Trustee a Company Order, an Officers’ Certificate and an
Opinion of Counsel, such Officers’ Certificate and Opinion of Counsel to cover such matters, in addition to those required by Section 17.05, as the Trustee shall reasonably request. The Company may also from time to time repurchase the
Notes in open market purchases or negotiated transactions without prior notice to Noteholders. 
 ARTICLE III 
 REDEMPTION 
 SECTION 3.01.
Company’s Right to Redeem; Notices to Trustee. Prior to August 15, 2013, the Notes shall not be redeemable at the Company’s option. On or after August 15, 2013, the Company, at its option, may redeem the Notes for cash at
any time, in whole or in part, at a redemption price (the “Redemption Price”) equal to 100% of the principal amount of the Notes redeemed, plus any accrued and unpaid interest and accrued and unpaid Additional Interest, if any, on
the Notes redeemed up to, but not including, the Redemption Date; provided however, that, in no event shall a Redemption Date be a Legal Holiday; provided further, that, if the Redemption Date is on a date that is after an Interest
Record Date and on or prior to the corresponding Interest Payment Date, the Redemption Price shall be 100% of the principal amount of the Notes redeemed but shall not include accrued and unpaid interest and Additional Interest, if any. Instead, the
Company shall pay such interest and Additional Interest, if any, on the Interest Payment Date to the holder of record on the corresponding Interest Record Date. If the Company elects to redeem Notes pursuant to this Section 3.01, it shall
notify the Trustee in writing of such election together with the Redemption Date, the Conversion Rate, the principal amount of Notes to be redeemed and the Redemption Price. Notwithstanding the foregoing, no Notes may be redeemed by the Company if
the principal amount of the Notes has been accelerated and such acceleration has not been rescinded on or prior to the Redemption Date (except in the case of an acceleration resulting from a default by the Company in the payment of the Redemption
Price with respect to such Notes). 
 The Company shall give the notice to the Trustee provided for in this Section 3.01 by a Company
Order, at least 45 days but not more than 60 days before the Redemption Date (unless a shorter notice shall be satisfactory to the Trustee). 
 SECTION 3.02. Selection of Notes to Be Redeemed. If less than all of the Notes are to be redeemed, unless the procedures of the Depositary provide otherwise, the Trustee shall select the Notes to be redeemed by lot, on a pro
rata basis or by another method the Trustee considers fair and appropriate (so long as such method is not prohibited by the rules of any stock exchange or quotation association on which the Notes are then traded or quoted). The Trustee may select
for redemption portions of the principal amount of Notes that are larger than the minimum denomination $1,000. 
 Notes and portions of Notes
that the Trustee selects shall be in principal amounts of $1,000 or an integral multiple of $1,000. Provisions of this Indenture that apply to Notes called for redemption also apply to portions of Notes called for redemption. The Trustee shall
notify 

  

 31 

 
the Company promptly (but in any case within 7 days of the Company Order referred to in Section 3.01) of the Notes or portions of the Notes selected to
be redeemed and, in the case of any Notes selected for partial redemption, the method it has chosen for the selection of the Note. 
 Following a notice of redemption, Notes and portions of Notes are convertible, pursuant to Section 15.01(b)(v), by the holder until the close of business on the Business Day prior to the Redemption Date. If any Note selected for
partial redemption is converted in part before termination of the conversion right with respect to the portion of the Note so selected, the converted portion of such Note shall be deemed (to the extent possible) to be from the portion selected for
redemption. Notes that have been converted during a selection of Notes to be redeemed may be treated by the Trustee as outstanding for the purpose of such selection. 
 SECTION 3.03. Notice of Redemption. At least 30 days but not more than 60 days before a Redemption Date, the Company shall provide a notice of redemption by electronic transmission or first-class mail,
postage prepaid, to each holder of Notes to be redeemed. Simultaneously with the providing of such notice, the Company shall also issue a press release announcing such notice of redemption and make the press release available on the Company’s
website. 
 The notice shall identify the Notes to be redeemed and shall state (along with any other information the Company wishes to
include): 
 (i) the Redemption Date; 
 (ii) the Redemption Price; 
 (iii) the Conversion Rate and the Conversion Price; 
 (iv) whether the Company will deliver
Common Stock, cash or a combination thereof to holders electing to convert their Notes; 
 (v) the name and address of the
Paying Agent and Conversion Agent; 
 (vi) that Notes may be converted at any time before the close of business on the
Business Day prior to the Redemption Date; 
 (vii) that Notes called for redemption and not converted shall be redeemed on
the Redemption Date; 
 (viii) that holders who want to convert their Notes must satisfy the requirements set forth in the
Notes; 
 (ix) that Notes called for redemption must be surrendered to the Paying Agent (by effecting book-entry transfer of
the Notes or delivering Notes in certificated form, together with necessary endorsements, as the case may be) to collect the Redemption Price; 
  

 32 

 (x) if fewer than all of the outstanding Notes are to be redeemed, the certificate
numbers, if any, and principal amounts of the particular Notes to be redeemed; 
 (xi) that, unless the Company defaults in
making payment of such Redemption Price, interest, and Additional Interest, if any, on the Notes or portions of Notes called for redemption shall cease to accrue from and after the Redemption Date; and 
 (xii) the “CUSIP”, “ISIN” or other similar number(s), as the case may be, of the Notes being redeemed. 
 At the Company’s request, the Trustee shall give the notice of redemption in the Company’s name and at the Company’s expense; provided
that, the Company makes such request at least seven Business Days (or such shorter period as may be satisfactory to the Trustee) prior to the date by which such notice of redemption must be given to holders in accordance with this
Section 3.03. 
 SECTION 3.04. Effect of Notice of Redemption. Once notice of redemption is given, Notes called for
redemption become due and payable on the Redemption Date and at the Redemption Price stated in the notice except for Notes that are converted in accordance with the terms of this Indenture. Upon surrender to the Paying Agent, such Notes shall be
paid at the Redemption Price stated in the notice and from and after the Redemption Date (unless the Company shall default in the payment of the Redemption Price) such Notes shall cease to bear interest and Additional Interest, if any, and the
rights of the holders therein shall terminate (other than the right to receive the Redemption Price). 
 If any Note shall not be fully and
duly paid in accordance herewith upon redemption, the principal of, and accrued and unpaid interest and accrued and unpaid Additional Interest, if any, on such Note shall, until paid, bear Interest at the rate borne by such Note on the principal
amount of such Note, and such Note shall continue to be convertible pursuant to Article 15. 
 SECTION 3.05. Notes Redeemed in
Part. Upon surrender of a Note that is redeemed in part, the Company shall execute and the Trustee shall, without charge, authenticate and deliver to the holder a new Note in an authorized denomination equal in principal amount to the unredeemed
portion of the Note surrendered. 
 In the event of any redemption in part, the Company will not be required to: 
  

	 	(a)	issue, register the transfer of or exchange any Note during a period beginning at the opening of business 15 days before any selection of Notes for redemption and ending at the
close of business on the earliest date on which the relevant notice of redemption is deemed to have been given to all holders of Notes to be so redeemed; or 

  

	 	(b)	register the transfer of or exchange any Note so selected for redemption, in whole or in part, except the unredeemed portion of any Note being redeemed in part.

  

 33 

 The Company may not redeem the Notes on any date if the principal amount of the Notes has been
accelerated, and such acceleration has not been rescinded, on or prior to such date. 
 ARTICLE IV 
 SATISFACTION AND DISCHARGE 
 SECTION 4.01. Satisfaction and Discharge. This Indenture shall upon request of the Company contained in an Officers’ Certificate cease to be of further effect, and the Trustee, at the expense of the Company, shall execute
proper instruments acknowledging satisfaction and discharge of this Indenture, when (a) (i) all Notes theretofore authenticated and delivered (other than (x) Notes which have been destroyed, lost or stolen and which have been replaced
or paid as provided in Section 2.07 and (y) Notes for whose payment money has theretofore been deposited in trust or segregated and held in trust by the Company and thereafter repaid to the Company or discharged from such trust, as
provided in Section 5.04(d)) have been delivered to the Trustee for cancellation; or (ii) the Company has deposited with the Trustee or delivered to Noteholders, as applicable, after the Notes have become due and payable, whether at the
Maturity Date, any Redemption Date, any Repurchase Date, any Fundamental Change Repurchase Date, upon conversion or otherwise, cash or cash and shares of Common Stock, if any (solely to satisfy the Company’s Conversion Obligation, if
applicable), sufficient to pay all of the outstanding Notes and all other sums due and payable under this Indenture by the Company; and (b) the Company has delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel, each
stating that all conditions precedent herein provided for relating to the satisfaction and discharge of this Indenture have been complied with. Notwithstanding the satisfaction and discharge of this Indenture, the obligations of the Company to the
Trustee under Section 8.06 shall survive. 
 ARTICLE V 
 PARTICULAR COVENANTS OF THE COMPANY 
 SECTION 5.01. Payment of
Principal, Interest and Additional Interest. The Company covenants and agrees that it will cause to be paid the principal of (including the Redemption Price, Repurchase Price or Fundamental Change Repurchase Price, as applicable), and accrued
and unpaid interest and Additional Interest, if any, on each of the Notes at the places, at the respective times and in the manner provided herein and in the Notes. Each installment of accrued and unpaid interest, and Additional Interest, if any, on
the Notes due may be paid by mailing checks for the amount payable to Noteholders entitled thereto as they shall appear on the registry books of the Company; provided that payment of accrued and unpaid interest and Additional Interest, if
any, made to the Depositary shall be paid by wire transfer in immediately available funds in accordance with such wire transfer instructions and other procedures provided by the Depositary from time to time. 
 SECTION 5.02. Maintenance of Office or Agency. The Company will maintain in the Borough of Manhattan, The City of New York, an office or
agency where the Notes in certificated form may be surrendered for registration of transfer or exchange or for presentation for payment, redemption or repurchase (“Paying Agent”) or for conversion (“Conversion Agent”). Except for
the surrender or presentation of Notes in certificated form as 

  

 34 

 
described in the preceding sentence, the Corporate Trust Office will be the office where notices and demands to or upon the Company in respect of the Notes
and this Indenture may be served. The Company will give prompt written notice to the Trustee of the location, and any change in the location, of such office or agency maintained in the Borough of Manhattan, The City of New York. If at any time the
Company shall fail to maintain any such required office or agency or shall fail to furnish the Trustee with the address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust Office. 
 The Company may also from time to time designate co-registrars, one or more other offices or agencies where the Notes may be presented or surrendered for
any or all such purposes and may from time to time rescind such designations; provided that no such designation or rescission shall in any manner relieve the Company of its obligation to maintain an office or agency in the Borough of Manhattan, The
City of New York, to facilitate the surrender or presentation of Notes in certificated form. The Company will give prompt written notice to the Trustee of any such designation or rescission and of any change in the location of any such other office
or agency. The terms “Paying Agent” and “Conversion Agent” include any such additional or other offices or agencies, as applicable. 
 The Company hereby initially designates the Trustee as the Paying Agent, Note Registrar, Custodian and Conversion Agent. 
 SECTION 5.03. Appointments to Fill Vacancies in Trustee’s Office. The Company, whenever necessary to avoid or fill a vacancy in the office of Trustee, will appoint, in the manner provided in
Section 8.10, a Trustee, so that there shall at all times be a Trustee hereunder. 
 SECTION 5.04. Provisions as to Paying
Agent. 
 (a) If the Company shall appoint a Paying Agent other than the Trustee, the Company will cause such Paying Agent to execute and
deliver to the Trustee an instrument in which such agent shall agree with the Trustee, subject to the provisions of this Section 5.04: 
 (i) that it will hold all sums held by it as such agent for the payment of the principal of and accrued and unpaid interest and Additional Interest, if any, on the Notes in trust for the benefit of the holders of the
Notes; 
 (ii) that it will give the Trustee prompt notice of any failure by the Company to make any payment of the principal
of and accrued and unpaid interest and Additional Interest, if any, on the Notes when the same shall be due and payable; and 
 (iii) that at any time during the continuance of an Event of Default, upon request of the Trustee, it will forthwith pay to the Trustee all sums so held in trust. 
 Subject to Sections 16.03 and 16.06, as applicable, the Company shall, on or before each due date of the principal of (including the Redemption Price,
Repurchase Price or Fundamental Change Repurchase Price, as applicable), or accrued and unpaid interest or 

  

 35 

 
Additional Interest, if any, on the Notes, deposit with the Paying Agent a sum sufficient to pay such principal (including the Redemption Price, Repurchase
Price or Fundamental Change Repurchase Price, as applicable), or accrued and unpaid interest or Additional Interest, if any, and (unless such Paying Agent is the Trustee) the Company will promptly notify the Trustee of any failure to take such
action, provided that if such deposit is made on the due date, such deposit must be received by the Paying Agent by 11:00 a.m., New York City time, on such date. 
 (b) If the Company shall act as its own Paying Agent, it will, on or before each due date of the principal of (including the Redemption Price, Repurchase Price or Fundamental Change Repurchase Price, as applicable),
accrued and unpaid interest and Additional Interest, if any, on the Notes, set aside, segregate and hold in trust for the benefit of the holders of the Notes a sum sufficient to pay such principal (including the Redemption Price, Repurchase Price or
Fundamental Change Repurchase Price, as applicable), accrued and unpaid interest and Additional Interest, if any, so becoming due and will promptly notify the Trustee in writing of any failure to take such action and of any failure by the Company to
make any payment of the principal of (including the Redemption Price, Repurchase Price or Fundamental Change Repurchase Price, as applicable), accrued and unpaid interest and Additional Interest, if any, on the Notes when the same shall become due
and payable. 
 (c) Anything in this Section 5.04 to the contrary notwithstanding, the Company may, at any time, for the purpose of
obtaining a satisfaction and discharge of this Indenture, or for any other reason, pay or cause to be paid to the Trustee all sums held in trust by the Company or any Paying Agent hereunder as required by this Section 5.04, such sums to be held
by the Trustee upon the trusts herein contained, and upon such payment by the Company or any Paying Agent to the Trustee, the Company or such Paying Agent shall be released from all further liability with respect to such sums. 
 (d) Any money deposited with the Trustee or any Paying Agent, or then held by the Company, in trust for the payment of the principal of (including the
Redemption Price, Repurchase Price or Fundamental Change Repurchase Price, as applicable), accrued and unpaid interest and Additional Interest, if any, on any Note and remaining unclaimed for two years after such principal (including the Redemption
Price, Repurchase Price or Fundamental Change Repurchase Price, as applicable), interest or Additional Interest has become due and payable shall be paid to the Company on request of the Company contained in an Officers’ Certificate, or (if then
held by the Company) shall be discharged from such trust; and the holder of such Note shall thereafter, as an unsecured general creditor, look only to the Company for payment thereof, and all liability of the Trustee or such Paying Agent with
respect to such trust money, and all liability of the Company as trustee thereof, shall thereupon cease; provided, however, that the Trustee or such Paying Agent, before being required to make any such repayment, may at the expense of
the Company cause to be published once, in a newspaper published in the English language, customarily published on each Business Day and of general circulation in The Borough of Manhattan, The City of New York, New York, notice that such money
remains unclaimed and that, after a date specified therein, which shall not be less than thirty days from the date of such publication, any unclaimed balance of such money then remaining will be repaid to the Company. 
  

 36 

 SECTION 5.05. Existence. Subject to Article 12, the Company will do or cause to be done all
things necessary to preserve and keep in full force and effect its corporate existence. 
 SECTION 5.06. Rule 144A Information
Requirement and Annual Reports. 
 (a) At any time the Company is not subject to Section 13 or 15(d) of the Exchange Act, the Company
shall, so long as any of the Notes or any shares of Common Stock issuable upon conversion thereof shall, at such time, constitute “restricted securities” within the meaning of Rule 144(a)(3) under the Securities Act, promptly provide to
the Trustee and shall, upon written request, provide to any holder, beneficial owner or prospective purchaser of such Notes or any shares of Common Stock issued upon conversion of such Notes, the information required to be delivered pursuant to Rule
144A(d)(4) under the Securities Act to facilitate the resale of such Notes or shares of Common Stock pursuant to Rule 144A under the Securities Act. The Company shall take such further action as any holder or beneficial owner of such Notes or such
Common Stock may reasonably request to the extent required from time to time to enable such holder or beneficial holder to sell such Notes or shares of Common Stock in accordance with Rule 144A under the Securities Act, as such rule may be amended
from time to time. 
 (b) The Company shall deliver to the Trustee within fifteen days after the same is required to be filed with the
Commission, copies of the quarterly and annual reports and of the information, documents and other reports, if any, that the Company is required to file with the Commission pursuant to Section 13 or 15(d) of the Exchange Act (giving effect to
any grace period provided by Rule 12b-25 under the Exchange Act), and the Company shall otherwise comply with the requirements of Section 314(a) of Trust Indenture Act. Any such report, information or document that the Company files with the
Commission through the Commission’s EDGAR database shall be deemed delivered to the Trustee for purposes of this Section 5.06(b) at the time of such filing through the EDGAR database. 
 (c) Delivery of the reports, information and documents described in clause (b) above to the Trustee is for informational purposes only, and the
Trustee’s receipt of such shall not constitute constructive notice of any information contained therein or determinable from information contained therein, including the Company’s compliance with any of its covenants hereunder (as to which
the Trustee is entitled to conclusively rely exclusively on an Officers’ Certificate). 
 (d) If, at any time during the six-month
period beginning on, and including, the date which is six months after the last date of original issuance of the Notes, the Company fails to timely file any document or report that the Company is required to file with the Commission pursuant to
Section 13 or 15(d) of the Exchange Act, as applicable (other than current reports on Form 8-K), or the Notes are not otherwise freely tradable by holders other than the Company’s affiliates (as a result of restrictions pursuant to U.S.
securities law or the terms of this Indenture or the Notes), the Company shall pay Additional Interest on the Notes. Such Additional Interest will accrue on the Notes at an annual rate of 0.50% per annum of the principal amount of Notes
outstanding for each day during such period for which the Company’s failure to file continues; provided that the Company shall have 14 days, in the aggregate, to cure any such late filings before any Additional Interest shall accrue.

  

 37 

 (e) If, at any time after the 365th day after the last date of original issuance of the Notes pursuant to
the Purchase Agreement, (i) the restrictive legend on the Notes has not been removed in accordance with Section 2.06(d), and (ii) the Notes are not freely tradable pursuant to Rule 144 without restrictions by holders other than the
Company’s affiliates, the Company shall pay Additional Interest on the Notes. Such Additional Interest will accrue on the Notes at an annual rate of 0.50% per annum of the principal amount of Notes outstanding for each day after the 365th
day after the last date of original issuance of the Notes until (i) the restrictive legend on the Notes has been removed in accordance with Section 2.06(d), and (ii) the Notes are freely tradable pursuant to Rule 144 without
restrictions by holders other than the Company’s affiliates. 
 Additional Interest payable in accordance with Section 5.06(d) or
(e) will be payable in arrears on each Interest Payment Date following accrual in the same manner as regular interest on the Notes. Any Additional Interest required to be paid in the circumstances set forth in this Section 5.06 would be in
addition to, and not in lieu of, any Additional Interest owed in the circumstances set forth under Section 7.03 herein; provided, however, that in no event will Additional Interest accrue at a rate per year exceeding 0.50% in the
aggregate during the period beginning on, and including, the date that is six months after the date of the last original issuance of the Notes through the date that is 365 days after the date of the last original issuance of the Notes. 

SECTION 5.07. Stay, Extension and Usury Laws. The Company covenants (to the extent that it may lawfully do so) that it shall not at any
time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law or other law that would prohibit or forgive the Company from paying all or any portion of the principal of or interest
on the Notes as contemplated herein, wherever enacted, now or at any time hereafter in force, or that may affect the covenants or the performance of this Indenture; and the Company (to the extent it may lawfully do so) hereby expressly waives all
benefit or advantage of any such law, and covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted to the Trustee, but will suffer and permit the execution of every such power as though
no such law had been enacted. 
 SECTION 5.08. Compliance Certificate; Statements as to Defaults. The Company shall deliver to
the Trustee within 120 days after the end of each Fiscal Year (beginning with the Fiscal Year ending on December 31, 2008) an Officers’ Certificate stating whether or not the signer thereof has knowledge of any failure by the Company to
comply with all conditions and covenants then required to be performed under this Indenture and, if so, specifying each such failure and the nature thereof. 
 In addition, the Company shall deliver to the Trustee, as soon as possible, and in any event within thirty days after the Company becomes aware of the occurrence of any Event of Default or Default, an Officers’
Certificate setting forth the details of such Event of Default or Default, its status and the action that the Company proposes to take with respect thereto. 
 SECTION 5.09. Limitation on Incurrence of Additional Debt. For so long as any Notes are outstanding, the Company shall not, nor shall it permit any Subsidiary to, directly or indirectly, incur any
Indebtedness other than Permitted Debt; provided, however, that the Company may, and may permit any Subsidiary to, incur Indebtedness if: 
 (a) no Default or Event of Default shall have occurred and be continuing at the time of such incurrence or would occur as a consequence of such incurrence; 
  

 38 

 (b) after giving pro forma effect to such incurrence, the Consolidated Leverage Ratio would not exceed
2.75 to 1.00; and 
 (c) after giving pro forma effect to such incurrence, the Consolidated Fixed Charge Coverage Ratio would not be less
than 1.25 to 1.00; 
 provided, however, that the Credit Facility may be Refinanced so long as any such Refinanced Credit Facility contains
substantially the same restrictive negative covenants with respect to financial ratios as the Credit Facility (as it exists on the date hereof but excluding any existing amendments to Section 7.12 thereof). 
 SECTION 5.10. Further Instruments and Acts. Upon request of the Trustee, the Company will execute and deliver such further instruments and do
such further acts as may be reasonably necessary or proper to carry out more effectively the purposes of this Indenture. 
 ARTICLE VI 

 LISTS OF NOTEHOLDERS AND REPORTS BY 
 THE COMPANY AND THE TRUSTEE 
 SECTION 6.01. Lists of Noteholders. The Company covenants
and agrees that it will furnish or cause to be furnished to the Trustee, semi-annually, not more than fifteen days after each February 1 and August 1 in each year, beginning with February 1, 2009, and at such other times as the
Trustee may request in writing, within thirty days after receipt by the Company of any such request (or such lesser time as the Trustee may reasonably request in order to enable it to timely provide any notice to be provided by it hereunder), a list
in such form as the Trustee may reasonably require of the names and addresses of the Noteholders as of a date not more than fifteen days (or such other date as the Trustee may reasonably request in order to so provide any such notices) prior to the
time such information is furnished, except that no such list need be furnished so long as the Trustee is acting as Note Registrar. 
 SECTION 6.02. Preservation and Disclosure of Lists. 
 (a) The Trustee shall preserve, in as current a form as is
reasonably practicable, all information as to the names and addresses of the Noteholders contained in the most recent list furnished to it as provided in Section 6.01 or maintained by the Trustee in its capacity as Note Registrar, if so acting.
The Trustee may destroy any list furnished to it as provided in Section 6.01 upon receipt of a new list so furnished. 
 (b) The rights
of Noteholders to communicate with other Noteholders with respect to their rights under this Indenture or under the Notes and the corresponding rights and duties of the Trustee, shall be as provided by the Trust Indenture Act. 
  

 39 

 (c) Every Noteholder, by receiving and holding the same, agrees with the Company and the Trustee that
neither the Company nor the Trustee nor any agent of either of them shall be held accountable by reason of any disclosure of information as to names and addresses of Noteholders made pursuant to the Trust Indenture Act. 
 SECTION 6.03. Reports by Trustee. 
 (a) The Trustee shall transmit to holders such reports concerning the Trustee and its actions under this Indenture as may be required pursuant to the Trust Indenture Act at the times and in the manner provided pursuant thereto. If required
by Section 313(a) of the Trust Indenture Act, the Trustee shall, within sixty days after each May 15 following the date of this Indenture, deliver to holders a brief report, dated as of such May 15, that complies with the provisions
of such Section 313(a). 
 (b) A copy of each such report shall, at the time of such transmission to Noteholders, be filed by the
Trustee with each stock exchange and automated quotation system upon which the Notes are listed and with the Company. The Company will notify the Trustee in writing within a reasonable time when the Notes are listed on any stock exchange or
automated quotation system and when any such listing is discontinued. 
 ARTICLE VII 
 DEFAULTS AND REMEDIES 
 SECTION 7.01. Events of Default. Each of the following shall be an “Event of Default”: 
 (a) default in the
payment in respect of the principal of any Note at its maturity, upon redemption, upon required repurchase, upon declaration of acceleration or otherwise; 
 (b) default in the payment of any interest (including Additional Interest, if any) upon any Note when it becomes due and payable, and continuance of such default for a period of 30 days; 
 (c) default in the performance, or breach, of any covenant or agreement of the Company in this Indenture (other than a covenant or agreement a default in
whose performance or whose breach is specifically dealt with in clauses (a), (b) or (f) of this Section 7.01), and continuance of such default or breach for a period of 60 days after written notice thereof has been given to the
Company by the Trustee or to the Company and the Trustee by the holders of at least 25% in aggregate principal amount of the outstanding Notes; 
 (d) a default or defaults under any bonds, debentures, notes or other evidences of indebtedness (other than the Notes) by the Company or any Subsidiary that is a Significant Subsidiary (or any group of Subsidiaries that, taken as a whole,
would constitute a Significant Subsidiary) having, individually or in the aggregate, a principal or similar amount outstanding of at least $5.0 million, whether such indebtedness now exists or shall hereafter be created, which default or defaults
shall have resulted in the acceleration of the maturity of such indebtedness prior to its express maturity or shall constitute a failure to pay at least $5.0 million of such indebtedness when due and payable after the expiration of any applicable
grace period with respect thereto; 
  

 40 

 (e) the entry against the Company or any Subsidiary that is a Significant Subsidiary (or any group of
Subsidiaries that, taken as a whole, would constitute a Significant Subsidiary) of a final judgment or final judgments for the payment of money in an aggregate amount in excess of $5.0 million, by a court or courts of competent jurisdiction, which
judgments remain undischarged, unwaived, unstayed, unbonded or unsatisfied for a period of 60 consecutive days; 
 (f) the failure to comply
with the obligations to convert the Notes into Common Stock, cash or a combination of cash and Common Stock, as applicable, upon exercise of a holder’s conversion right; 
 (g) the failure to timely issue a Fundamental Change Company Notice in accordance with Section 16.04(b); or 
 (h) the Company, any Subsidiary that is a Significant Subsidiary or any group of Subsidiaries that, taken as a whole, would constitute a Significant
Subsidiary, pursuant to or within the meaning of any Bankruptcy Law: 
 (i) commences a voluntary case; 
 (ii) consents to the entry of an order for relief against it in an involuntary case; 
 (iii) consents to the appointment of a custodian of it or for all or substantially all of its property; 
 (iv) makes a general assignment for the benefit of its creditors; 
 (v) generally is not paying its debts as they become due; or 
 (vi) a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that: 
 (A) is for relief against the Company or any Subsidiary that is a Significant Subsidiary or any group of Subsidiaries that, taken
together, would constitute a Significant Subsidiary, in an involuntary case; 
 (B) appoints a Custodian of the Company or
any Subsidiary that is a Significant Subsidiary or any group of Subsidiaries that, taken together, would constitute a Significant Subsidiary or for all or substantially all of the property of the Company or any of its Subsidiaries; or 
  

 41 

 (C) orders the liquidation of the Company or any Subsidiary that is a Significant
Subsidiary or any group of Subsidiaries that, taken together, would constitute a Significant Subsidiary; 
 and the order or
decree remains unstayed and in effect for 60 consecutive days. 
 SECTION 7.02. Acceleration. In case one or more Events of
Default shall have occurred and be continuing (whatever the reason for such Event of Default and whether it shall be voluntary or involuntary or be effected by operation of law or pursuant to any judgment, decree or order of any court or any order,
rule or regulation of any administrative or governmental body), then, and in each and every such case (other than an Event of Default specified in Section 7.01(h), unless the principal of all of the Notes shall have already become due and
payable (or waived), either the Trustee or the holders of at least 25% in aggregate principal amount of the Notes then outstanding, determined in accordance with Section 9.04, by notice in writing to the Company (and to the Trustee if given by
Noteholders), may declare 100% of the principal of and accrued and unpaid interest and accrued and unpaid Additional Interest, if any, on all the Notes to be due and payable immediately, and upon any such declaration the same shall become and shall
automatically be immediately due and payable, anything in this Indenture or in the Notes contained to the contrary notwithstanding. 
 If an
Event of Default specified in Section 7.01(h) occurs and is continuing, the principal of all the Notes and accrued and unpaid interest and accrued and unpaid Additional Interest, if any, shall be immediately due and payable. This provision,
however, is subject to the conditions that if, at any time after the principal of the Notes shall have been so declared due and payable, and before any judgment or decree for the payment of the monies due shall have been obtained or entered as
hereinafter provided, the Company shall pay or shall deposit with the Trustee a sum sufficient to pay installments of accrued and unpaid interest and accrued and unpaid Additional Interest, if any, upon all Notes and the principal of any and all
Notes that shall have become due otherwise than by acceleration (with interest on overdue installments of accrued and unpaid interest and accrued and unpaid Additional Interest, if any (to the extent that payment of such interest is enforceable
under applicable law), and on such principal at the rate borne by the Notes at such time) and amounts due to the Trustee pursuant to Section 8.06, and if (1) rescission would not conflict with any judgment or decree of a court of competent
jurisdiction and (2) any and all Events of Defaults under this Indenture, other than the nonpayment of principal of and accrued and unpaid interest and accrued and unpaid Additional Interest, if any, on Notes that shall have become due solely
by such acceleration, shall have been cured or waived pursuant to Section 7.09, then and in every such case the holders of a majority in aggregate principal amount of the Notes then outstanding, by written notice to the Company and to the
Trustee, may waive all Defaults or Events of Default with respect to the Notes (other than a Default or an Event of Default resulting from a failure to redeem any Notes, a failure to repurchase any Notes when required upon a Fundamental Change or a
failure to deliver, upon conversion, cash, shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, due upon conversion) and rescind and annul such declaration and its consequences (other than a declaration or
consequences, as the case may be, resulting from a failure to redeem any Notes, a failure to repurchase any Notes when required upon a Fundamental Change or a failure to deliver, upon conversion, cash, shares of Common Stock or a 

  

 42 

 
combination of cash and shares of Common Stock, as applicable, due upon conversion) and such Default (other than a Default resulting from a failure to
redeem, a failure to repurchase any Notes when required upon a Fundamental Change or a failure to deliver, upon conversion, cash, shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, due upon conversion) shall
cease to exist, and any Event of Default arising therefrom (other than a Default resulting from a failure to redeem, a failure to repurchase any Notes when required upon a Fundamental Change or a failure to deliver, upon conversion, cash, shares of
Common Stock or a combination of cash and shares of Common Stock, as applicable, due upon conversion) shall be deemed to have been cured for every purpose of this Indenture; but no such waiver or rescission and annulment shall extend to or shall
affect any subsequent Default or Event of Default, or shall impair any right consequent thereon. 
 SECTION 7.03. Additional
Interest. Notwithstanding anything in this Indenture or in the Notes to the contrary (except as provided in Section 5.06(d) or 5.06(e)), if the Company so elects, the sole remedy of Noteholders for an Event of Default relating to any
obligation to file reports as required under Section 5.06(a) or (b) shall, for the first 365 days after the occurrence of such an Event of Default (which will be the 60th day after written notice is provided to the Company in accordance
with Section 7.01(c)), consist exclusively of the right to receive Additional Interest on the Notes at an annual rate equal to (x) 0.25% of the outstanding principal amount of the Notes for the first 180 days an Event of Default is
continuing in such 365-day period and (y) 0.50% of the outstanding principal amount of the Notes for the remaining 185 days an Event of Default is continuing in such 365-day period. Additional Interest shall be payable in arrears on each
Interest Payment Date following the occurrence of such Event of Default in the same manner as regular interest on the Notes. The Company may elect to pay Additional Interest as the sole remedy under this Section 7.03 by giving notice to the
holders, the Trustee and Paying Agent of such election on or before the close of business on the 5th Business Day after the date on which such Event of Default otherwise would occur. If the Company fails to timely give such notice or pay Additional
Interest, the Notes will be immediately subject to acceleration as provided in Section 7.02. On the 366th day after such Event of Default (if such violation is not cured or waived prior to such 366th day), the Notes will be subject to
acceleration as provided in Section 7.02. This Section 7.03 shall not affect the rights of the Noteholders in the event of the occurrence of any other Event of Default. In the event the Company does not elect to pay Additional Interest
upon an Event of Default in accordance with this Section, the Notes will be subject to acceleration as provided in Section 7.02. Whenever in this Indenture there is mentioned, in any context, the payment of interest on, or in respect of, any
Note, such mention shall be deemed to include mention of the payment of “Additional Interest” provided for in this Section 7.03 and Sections 5.06(d) and 5.06(e) to the extent that, in such context, Additional Interest is, was or would
be payable in respect thereof pursuant to the provisions of such sections, and express mention of the payment of Additional Interest (if applicable) in any provision shall not be construed as excluding Additional Interest in those provisions where
such express mention is not made. 
 SECTION 7.04. Payments of Notes on Default; Suit Therefor. If an Event of Default under
clause (a) or (b) of Section 7.01 shall have occurred and be continuing, the Company shall, upon demand of the Trustee, pay to it, for the benefit of the holders of the Notes, the whole amount then due and payable on the Notes for
principal and interest and Additional Interest, if any, with interest on any overdue principal, interest and Additional Interest, if any, at 

  

 43 

 
the rate borne by the Notes at such time, and, in addition thereto, such further amount as shall be sufficient to cover any amounts due to the Trustee under
Section 8.06. If the Company shall fail to pay such amounts forthwith upon such demand, the Trustee, in its own name and as trustee of an express trust, may institute a judicial proceeding for the collection of the sums so due and unpaid, may
prosecute such proceeding to judgment or final decree and may enforce the same against the Company or any other obligor upon the Notes and collect the monies adjudged or decreed to be payable in the manner provided by law out of the property of the
Company or any other obligor upon the Notes, wherever situated. 
 In the event there shall be pending proceedings for the bankruptcy or for
the reorganization of the Company or any other obligor on the Notes under any Bankruptcy Law, or in case a receiver, assignee or trustee in bankruptcy or reorganization, liquidator, sequestrator or similar official shall have been appointed for or
taken possession of the Company or such other obligor, the property of the Company or such other obligor, or in the event of any other judicial proceedings relative to the Company or such other obligor upon the Notes, or to the creditors or property
of the Company or such other obligor, the Trustee, irrespective of whether the principal of the Notes shall then be due and payable as therein expressed or by declaration or otherwise and irrespective of whether the Trustee shall have made any
demand pursuant to the provisions of this Section 7.04, shall be entitled and empowered, by intervention in such proceedings or otherwise, to file and prove a claim or claims for the whole amount of principal and accrued and unpaid interest and
accrued and unpaid Additional Interest, if any, in respect of the Notes, and, in case of any judicial proceedings, to file such proofs of claim and other papers or documents and to take such other actions as it may deem necessary or advisable in
order to have the claims of the Trustee (including any claim for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel) and of the Noteholders allowed in such judicial proceedings relative to the
Company or any other obligor on the Notes, its or their creditors, or its or their property, and to collect and receive any monies or other property payable or deliverable on any such claims, and to distribute the same after the deduction of any
amounts due the Trustee under Section 8.06; and any receiver, assignee or trustee in bankruptcy or reorganization, liquidator, custodian or similar official is hereby authorized by each of the Noteholders to make such payments to the Trustee,
as administrative expenses, and, in the event that the Trustee shall consent to the making of such payments directly to the Noteholders, to pay to the Trustee any amount due it for reasonable compensation, expenses, advances and disbursements,
including agent’s and counsel fees, and including any other amounts due to the Trustee under Section 8.06 hereof, incurred by it up to the date of such distribution. To the extent that such payment of reasonable compensation, expenses,
advances and disbursements out of the estate in any such proceedings shall be denied for any reason, payment of the same shall be secured by a lien on, and shall be paid out of, any and all distributions, dividends, monies, securities and other
property that the holders of the Notes may be entitled to receive in such proceedings, whether in liquidation or under any plan of reorganization or arrangement or otherwise. 
 Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Noteholder any plan of
reorganization, arrangement, adjustment or composition affecting the Noteholder or the rights of any Noteholder thereof, or to authorize the Trustee to vote in respect of the claim of any Noteholder in any such proceeding. 
  

 44 

 All rights of action and of asserting claims under this Indenture, or under any of the Notes, may be
enforced by the Trustee without the possession of any of the Notes, or the production thereof at any trial or other proceeding relative thereto, and any such suit or proceeding instituted by the Trustee shall be brought in its own name as trustee of
an express trust, and any recovery of judgment shall, after provision for the payment of the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, be for the ratable benefit of the holders of the
Notes. 
 In any proceedings brought by the Trustee (and in any proceedings involving the interpretation of any provision of this Indenture
to which the Trustee shall be a party) the Trustee shall be held to represent all the holders of the Notes, and it shall not be necessary to make any holders of the Notes parties to any such proceedings. 
 In case the Trustee shall have proceeded to enforce any right under this Indenture and such proceedings shall have been discontinued or abandoned because
of such waiver or rescission and annulment or for any other reason or shall have been determined adversely to the Trustee, then and in every such case the Company, the Noteholders, and the Trustee shall, subject to any determination in such
proceeding, be restored respectively to their several positions and rights hereunder, and all rights, remedies and powers of the Company, the Noteholders, and the Trustee shall continue as though no such proceeding had been instituted. 

SECTION 7.05. Application of Monies Collected by Trustee. Any monies collected by the Trustee pursuant to this Article 7 with respect to
the Notes shall be applied in the order following, at the date or dates fixed by the Trustee for the distribution of such monies, upon presentation of the several Notes, and stamping thereon the payment, if only partially paid, and upon surrender
thereof, if fully paid: 
 First, to the payment of all amounts due the Trustee under Section 8.06; 
 Second, in case the principal of the outstanding Notes shall not have become due and be unpaid, to the payment of interest on the Notes,
including Additional Interest, if any, in default in the order of the date due of the installments of such interest, with interest (to the extent that such interest has been collected by the Trustee) upon the overdue installments of interest at the
rate borne by the Notes at such time, such payments to be made ratably to the Persons entitled thereto; 
 Third, in case the
principal of the outstanding Notes shall have become due, by declaration or otherwise, and be unpaid to the payment of the whole amount including the payment of the Redemption Price, Repurchase Price or Fundamental Change Repurchase Price, as
applicable, and the cash component of the Conversion Obligation, if any, then owing and unpaid upon the Notes for principal and interest, including Additional Interest, if any, with interest on the overdue principal and (to the extent that such
interest has been collected by the Trustee) upon overdue installments of interest at the rate borne by the Notes at such time, and in case such monies shall be insufficient to pay in full the whole amounts so due and unpaid upon the Notes, then to
the payment of such principal and interest without preference or priority of principal over interest, or of interest over principal or of any installment of interest over any other installment of interest, or of any Note over any other Note, ratably
to the aggregate of such principal and accrued and unpaid interest, and Additional Interest, if any; and 
  

 45 

 Fourth, to the payment of the remainder, if any, to the Company. 
 SECTION 7.06. Proceedings by Noteholders. No holder of any Note shall have any right by virtue of or by availing of any provision of this
Indenture to institute any suit, action or proceeding in equity or at law upon or under or with respect to this Indenture, or for the appointment of a receiver, trustee, liquidator, custodian or other similar official, or for any other remedy
hereunder, unless such holder previously shall have given to the Trustee written notice of an Event of Default and of the continuance thereof, as hereinbefore provided, and unless also the holders of not less than 25% in aggregate principal amount
of the Notes then outstanding shall have made written request to the Trustee to institute such action, suit or proceeding in its own name as Trustee hereunder and shall have offered to the Trustee such security or indemnity reasonably satisfactory
to it against any loss, liability or expense to be incurred therein or thereby, and the Trustee for sixty days after its receipt of such notice, request and offer of indemnity, shall have neglected or refused to institute any such action, suit or
proceeding and no direction that, in the opinion of the Trustee, is inconsistent with such written request shall have been given to the Trustee by the holders of a majority in principal amount of the Notes outstanding within such sixty-day period
pursuant to Section 7.09; it being understood and intended, and being expressly covenanted by the taker and holder of every Note with every other taker and holder and the Trustee that no one or more Noteholders shall have any right in any
manner whatever by virtue of or by availing of any provision of this Indenture to affect, disturb or prejudice the rights of any other Noteholder, or to obtain or seek to obtain priority over or preference to any other such holder, or to enforce any
right under this Indenture, except in the manner herein provided and for the equal, ratable and common benefit of all Noteholders (except as otherwise provided herein). For the protection and enforcement of this Section 7.06, each and every
Noteholder and the Trustee shall be entitled to such relief as can be given either at law or in equity. 
 Notwithstanding any other
provision of this Indenture and any provision of any Note, the right of any Noteholder to receive payment of the principal of (including the Redemption Price upon redemption pursuant to Article 3, the Repurchase Price upon repurchase pursuant to
Section 16.01 or the Fundamental Change Repurchase Price upon repurchase pursuant to Section 16.04, as applicable), and accrued and unpaid interest and accrued and unpaid Additional Interest, if any, on such Note, on or after the
respective due dates expressed or provided for in such Note or in this Indenture, or to institute suit for the enforcement of any such payment on or after such respective dates against the Company shall not be impaired or affected without the
consent of such Noteholder. 
 Anything in this Indenture or the Notes to the contrary notwithstanding, the holder of any Note, without the
consent of either the Trustee or the holder of any other Note, in its own behalf and for its own benefit, may enforce, and may institute and maintain any proceeding suitable to enforce, its rights of conversion as provided herein. 
 SECTION 7.07. Proceedings by Trustee. In case of an Event of Default the Trustee may in its discretion proceed to protect and enforce the
rights vested in it by this Indenture by such appropriate judicial proceedings as are necessary to protect and enforce any of 

  

 46 

 
such rights, either by suit in equity or by action at law or by proceeding in bankruptcy or otherwise, whether for the specific enforcement of any covenant
or agreement contained in this Indenture or in aid of the exercise of any power granted in this Indenture, or to enforce any other legal or equitable right vested in the Trustee by this Indenture or by law. 
 SECTION 7.08. Remedies Cumulative and Continuing. Except as provided in the second paragraph of Section 2.07 and Section 7.04, all
powers and remedies given by this Article 7 to the Trustee or to the Noteholders shall, to the extent permitted by law, be deemed cumulative and not exclusive of any thereof or of any other powers and remedies available to the Trustee or the holders
of the Notes, by judicial proceedings or otherwise, to enforce the performance or observance of the covenants and agreements contained in this Indenture, and no delay or omission of the Trustee or of any holder of any of the Notes to exercise any
right or power accruing upon any Default or Event of Default shall impair any such right or power, or shall be construed to be a waiver of any such Default or any acquiescence therein; and, subject to the provisions of Section 7.06, every power
and remedy given by this Article 7 or by law to the Trustee or to the Noteholders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Noteholders. 
 SECTION 7.09. Direction of Proceedings and Waiver of Defaults by Majority of Noteholders. The holders of a majority in aggregate principal
amount of the Notes at the time outstanding determined in accordance with Section 9.04 shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee or exercising any trust or
power conferred on the Trustee with respect to Notes; provided, however, that (a) such direction shall not be in conflict with any rule of law or with this Indenture, and (b) the Trustee may take any other action deemed proper by the
Trustee that is not inconsistent with such direction. The Trustee may refuse to follow any direction that it determines is unduly prejudicial to the rights of any other holder or that would involve the Trustee in personal liability. The holders of a
majority in aggregate principal amount of the Notes at the time outstanding determined in accordance with Section 9.04 may on behalf of the holders of all of the Notes waive any past Default or Event of Default hereunder and its consequences
except (i) a default in the payment of accrued and unpaid interest or accrued and unpaid Additional Interest, if any, on, or the principal (including any Redemption Price, any Repurchase Price or any Fundamental Change Repurchase Price) of, the
Notes when due that has not been cured pursuant to the provisions of Section 7.01, (ii) a failure by the Company to deliver cash, shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, upon conversion of
the Notes or (iii) a default in respect of a covenant or provision hereof which under Article 11 cannot be modified or amended without the consent of each holder of an outstanding Note affected. Upon any such waiver the Company, the Trustee and
the holders of the Notes shall be restored to their former positions and rights hereunder; but no such waiver shall extend to any subsequent or other Default or Event of Default or impair any right consequent thereon. Whenever any Default or Event
of Default hereunder shall have been waived as permitted by this Section 7.09, said Default or Event of Default shall for all purposes of the Notes and this Indenture be deemed to have been cured and to be not continuing; but no such waiver
shall extend to any subsequent or other Default or Event of Default or impair any right consequent thereon. 
  

 47 

 SECTION 7.10. Notice of Defaults. The Trustee shall, within ninety days after the occurrence
and continuance of a Default of which a Responsible Officer has actual knowledge, mail to all Noteholders as the names and addresses of such holders appear upon the Note Register, notice of all Defaults known to a Responsible Officer, unless such
Defaults shall have been cured or waived before the giving of such notice; and provided that, except in the case of a Default in the payment of the principal of, accrued and unpaid interest or accrued and unpaid Additional Interest, if any,
on any of the Notes, including without limiting the generality of the foregoing any Default in the payment of any Redemption Price, any Repurchase Price or any Fundamental Change Repurchase Price, then in any such event the Trustee shall be
protected in withholding such notice if and so long as a committee of Responsible Officers of the Trustee in good faith determine that the withholding of such notice is in the interests of the Noteholders. 
 SECTION 7.11. Undertaking to Pay Costs. All parties to this Indenture agree, and each holder of any Note by its acceptance thereof shall be
deemed to have agreed, that any court may, in its discretion, require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken or omitted by it as Trustee, the filing by
any party litigant in such suit of an undertaking to pay the costs of such suit and that such court may in its discretion assess reasonable costs, including reasonable attorneys’ fees and expenses, against any party litigant in such suit,
having due regard to the merits and good faith of the claims or defenses made by such party litigant; provided that the provisions of this Section 7.11 (to the extent permitted by law) shall not apply to any suit instituted by the Trustee, to
any suit instituted by any Noteholder, or group of Noteholders, holding in the aggregate more than 10% in principal amount of the Notes at the time outstanding determined in accordance with Section 9.04, or to any suit instituted by any
Noteholder for the enforcement of the payment of the principal of accrued and unpaid interest or accrued and unpaid Additional Interest, if any, on any Note (including, but not limited to, the Redemption Price, Repurchase Price or Fundamental Change
Repurchase Price, as applicable, with respect to the Notes being redeemed or repurchased, as applicable, as provided in this Indenture) on or after the due date expressed or provided for in such Note or to any suit for the enforcement of the right
to convert any Note in accordance with the provisions of Article 15. 
 ARTICLE VIII 
 CONCERNING THE TRUSTEE 
 SECTION 8.01. Duties and Responsibilities of Trustee. The Trustee, prior to the occurrence of an Event of Default and after the curing or waiver of all Events of Default that may have occurred, undertakes to perform such duties
and only such duties as are specifically set forth in this Indenture. In case an Event of Default has occurred (which has not been cured or waived) the Trustee shall exercise such of the rights and powers vested in it by this Indenture, and use the
same degree of care and skill in their exercise, as a prudent person would exercise or use under the circumstances in the conduct of such person’s own affairs; provided that if an Event of Default occurs and is continuing, the Trustee will be
under no obligation to exercise any of the rights or powers under this Indenture at the request or direction of any of the holders unless such holders have offered to the Trustee reasonable indemnity or security against the costs, expenses and
liabilities that might be incurred by it in compliance with such request or direction. 
  

 48 

 No provision of this Indenture shall be construed to relieve the Trustee from liability for its own
grossly negligent action, its own grossly negligent failure to act or its own willful misconduct, except that 
 (a) prior to
the occurrence of an Event of Default and after the curing or waiving of all Events of Default that may have occurred: 
 (i)
the duties and obligations of the Trustee shall be determined solely by the express provisions of this Indenture and, if applicable, after it has been qualified thereunder, the Trust Indenture Act, and the Trustee shall not be liable except for the
performance of such duties and obligations as are specifically set forth in this Indenture and no implied covenants or obligations shall be read into this Indenture and the Trust Indenture Act against the Trustee; and 
 (ii) in the absence of bad faith or willful misconduct on the part of the Trustee, the Trustee may conclusively rely, as to the truth of
the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to the Trustee and conforming to the requirements of this Indenture; but, in the case of any such certificates or opinions that by any
provisions hereof are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they conform to the requirements of this Indenture (but need not confirm or investigate the
accuracy of any mathematical calculations or other facts stated therein); 
 (b) the Trustee shall not be liable for any error
of judgment made in good faith by a Responsible Officer or Officers of the Trustee, unless it shall be proved that the Trustee was grossly negligent in ascertaining the pertinent facts; 
 (c) the Trustee shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance with the
direction of the holders of not less than a majority in principal amount of the Notes at the time outstanding determined as provided in Section 9.04 relating to the time, method and place of conducting any proceeding for any remedy available to
the Trustee, or exercising any trust or power conferred upon the Trustee, under this Indenture; 
 (d) whether or not therein
provided, every provision of this Indenture relating to the conduct or affecting the liability of, or affording protection to, the Trustee shall be subject to the provisions of this Section 8.01; 
 (e) the Trustee shall not be liable in respect of any payment (as to the correctness of amount, entitlement to receive or any other
matters relating to payment) or notice effected by the Company or any Paying Agent or any records maintained by any co-registrar with respect to the Notes; 
 (f) if any party fails to deliver a notice relating to an event the fact of which, pursuant to this Indenture, requires notice to be sent to the Trustee, the Trustee may conclusively rely on its failure to receive
such notice as reason to act as if no such event occurred, unless such Responsible Officer of the Trustee had actual knowledge of such event; 
  

 49 

 (g) in the absence of written investment direction from the Company, all cash received by
the Trustee shall be placed in a non-interest bearing trust account, and in no event shall the Trustee be liable for the selection of investments or for investment losses incurred thereon or for losses incurred as a result of the liquidation of any
such investment prior to its maturity date or the failure of the party directing such investments prior to its maturity date or the failure of the party directing such investment to provide timely written investment direction, and the Trustee shall
have no obligation to invest or reinvest any amounts held hereunder in the absence of such written investment direction from the Company; and 
 (h) in the event that the Trustee is also acting as Custodian, Note Registrar, Paying Agent, Conversion Agent or transfer agent hereunder, the rights and protections afforded to the Trustee pursuant to this Article 8
shall also be afforded to such Custodian, Note Registrar, Paying Agent, Conversion Agent or transfer agent. 
 None of the provisions
contained in this Indenture shall require the Trustee to expend or risk its own funds or otherwise incur personal financial liability in the performance of any of its duties or in the exercise of any of its rights or powers. 
 SECTION 8.02. Reliance on Documents, Opinions, Etc. Except as otherwise provided in Section 8.01: 
 (a) the Trustee may conclusively rely and shall be fully protected in acting upon any resolution, certificate, statement, instrument,
opinion, report, notice, request, consent, order, bond, note, coupon or other paper or document believed by it in good faith to be genuine and to have been signed or presented by the proper party or parties; 
 (b) any request, direction, order or demand of the Company mentioned herein shall be sufficiently evidenced by an Officers’
Certificate (unless other evidence in respect thereof be herein specifically prescribed); and any Board Resolution may be evidenced to the Trustee by a copy thereof certified by the Secretary or an Assistant Secretary of the Company; 
 (c) the Trustee may consult with counsel and require an Opinion of Counsel and any advice of such counsel or Opinion of Counsel shall be
full and complete authorization and protection in respect of any action taken or omitted by it hereunder in good faith and in accordance with such advice or Opinion of Counsel; 
 (d) the Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement,
instrument, opinion, report, notice, request, direction, consent, order, bond, debenture or other paper or document, but the Trustee, in its discretion, may make such further inquiry or investigation into such facts or matters as it may see fit,
and, if the Trustee shall determine to make such further inquiry or investigation, it shall be entitled, at a reasonable time on any Business Day, to examine the books, records and premises of the Company, personally or by agent or attorney at the
expense of the Company and shall incur no liability of any kind by reason of such inquiry or investigation; 
  

 50 

 (e) the Trustee may execute any of the trusts or powers hereunder or perform any duties
hereunder either directly or by or through agents, custodians, nominees or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent, custodian, nominee or attorney appointed by it with due care
hereunder; and 
 (f) the permissive rights of the Trustee enumerated herein shall not be construed as duties. 
 In no event shall the Trustee be liable for any consequential loss or damage of any kind whatsoever (including but not limited to lost profits), even if
the Trustee has been advised of the likelihood of such loss or damage and regardless of the form of action other than any such loss or damage caused by the Trustee’s willful misconduct, gross negligence or bad faith. The Trustee shall not be
charged with knowledge of any Default or Event of Default with respect to the Notes, unless either (1) a Responsible Officer shall have actual knowledge of such Default or Event of Default or (2) written notice of such Default or Event of
Default shall have been given to a Responsible Officer of the Trustee by the Company or by any holder of the Notes. 
 SECTION 8.03.
No Responsibility for Recitals, Etc. The recitals contained herein and in the Notes (except in the Trustee’s certificate of authentication) shall be taken as the statements of the Company, and the Trustee assumes no responsibility for
the correctness of the same. The Trustee makes no representations as to the validity or sufficiency of this Indenture or of the Notes. The Trustee shall not be accountable for the use or application by the Company of any Notes or the proceeds of any
Notes authenticated and delivered by the Trustee in conformity with the provisions of this Indenture. 
 SECTION 8.04. Trustee,
Paying Agents, Conversion Agents or Registrar May Own Notes. The Trustee, any Paying Agent, any Conversion Agent or Note Registrar, in its individual or any other capacity, may become the owner or pledgee of Notes with the same rights it would
have if it were not the Trustee, Paying Agent, Conversion Agent or Note Registrar. 
 SECTION 8.05. Monies to Be Held in Trust.
All monies received by the Trustee shall, until used or applied as herein provided, be held in trust for the purposes for which they were received. Money held by the Trustee in trust hereunder need not be segregated from other funds except to the
extent required by law. The Trustee shall be under no liability for interest on any money received by it hereunder except as may be agreed from time to time by the Company and the Trustee. 
 SECTION 8.06. Compensation and Expenses of Trustee. The Company covenants and agrees to pay to the Trustee from time to time, and the Trustee
shall be entitled to, reasonable compensation for all services rendered by it hereunder in any capacity (which shall not be limited by any provision of law in regard to the compensation of a trustee of an express trust) as mutually agreed to in
writing between the Trustee and the Company, and the Company will pay or reimburse the Trustee upon its request for all reasonable expenses, disbursements and 

  

 51 

 
advances reasonably incurred or made by the Trustee in accordance with any of the provisions of this Indenture in any capacity thereunder (including the
reasonable compensation and the expenses and disbursements of its agents and counsel and of all Persons not regularly in its employ) except any such expense, disbursement or advance as shall have been caused by its gross negligence, willful
misconduct or bad faith. The Company also covenants to indemnify the Trustee in any capacity under this Indenture and any other document or transaction entered into in connection herewith and its agents and any authenticating agent for, and to hold
them harmless against, any loss, claim, damage, liability or expense incurred without gross negligence, willful misconduct or bad faith on the part of the Trustee, its officers, directors, agents or employees, or such agent or authenticating agent,
as the case may be, and arising out of or in connection with the acceptance or administration of this trust or in any other capacity hereunder, including the costs and expenses of defending themselves against any claim of liability in the premises.
The obligations of the Company under this Section 8.06 to compensate or indemnify the Trustee and to pay or reimburse the Trustee for expenses, disbursements and advances shall be secured by a senior claim to which the Notes are hereby made
subordinate on all money or property held or collected by the Trustee, except, subject to the effect of Section 7.05, funds held in trust herewith for the benefit of the holders of particular Notes. The Trustee’s right to receive payment
of any amounts due under this Section 8.06 shall not be subordinate to any other liability or indebtedness of the Company (even though the Notes may be so subordinated). The obligation of the Company under this Section 8.06 shall survive
the satisfaction and discharge of this Indenture and the earlier resignation or removal or the Trustee. The Company need not pay for any settlement made without its consent, which consent shall not be unreasonably withheld. The indemnification
provided in this Section 8.06 shall extend to the officers, directors, agents and employees of the Trustee and shall survive the termination of this Indenture and the resignation or removal of the Trustee. 
 Without prejudice to any other rights available to the Trustee under applicable law, when the Trustee and its agents and any authenticating agent incur
expenses or render services after an Event of Default specified in Section 7.01(h) occurs, the expenses and the compensation for the services are intended to constitute expenses of administration under any bankruptcy, insolvency or similar
laws. 
 SECTION 8.07. Officers’ Certificate as Evidence. Except as otherwise provided in Section 8.01, whenever in the
administration of the provisions of this Indenture the Trustee shall deem it necessary or desirable that a matter be proved or established prior to taking or omitting any action hereunder, such matter (unless other evidence in respect thereof be
herein specifically prescribed) may, in the absence of gross negligence, willful misconduct or bad faith on the part of the Trustee, be deemed to be conclusively proved and established by an Officers’ Certificate delivered to the Trustee, and
such Officers’ Certificate, in the absence of gross negligence, willful misconduct or bad faith on the part of the Trustee, shall be full warrant to the Trustee for any action taken or omitted by it under the provisions of this Indenture upon
the faith thereof. 
 SECTION 8.08. Conflicting Interests of Trustee. After qualification of this Indenture under the Trust
Indenture Act (if applicable), if the Trustee has or shall acquire a conflicting interest within the meaning of the Trust Indenture Act, the Trustee shall either (a) eliminate such interest within ninety days, (b) apply to the Commission
for permission to continue as Trustee or (c) resign, to the extent and in the manner provided by, and subject to the provisions of, the Trust Indenture Act and this Indenture. 
  

 52 

 SECTION 8.09. Eligibility of Trustee. There shall at all times be a Trustee hereunder which
shall be a Person that is eligible pursuant to the Trust Indenture Act to act as such and has a combined capital and surplus of at least $50,000,000. If such Person publishes reports of condition at least annually, pursuant to law or to the
requirements of any supervising or examining authority, then for the purposes of this Section 8.09, the combined capital and surplus of such Person shall be deemed to be its combined capital and surplus as set forth in its most recent report of
condition so published. If at any time the Trustee shall cease to be eligible in accordance with the provisions of this Section 8.09, it shall resign immediately in the manner and with the effect hereinafter specified in this Article.

 SECTION 8.10. Resignation or Removal of Trustee. 
 (a) The Trustee may at any time resign by giving written notice of such resignation to the Company and by mailing notice thereof to the Noteholders at their addresses as they shall appear on the Note Register. Upon
receiving such notice of resignation, the Company shall promptly appoint a successor trustee by written instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the resigning Trustee
and one copy to the successor trustee. If no successor trustee shall have been so appointed and have accepted appointment within sixty days after the mailing of such notice of resignation to the Noteholders, the resigning Trustee may, upon ten
Business Days’ notice to the Company and the Noteholders, petition any court of competent jurisdiction for the appointment of a successor trustee, or any Noteholder who has been a bona fide holder of a Note or Notes for at least six months may,
subject to the provisions of Section 7.11, on behalf of himself and all others similarly situated, petition any such court for the appointment of a successor trustee. Such court may thereupon, after such notice, if any, as it may deem proper
and prescribe, appoint a successor trustee. 
 (b) In case at any time any of the following shall occur: 
 (i) the Trustee shall fail to comply with Section 8.08 within a reasonable time after written request therefor by the Company or by
any Noteholder who has been a bona fide holder of a Note or Notes for at least six months, or 
 (ii) the Trustee shall cease
to be eligible in accordance with the provisions of Section 8.09 and shall fail to resign after written request therefor by the Company or by any such Noteholder, or 
 (iii) the Trustee shall become incapable of acting, or shall be adjudged a bankrupt or insolvent, or a receiver of the Trustee or of its
property shall be appointed, or any public officer shall take charge or control of the Trustee or of its property or affairs for the purpose of rehabilitation, conservation or liquidation, 
 then, in any such case, the Company may by a Board Resolution remove the Trustee and appoint a successor trustee by written instrument, in duplicate, executed by order
of the Board of 

  

 53 

 
Directors, one copy of which instrument shall be delivered to the Trustee so removed and one copy to the successor trustee, or, subject to the provisions of
Section 7.11, any Noteholder who has been a bona fide holder of a Note or Notes for at least six months may, on behalf of himself and all others similarly situated, petition any court of competent jurisdiction for the removal of the Trustee and
the appointment of a successor trustee. Such court may thereupon, after such notice, if any, as it may deem proper and prescribe, remove the Trustee and appoint a successor trustee. 
 (c) The holders of a majority in aggregate principal amount of the Notes at the time outstanding, as determined in accordance with Section 9.04, may
at any time remove the Trustee and nominate a successor trustee that shall be deemed appointed as successor trustee unless within ten days after notice to the Company of such nomination the Company objects thereto, in which case the Trustee so
removed or any Noteholder, upon the terms and conditions and otherwise as in Section 8.10(a) provided, may petition any court of competent jurisdiction for an appointment of a successor trustee. 
 (d) Any resignation or removal of the Trustee and appointment of a successor trustee pursuant to any of the provisions of this Section 8.10 shall
become effective upon acceptance of appointment by the successor trustee as provided in Section 8.11. 
 SECTION 8.11.
Acceptance by Successor Trustee. Any successor trustee appointed as provided in Section 8.10 shall execute, acknowledge and deliver to the Company and to its predecessor trustee an instrument accepting such appointment hereunder, and
thereupon the resignation or removal of the predecessor trustee shall become effective and such successor trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, duties and obligations of its
predecessor hereunder, with like effect as if originally named as trustee herein; but, nevertheless, on the written request of the Company or of the successor trustee, the trustee ceasing to act shall, upon payment of any amounts then due it
pursuant to the provisions of Section 8.06, execute and deliver an instrument transferring to such successor trustee all the rights and powers of the trustee so ceasing to act. 
 Upon request of any such successor trustee, the Company shall execute any and all instruments in writing for more fully and certainly vesting in and
confirming to such successor trustee all such rights and powers. Any trustee ceasing to act shall, nevertheless, retain a senior claim to which the Notes are hereby made subordinate on all money or property held or collected by such trustee as such,
except for funds held in trust for the benefit of holders of particular Notes, to secure any amounts then due it pursuant to the provisions of Section 8.06. 
 No successor trustee shall accept appointment as provided in this Section 8.11 unless at the time of such acceptance such successor trustee shall be qualified under the provisions of Section 8.08 and be
eligible under the provisions of Section 8.09. 
 Upon acceptance of appointment by a successor trustee as provided in this
Section 8.11, each of the Company and the successor trustee, at the written direction and at the expense of the Company, shall mail or cause to be mailed notice of the succession of such trustee hereunder to the Noteholders at their addresses
as they shall appear on the Note Register. If the Company fails to mail such notice within ten days after acceptance of appointment by the successor trustee, the successor trustee shall cause such notice to be mailed at the expense of the Company.

  

 54 

 SECTION 8.12. Succession by Merger, Etc. Any corporation or other entity into which the
Trustee may be merged or converted or with which it may be consolidated, or any corporation or other entity resulting from any merger, conversion or consolidation to which the Trustee shall be a party, or any corporation or other entity succeeding
to all or substantially all of the corporate trust business of the Trustee (including the administration of this Indenture), shall be the successor to the Trustee hereunder without the execution or filing of any paper or any further act on the part
of any of the parties hereto, provided that in the case of any corporation or other entity succeeding to all or substantially all of the corporate trust business of the Trustee, such corporation or other entity shall be qualified under the
provisions of Section 8.08 and eligible under the provisions of Section 8.09. 
 In case at the time such successor to the Trustee
shall succeed to the trusts created by this Indenture, any of the Notes shall have been authenticated but not delivered, any such successor to the Trustee may adopt the certificate of authentication of any predecessor trustee or authenticating agent
appointed by such predecessor trustee, and deliver such Notes so authenticated; and in case at that time any of the Notes shall not have been authenticated, any successor to the Trustee or an authenticating agent appointed by such successor trustee
may authenticate such Notes either in the name of any predecessor trustee hereunder or in the name of the successor trustee; and in all such cases such certificates shall have the full force which it is anywhere in the Notes or in this Indenture
provided that the certificate of the Trustee shall have; provided, however, that the right to adopt the certificate of authentication of any predecessor Trustee or to authenticate Notes in the name of any predecessor Trustee shall apply only to its
successor or successors by merger, conversion or consolidation. 
 SECTION 8.13. Limitation on Rights of Trustee as Creditor. If
and when the Trustee shall be or become a creditor of the Company (or any other obligor upon the Notes), after qualification under the Trust Indenture Act (if applicable), the Trustee shall be subject to the provisions of the Trust Indenture Act
regarding the collection of the claims against the Company (or any such other obligor). 
 SECTION 8.14. Trustee’s Application
for Instructions from the Company. Any application by the Trustee for written instructions from the Company (other than with regard to any action proposed to be taken or omitted to be taken by the Trustee that affects the rights of the holders
of the Notes under this Indenture) may, at the option of the Trustee, set forth in writing any action proposed to be taken or omitted by the Trustee under this Indenture and the date on and/or after which such action shall be taken or such omission
shall be effective. The Trustee shall not be liable for any action taken by, or omission of, the Trustee in accordance with a proposal included in such application on or after the date specified in such application (which date shall not be less than
three Business Days after the date any officer that the Company has indicated to the Trustee should receive such application actually receives such application, unless any such officer shall have consented in writing to any earlier date), unless,
prior to taking any such action (or the effective date in the case of any omission), the Trustee shall have received written instructions in accordance with this Indenture in response to such application specifying the action to be taken or omitted.

  

 55 

 ARTICLE IX 
 CONCERNING THE NOTEHOLDERS 
 SECTION 9.01. Action by Noteholders. Whenever in this
Indenture it is provided that the holders of a specified percentage in aggregate principal amount of the Notes may take any action (including the making of any demand or request, the giving of any notice, consent or waiver or the taking of any other
action), the fact that at the time of taking any such action, the holders of such specified percentage have joined therein may be evidenced (a) by any instrument or any number of instruments of similar tenor executed by Noteholders in person or
by agent or proxy appointed in writing, or (b) by the record of the Noteholders voting in favor thereof at any meeting of Noteholders duly called and held in accordance with the provisions of Article 10, or (c) by a combination of such
instrument or instruments and any such record of such a meeting of Noteholders. Whenever the Company or the Trustee solicits the taking of any action by the holders of the Notes, the Company or the Trustee may, but shall not be required to, fix in
advance of such solicitation, a date as the record date for determining Noteholders entitled to take such action. The record date if one is selected shall be not more than fifteen days prior to the date of commencement of solicitation of such
action. 
 SECTION 9.02. Proof of Execution by Noteholders. Subject to the provisions of Section 8.01, Section 8.02 and
Section 10.05, proof of the execution of any instrument by a Noteholder or its agent or proxy shall be sufficient if made in accordance with such reasonable rules and regulations as may be prescribed by the Trustee or in such manner as shall be
satisfactory to the Trustee. The holding of Notes shall be proved by the Note Register or by a certificate of the Note Registrar. The record of any Noteholders’ meeting shall be proved in the manner provided in Section 10.06. 

SECTION 9.03. Who Are Deemed Absolute Owners. The Company, the Trustee, any authenticating agent, any Paying Agent, any Conversion Agent
and any Note Registrar may deem the Person in whose name a Note shall be registered upon the Note Register to be, and may treat it as, the absolute owner of such Note (whether or not such Note shall be overdue and notwithstanding any notation of
ownership or other writing thereon made by any Person other than the Company or any Note Registrar) for the purpose of receiving payment of or on account of the principal of (including the payment of the Redemption Price, Repurchase Price or
Fundamental Change Repurchase Price, as applicable), and (subject to Section 2.03) accrued and unpaid interest and accrued and unpaid Additional Interest, if any, on such Note, for conversion of such Note and for all other purposes; and neither
the Company nor the Trustee nor any Paying Agent nor any Conversion Agent nor any Note Registrar shall be affected by any notice to the contrary. All such payments so made to any holder for the time being, or upon its order, shall be valid and, to
the extent of the sum or sums so paid, effectual to satisfy and discharge the liability for monies payable upon any such Note. Notwithstanding anything to the contrary in this Indenture or the Notes following an Event of Default, any holder of a
beneficial interest in a Global Note may directly enforce against the Company, without the consent, solicitation, proxy, authorization or any other action of the Depositary or any other Person, such holder’s right to exchange such beneficial
interest for a Note in certificated form in accordance with the provisions of this Indenture. 
  

 56 

 SECTION 9.04. Company-Owned Notes Disregarded. In determining whether the holders of the
requisite aggregate principal amount of Notes have concurred in any direction, consent, waiver or other action under this Indenture, Notes that are owned by the Company or by any Person directly or indirectly controlling or controlled by or under
direct or indirect common control with the Company shall be disregarded and deemed not to be outstanding for the purpose of any such determination; provided that for the purposes of determining whether the Trustee shall be protected in relying on
any such direction, consent, waiver or other action only Notes that a Responsible Officer knows are so owned shall be so disregarded. Notes so owned that have been pledged in good faith may be regarded as outstanding for the purposes of this
Section 9.04 if the pledgee shall establish to the satisfaction of the Trustee the pledgee’s right to so act with respect to such Notes and that the pledgee is not the Company or a Person directly or indirectly controlling or controlled by
or under direct or indirect common control with the Company. In the case of a dispute as to such right, any decision by the Trustee taken upon the advice of counsel shall be full protection to the Trustee. Upon request of the Trustee, the Company
shall furnish to the Trustee promptly an Officers’ Certificate listing and identifying all Notes, if any, known by the Company to be owned or held by or for the account of any of the above described Persons; and, subject to Section 8.01,
the Trustee shall be entitled to accept such Officers’ Certificate as conclusive evidence of the facts therein set forth and of the fact that all Notes not listed therein are outstanding for the purpose of any such determination. 
 SECTION 9.05. Revocation of Consents; Future Noteholders Bound. At any time prior to (but not after) the evidencing to the Trustee, as
provided in Section 9.01, of the taking of any action by the holders of the percentage in aggregate principal amount of the Notes specified in this Indenture in connection with such action, any holder of a Note that is shown by the evidence to
be included in the Notes the holders of which have consented to such action may, by filing written notice with the Trustee at its Corporate Trust Office and upon proof of holding as provided in Section 9.02, revoke such action so far as
concerns such Note. Except as aforesaid, any such action taken by the holder of any Note shall be conclusive and binding upon such holder and upon all future holders and owners of such Note and of any Notes issued in exchange or substitution
therefor or upon registration of transfer thereof, irrespective of whether any notation in regard thereto is made upon such Note or any Note issued in exchange or substitution therefor or upon registration of transfer thereof. 
 ARTICLE X 
 NOTEHOLDERS’
MEETINGS 
 SECTION 10.01. Purpose of Meetings. A meeting of Noteholders may be called at any time and from time to time
pursuant to the provisions of this Article 10 for any of the following purposes: 
 (a) to give any notice to the Company or to the Trustee or
to give any directions to the Trustee permitted under this Indenture, or to consent to the waiving of any Default or Event of Default hereunder and its consequences, or to take any other action authorized to be taken by Noteholders pursuant to any
of the provisions of Article 7; 
  

 57 

 (b) to remove the Trustee and nominate a successor trustee pursuant to the provisions of Article 8;

 (c) to consent to the execution of an indenture or indentures supplemental hereto pursuant to the provisions of Section 11.02; or

 (d) to take any other action authorized to be taken by or on behalf of the holders of any specified aggregate principal amount of the
Notes under any other provision of this Indenture or under applicable law. 
 SECTION 10.02. Call of Meetings by Trustee. The
Trustee may at any time call a meeting of Noteholders to take any action specified in Section 10.01, to be held at such time and at such place as the Trustee shall determine. Notice of every meeting of the Noteholders, setting forth the time
and the place of such meeting and in general terms the action proposed to be taken at such meeting and the establishment of any record date pursuant to Section 9.01, shall be mailed to holders of such Notes at their addresses as they shall
appear on the Note Register. Such notice shall also be mailed to the Company. Such notices shall be mailed not less than twenty nor more than ninety days prior to the date fixed for the meeting. 
 Any meeting of Noteholders shall be valid without notice if the holders of all Notes then outstanding are present in person or by proxy or if notice is
waived before or after the meeting by the holders of all Notes outstanding, and if the Company and the Trustee are either present by duly authorized representatives or have, before or after the meeting, waived notice. 
 SECTION 10.03. Call of Meetings by Company or Noteholders. In case at any time the Company, pursuant to a Board Resolution, or the holders of
at least 10% in aggregate principal amount of the Notes then outstanding (for the avoidance of doubt, excluding those Notes identified in Section 9.04), shall have requested the Trustee to call a meeting of Noteholders, by written request
setting forth in reasonable detail the action proposed to be taken at the meeting, and the Trustee shall not have mailed the notice of such meeting within twenty days after receipt of such request, then the Company or such Noteholders may determine
the time and the place for such meeting and may call such meeting to take any action authorized in Section 10.01, by mailing notice thereof as provided in Section 10.02. 
 SECTION 10.04. Qualifications for Voting. To be entitled to vote at any meeting of Noteholders a Person shall (a) be a holder of one or
more Notes on the record date pertaining to such meeting or (b) be a Person appointed by an instrument in writing as proxy by a holder of one or more Notes on the record date pertaining to such meeting. The only Persons who shall be entitled to
be present or to speak at any meeting of Noteholders shall be the Persons entitled to vote at such meeting and their counsel and any representatives of the Trustee and its counsel and any representatives of the Company and its counsel. 

SECTION 10.05. Regulations. Notwithstanding any other provisions of this Indenture, the Trustee may make such reasonable regulations as it
may deem advisable for any meeting of Noteholders, in regard to proof of the holding of Notes and of the appointment of proxies, and in regard to the appointment and duties of inspectors of votes, the submission and examination of proxies,
certificates and other evidence of the right to vote, and such other matters concerning the conduct of the meeting as it shall think fit. 
  

 58 

 The Trustee shall, by an instrument in writing, appoint a temporary chairman of the meeting, unless the
meeting shall have been called by the Company or by Noteholders as provided in Section 10.03, in which case the Company or the Noteholders calling the meeting, as the case may be, shall in like manner appoint a temporary chairman. A permanent
chairman and a permanent secretary of the meeting shall be elected by vote of the holders of a majority in principal amount of the Notes represented at the meeting and entitled to vote at the meeting. 
 Subject to the provisions of Section 9.04, at any meeting of Noteholders each Noteholder or proxyholder shall be entitled to one vote for each
$1,000 principal amount of Notes held or represented by him; provided, however, that no vote shall be cast or counted at any meeting in respect of any Note challenged as not outstanding and ruled by the chairman of the meeting to be not outstanding.
The chairman of the meeting shall have no right to vote other than by virtue of Notes held by it or instruments in writing as aforesaid duly designating it as the proxy to vote on behalf of other Noteholders. Any meeting of Noteholders duly called
pursuant to the provisions of Section 10.02 or Section 10.03 may be adjourned from time to time by the holders of a majority of the aggregate principal amount of Notes represented at the meeting, whether or not constituting a quorum, and
the meeting may be held as so adjourned without further notice. 
 SECTION 10.06. Voting. The vote upon any resolution submitted
to any meeting of Noteholders shall be by written ballot on which shall be subscribed the signatures of the Noteholders or of their representatives by proxy and the outstanding principal amount of the Notes held or represented by them. The permanent
chairman of the meeting shall appoint two inspectors of votes who shall count all votes cast at the meeting for or against any resolution and who shall make and file with the secretary of the meeting their verified written reports in duplicate of
all votes cast at the meeting. A record in duplicate of the proceedings of each meeting of Noteholders shall be prepared by the secretary of the meeting and there shall be attached to said record the original reports of the inspectors of votes on
any vote by ballot taken thereat and affidavits by one or more Persons having knowledge of the facts setting forth a copy of the notice of the meeting and showing that said notice was mailed as provided in Section 10.02. The record shall show
the principal amount of the Notes voting in favor of or against any resolution. The record shall be signed and verified by the affidavits of the permanent chairman and secretary of the meeting and one of the duplicates shall be delivered to the
Company and the other to the Trustee to be preserved by the Trustee, the latter to have attached thereto the ballots voted at the meeting. 
 Any record so signed and verified shall be conclusive evidence of the matters therein stated. 
 SECTION 10.07. No Delay of
Rights by Meeting. Nothing contained in this Article 10 shall be deemed or construed to authorize or permit, by reason of any call of a meeting of Noteholders or any rights expressly or impliedly conferred hereunder to make such call, any
hindrance or delay in the exercise of any right or rights conferred upon or reserved to the Trustee or to the Noteholders under any of the provisions of this Indenture or of the Notes. 
  

 59 

 ARTICLE XI 
 SUPPLEMENTAL INDENTURES 
 SECTION 11.01. Supplemental Indentures Without Consent of
Noteholders. The Company and the Trustee, at the Company’s expense, may from time to time and at any time enter into an indenture or indentures supplemental hereto for one or more of the following purposes: 
 (a) to cure any ambiguity, omission, defect or inconsistency in this Indenture or the Notes; 
 (b) to conform the terms of the Indenture or the Notes to the description thereof in the Offering Memorandum; 
 (c) to provide for the assumption by a Successor Company of the obligations of the Company under this Indenture pursuant to Article 12;

 (d) to add guarantees with respect to the Notes; 
 (e) to secure the Notes; 
 (f) to add to the covenants of the Company such further covenants, restrictions or conditions for the benefit of the Noteholders or surrender any right or power conferred upon the Company; 
 (g) to make any change that does not materially adversely affect the rights of any holder; 
 (h) to appoint a successor Trustee with respect to the Notes; or 
 (i) to comply with any requirements of the Commission in connection with the qualification of this Indenture under the Trust Indenture
Act. 
 Upon the written request of the Company, the Trustee is hereby authorized to join with the Company in the execution of any such
supplemental indenture, to make any further appropriate agreements and stipulations that may be therein contained, but the Trustee shall not be obligated to, but may in its discretion, enter into any supplemental indenture that affects the
Trustee’s own rights, duties or immunities under this Indenture or otherwise. 
 Any supplemental indenture authorized by the provisions
of this Section 11.01 may be executed by the Company and the Trustee without the consent of the holders of any of the Notes at the time outstanding, notwithstanding any of the provisions of Section 11.02. 
 SECTION 11.02. Supplemental Indentures With Consent of Noteholders. With the consent (evidenced as provided in Article 9) of the holders of
at least a majority in aggregate principal amount of the Notes at the time outstanding (determined in accordance with Article 9 and including, without limitation, consents obtained in connection with a purchase of, or tender offer or exchange offer
for, Notes), the Company, when authorized by the resolutions of the 

  

 60 

 
Board of Directors, and the Trustee, at the Company’s expense, may from time to time and at any time enter into an indenture or indentures supplemental
hereto for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Indenture or any supplemental indenture or of modifying in any manner the rights of the holders of the Notes or waiving any
past default; provided, however, that no such supplemental indenture shall: 
 (a) reduce the percentage in
aggregate principal amount of Notes outstanding necessary to modify or amend this Indenture or to waive any past Default or Event of Default; 
 (b) reduce the rate or extend the stated time for payment of interest, including Additional Interest, on any Note; 
 (c) reduce the principal of, or extend the Maturity Date of, any Note; 
 (d) make any change
that impairs or adversely affects the conversion rights of any Notes; 
 (e) reduce the Redemption Price, Repurchase Price or
Fundamental Change Repurchase Price of any Note or amend or modify in any manner adverse to the holders of the Notes the Company’s obligation to make such payments, whether through an amendment or waiver of provisions in the covenants,
definitions or otherwise; 
 (f) make any Note payable in a currency other than that stated in the Note; 
 (g) change the ranking of the Notes; 
 (h) impair the right of any holder to receive payment of principal of and interest, including Additional Interest, if any, on such holder’s Notes on or after the due dates therefor or to institute suit for the
enforcement of any payment on or with respect to such holder’s Note; 
 (i) make any change in this Article 11 that
requires each holder’s consent or in the waiver provisions in Section 7.01 or Section 7.09; or 
 (j) reduce
the quorum or voting requirements under this Indenture, 
 in each case without the consent of each holder of an outstanding Note affected. 
 Upon the written request of the Company, and upon the filing with the Trustee of evidence of the consent of Noteholders as aforesaid and subject to
Section 11.05, the Trustee shall join with the Company in the execution of such supplemental indenture unless such supplemental indenture affects the Trustee’s own rights, duties or immunities under this Indenture or otherwise, in which
case the Trustee may in its discretion, but shall not be obligated to, enter into such supplemental indenture. 
 It shall not be necessary
for the consent of the Noteholders under this Section 11.02 to approve the particular form of any proposed supplemental indenture, but it shall be 

  

 61 

 
sufficient if such consent shall approve the substance thereof. After an amendment under this Indenture becomes effective, the Company shall mail to the
holders a notice briefly describing such amendment. However, the failure to give such notice to all the holders, or any defect in the notice, will not impair or affect the validity of the amendment. 
 SECTION 11.03. Effect of Supplemental Indentures. Any supplemental indenture executed pursuant to the provisions of this Article 11 shall
comply with the Trust Indenture Act, as then in effect; provided that this Section 11.03 shall not require such supplemental indenture to be qualified under the Trust Indenture Act prior to the time such qualification is in fact required under
the terms of the Trust Indenture Act or this Indenture has been qualified under the Trust Indenture Act, nor shall any such qualification constitute any admission or acknowledgment by any party to such supplemental indenture that any such
qualification is required prior to the time such qualification is in fact required under the terms of the Trust Indenture Act or this Indenture has been qualified under the Trust Indenture Act. Upon the execution of any supplemental indenture
pursuant to the provisions of this Article 11, this Indenture shall be and be deemed to be modified and amended in accordance therewith and the respective rights, limitation of rights, obligations, duties and immunities under this Indenture of the
Trustee, the Company and the Noteholders shall thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments and all the terms and conditions of any such supplemental indenture shall be and
be deemed to be part of the terms and conditions of this Indenture for any and all purposes. 
 SECTION 11.04. Notation on Notes.
Notes authenticated and delivered after the execution of any supplemental indenture pursuant to the provisions of this Article 11 may, at the Company’s expense, bear a notation as to any matter provided for in such supplemental indenture. If
the Company shall so determine, new Notes so modified as to conform, in the opinion of the Board of Directors, to any modification of this Indenture contained in any such supplemental indenture may, at the Company’s expense, be prepared and
executed by the Company, authenticated by the Trustee (or an authenticating agent duly appointed by the Trustee pursuant to Section 17.10) and delivered in exchange for the Notes then outstanding, upon surrender of such Notes then outstanding.

 SECTION 11.05. Evidence of Compliance of Supplemental Indenture to Be Furnished to Trustee. In addition to the documents
required by Section 17.05, the Trustee shall receive an Officers’ Certificate and an Opinion of Counsel as conclusive evidence that any supplemental indenture executed pursuant hereto complies with the requirements of this Article 11 and
is permitted or authorized by the Indenture. 
 ARTICLE XII 
 CONSOLIDATION, MERGER, SALE, CONVEYANCE AND LEASE 
 SECTION 12.01.
Company May Consolidate, Etc. on Certain Terms. Subject to the provisions of Section 12.02, the Company shall not consolidate with, merge with or into, or convey, transfer or lease all or substantially all of its properties and assets to
another Person, unless: 
 (a) the resulting, surviving or transferee Person (the “Successor Company”), if not the
Company, shall be a corporation organized and existing under the laws of the United States of America, any State thereof or the District of Columbia, and the Successor Company (if not the Company) shall expressly assume, by supplemental indenture,
executed and delivered to the Trustee, in form satisfactory to the Trustee, all the obligations of the Company under the Notes and this Indenture; and 
  

 62 

 (b) immediately after giving effect to such transaction, no Default or Event of Default
shall have occurred and be continuing under this Indenture. 
 Upon any such consolidation, merger, conveyance, transfer or lease the
Successor Company (if not the Company) shall succeed to, and may exercise every right and power of, the Company under this Indenture. 
 For
purposes of this Section 12.01, the conveyance, transfer or lease of all or substantially all of the properties and assets of one or more Subsidiaries of the Company to another Person, which properties and assets, if held by the Company instead
of such Subsidiaries, would constitute all or substantially all of the properties and assets of the Company, shall be deemed to be the transfer of all or substantially all of the properties and assets of the Company to another Person. 
 SECTION 12.02. Successor Corporation to Be Substituted. In case of any such consolidation, merger, conveyance, transfer or lease and upon the
assumption by the Successor Company, by supplemental indenture, executed and delivered to the Trustee and satisfactory in form to the Trustee, of the due and punctual payment of the principal of (including any Redemption Price, Repurchase Price or
Fundamental Change Repurchase Price, as applicable), accrued and unpaid interest and accrued and unpaid Additional Interest, if any, on all of the Notes, the due and punctual delivery or payment, as the case may be, of any consideration due upon
conversion of the Notes and the due and punctual performance of all of the covenants and conditions of this Indenture to be performed by the Company, such Successor Company shall succeed to and be substituted for the Company, with the same effect as
if it had been named herein as the party of the first part. Such Successor Company thereupon may cause to be signed, and may issue in its own name any or all of the Notes issuable hereunder which theretofore shall not have been signed by the Company
and delivered to the Trustee; and, upon the order of such Successor Company instead of the Company and subject to all the terms, conditions and limitations in this Indenture prescribed, the Trustee shall authenticate and shall deliver, or cause to
be authenticated and delivered, any Notes that such Successor Company thereafter shall cause to be signed and delivered to the Trustee for that purpose. All the Notes so issued shall in all respects have the same legal rank and benefit under this
Indenture as the Notes theretofore or thereafter issued in accordance with the terms of this Indenture as though all of such Notes had been issued at the date of the execution hereof. In the event of any such consolidation, merger, conveyance or
transfer (but not in the case of a lease), the Person named as the “Company” in the first paragraph of this Indenture or any successor that shall thereafter have become such in the manner prescribed in this Article 12 may be dissolved,
wound up and liquidated at any time thereafter and, except in the case of a lease, such Person shall be released from its liabilities as obligor and maker of the Notes and from its obligations under this Indenture. 
  

 63 

 In case of any such consolidation, merger, conveyance, transfer or lease, such changes in phraseology and
form (but not in substance) may be made in the Notes thereafter to be issued as may be appropriate. 
 SECTION 12.03. Opinion of
Counsel to Be Given to Trustee. The Company shall not effect any merger, consolidation, conveyance, transfer or lease referred to in Section 12.01 unless the Trustee shall receive an Officers’ Certificate and an Opinion of Counsel as
conclusive evidence that any such consolidation, merger, conveyance, transfer or lease and any such assumption and, if a supplemental indenture is required in connection with such transaction, such supplemental indenture, complies with the
provisions of this Article 12. 
 ARTICLE XIII 
 IMMUNITY OF INCORPORATORS, STOCKHOLDERS, 
 OFFICERS AND DIRECTORS 
 SECTION 13.01. Indenture and Notes Solely Corporate Obligations. No recourse for the payment of the principal of (including any Redemption
Price, Repurchase Price or Fundamental Change Repurchase Price, as applicable) or accrued and unpaid interest and accrued and unpaid Additional Interest, if any, on any Note, nor for any claim based thereon or otherwise in respect thereof, and no
recourse under or upon any obligation, covenant or agreement of the Company in this Indenture or in any supplemental indenture or in any Note, nor because of the creation of any indebtedness represented thereby, shall be had against any
incorporator, stockholder, employee, agent, officer or director or Subsidiary, as such, past, present or future, of the Company or of any successor corporation or entity, either directly or through the Company or any successor corporation or entity,
whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise; it being expressly understood that all such liability is hereby expressly waived and released as a condition of, and as a
consideration for, the execution of this Indenture and the issuance of the Notes. 
  

 64 

 ARTICLE XIV 
 [INTENTIONALLY OMITTED] 
 ARTICLE XV 
 CONVERSION OF NOTES 
 SECTION 15.01. Conversion Privilege.

 (a) Upon compliance with the provisions of this Article 15, a Noteholder shall have the right, at such holder’s option, to convert all
or any portion (if the portion to be converted is $1,000 principal amount or an integral multiple thereof) of such Note (i) subject to satisfaction of the conditions set forth in Section 15.01(b), at any time prior to March 15, 2028
under the circumstances and during the periods set forth in Section 15.01(b), and (ii) irrespective of the conditions set forth in Section 15.01(b), on or after March 15, 2028 and prior to the close of business on the Business
Day immediately preceding the Maturity Date, in each case, at an initial conversion rate (the “Conversion Rate”) of 108.0847 shares of Common Stock (subject to adjustment as provided in Section 15.04 of this Indenture) per $1,000
principal amount of Notes (subject to the settlement provisions of Section 15.02, the “Conversion Obligation”). 
 (b)(i)
Prior to the Business Day immediately preceding the Maturity Date, the Notes may be surrendered for conversion during the five Business Day period immediately after any five consecutive Trading Day period (the “Measurement Period”) in
which the Trading Price per $1,000 principal amount of Notes for each day of such Measurement Period was less than 98% of the product of the then-applicable Conversion Rate on such Trading Day and the Last Reported Sale Price of the Common Stock on
such Trading Day. The Company shall have no obligation to determine the Trading Price of the Notes unless a Noteholder provides the Company and the Trustee with reasonable evidence that the Trading Price per $1,000 principal amount of the Notes
would be less than 98% of the product of the then-applicable Conversion Rate and the Last Reported Sale Price of the Common Stock at such time, at which time the Company will determine, or will instruct the Trustee to determine, the Trading Price of
the Notes beginning on the next Trading Day and on each successive Trading Day until the Trading Price per Note is greater than or equal to 98% of the product of the then-applicable Conversion Rate and the Last Reported Sale Price of the Common
Stock on such Trading Day. If the Company does not determine the Trading Price of the Notes as provided in the preceding sentence, then the Trading Price per $1,000 principal amount of Notes will be deemed to be less than 98% of the product of the
Last Reported Sale Price of the Common Stock and the then-applicable Conversion Rate. If the Trading Price condition set forth above has been met, the Company will so notify the Noteholders, the Trustee and the Conversion Agent and issue a press
release (and make the press release available on the Company’s website) announcing the satisfaction of the condition. If, at any time after the Trading Price condition set forth above has been met, the Trading Price per $1,000 principal amount
of Notes is greater than 98% of the product of the then-applicable Conversion Rate and the Last Reported Sale Price of the Common Stock on such Trading Day, the Company will so notify the holders of the Notes, the Trustee and the Conversion Agent.

  

 65 

 (ii) In the event that the Company elects to: 
 (A) distribute to all or substantially all holders of its Common Stock any rights, options or warrants entitling them, for a period of not
more than sixty calendar days after the record date for such distribution, to subscribe for or purchase its Common Stock, at a price per share less than the Last Reported Sale Price of the Common Stock for the Trading Day immediately preceding the
declaration date for such distribution; or 
 (B) distribute to all or substantially all holders of its Common Stock the
Company’s assets, debt securities, or rights to purchase securities of the Company, which distribution has a per share value (as determined by the Board of Directors) exceeding 10% of the Last Reported Sale Price of the Common Stock on the
Trading Day immediately preceding the date of declaration for such distribution, 
 then, in each case, the Company shall notify all holders of the Notes,
the Trustee and the Conversion Agent not less than fifty Business Days prior to the Ex-Dividend Date for such distribution. Once the Company has given such notice, the Notes may be surrendered for conversion at any time until the earlier of
(1) the close of business on the Business Day immediately prior to such Ex-Dividend Date and (2) the Company’s announcement that such distribution will not take place, even if the Notes are not otherwise convertible at such time. No
Noteholder may exercise this right to convert if the Noteholder otherwise may participate in the distribution without conversion (based upon the then-applicable Conversion Rate and upon the same terms as holders of the Company’s Common Stock).

 (iii) In the event of a Fundamental Change (determined without regard to the proviso to such definition) or a Make-Whole Fundamental
Change, a Noteholder may surrender Notes for conversion at any time from and after the forty-fifth Business Day prior to the anticipated effective date of such Fundamental Change or Make-Whole Fundamental Change, as the case may be, until the
Business Day immediately preceding the Fundamental Change Repurchase Date corresponding to such Fundamental Change (or, in the case of a Make-Whole Fundamental Change that does not constitute a Fundamental Change by virtue of the parenthetical in
the definition of Make-Whole Fundamental Change, the fortieth Trading Day immediately following the effective date of such Make-Whole Fundamental Change). The Company shall give notice of the anticipated effective date of any Fundamental Change or
Make-Whole Fundamental Change, as the case may be, as soon as practicable after the Company first determines the anticipated effective date of such Fundamental Change or Make-Whole Fundamental Change, as the case may be. The Company shall use
commercially reasonable efforts to make such determination in time to give such notice no later than fifty Business Days in advance of such anticipated effective date. 
 (iv) Prior to the Business Day immediately preceding the Maturity Date, the Notes may be surrendered for conversion in any Fiscal Quarter after the Fiscal Quarter ending September 30, 2008, and only during such
Fiscal Quarter, if the Last Reported Sale Price of the Common Stock for at least twenty Trading Days in a period of thirty consecutive Trading Days ending on, and including, the last Trading Day of the immediately preceding Fiscal Quarter is equal
to or more than 130% of the then-applicable Conversion Price on the last day of such preceding Fiscal Quarter (such price, the “Conversion Trigger Price”). The Company shall promptly determine, at the beginning of each Fiscal Quarter
commencing after September 30, 2008, whether the Notes may be surrendered for conversion in accordance with this clause (iv) and shall promptly notify the Trustee. 
  

 66 

 (v) In the event that the Company calls the Notes for redemption pursuant to Article 3 hereof, the
Notes may be surrendered for conversion at any time prior to the close of business on the Business Day immediately preceding the Redemption Date, whether or not the Notes are otherwise convertible at such time. 
 SECTION 15.02. Conversion Procedure. 
 (a) [Reserved] 
 (b) Subject to this Section 15.02, upon any conversion of any Note, the Company shall deliver to converting
Noteholders, in respect of each $1,000 principal amount of Notes being converted, solely cash, solely shares of Common Stock or a combination of cash and Common Stock (the “Settlement Amount”), at its election, as set forth in this
Section 15.02. 
 (i) All conversions on or after March 15, 2028 will be settled using the same Settlement Method.

 (ii) Prior to March 15, 2028, the Company will elect (or be deemed to have elected) the same Settlement Method for all
conversions occurring on any given Conversion Date. Except for any conversions that occur (i) during the period between a Redemption Notice and the related Redemption Date or (ii) on or after March 15, 2028, the Company need not elect
the same Settlement Method with respect to conversions that occur on different Trading Days. 
 (iii) If, in respect of any
Conversion Date (or the period beginning on, and including, March 15, 2028 and ending on, and including, the Business Day immediately preceding the Maturity Date, as the case may be), the Company elects to deliver a notice (the “Settlement
Notice”) of the relevant Settlement Method in respect of such Conversion Date (or such period, as the case may be), the Company, through the Trustee, shall deliver such Settlement Notice to converting Noteholders no later than the second
Business Day immediately following the relevant Conversion Date. Such Settlement Notice shall specify whether the Company shall satisfy its Conversion Obligation by (A) delivering solely shares of Common Stock, (B) paying solely cash or
(C) paying and delivering, as the case may be, a combination of cash and shares of Common Stock. In the case of an election to pay and deliver, as the case may be, a combination of cash and shares of Common Stock, the relevant Settlement Notice
shall indicate the Specified Dollar Amount. If the Company does not deliver a Settlement Notice, the Company will be deemed to have elected to deliver a combination of cash and shares of Common Stock in respect of its Conversion Obligation, and the
Specified Dollar Amount shall be deemed to be equal to $1,000. If the Company delivers a Settlement Notice electing to pay and deliver, as the case may be, a combination of cash and shares of Common Stock in respect of its Conversion Obligation but
does not indicate a Specified Dollar Amount in such Settlement Notice, the Specified Dollar Amount shall be deemed to be equal to $1,000. 
  

 67 

 (iv) The Settlement Amount in respect of any conversion of Notes shall be computed as
follows: 
 (A) if the Company elects to satisfy its Conversion Obligation in respect of such conversion by delivering solely
Common Stock, the Company will deliver to the converting Noteholder a number of shares of Common Stock equal to (1)(i) the aggregate principal amount of Notes to be converted, divided by (ii) $1,000, multiplied by (2) the
then-applicable Conversion Rate; 
 (B) if the Company elects to satisfy its Conversion Obligation in respect of such
conversion by paying solely cash, the Company shall pay to the converting Noteholder, cash in an amount per $1,000 principal amount of Notes being converted equal to the sum of the Daily Conversion Values for each of the forty consecutive Trading
Days during the related Cash Settlement Averaging Period; and 
 (C) if the Company elects to satisfy its Conversion
Obligation in respect of such conversion by paying and delivering, as the case may be, a combination of cash and shares of Common Stock, if any, the Company shall pay and deliver to the converting Noteholder, as the case may be, in respect of each
$1,000 principal amount of Notes being converted, a Settlement Amount equal to the sum of the Daily Settlement Amounts for each of the forty consecutive Trading Days during the related Cash Settlement Averaging Period. 
 (v) The Company will also deliver to each converting Noteholder cash in lieu of fractional shares of Common Stock as set forth pursuant to
clause (k) below. 
 (vi) The Daily Settlement Amounts (if applicable) and the Daily Conversion Values (if applicable)
shall be determined by the Company promptly following the last day of the Cash Settlement Averaging Period. Promptly after such determination of the Daily Settlement Amounts or the Daily Conversion Values, as the case may be, and the amount of cash
deliverable in lieu of fractional shares (if any), the Company shall notify the Trustee and the Conversion Agent of the Daily Settlement Amounts or the Daily Conversion Values, as the case may be, and the amount of cash deliverable in lieu of
fractional shares of Common Stock. The Trustee and the Conversion Agent shall have no responsibility for any such determination. 
 (c)
[Reserved] 
 (d) Before any holder of a Note shall be entitled to convert the same as set forth above, such holder shall (i) in the
case of a Global Note, comply with the procedures of the Depositary in effect at that time and, if required, pay funds equal to the amount of interest and Additional Interest, if any, payable on the next Interest Payment Date to which such holder is
not entitled as set forth in Section 15.02(j) and, if required, all transfer or similar taxes, if any, and 

  

 68 

 
(ii) in the case of a Note issued in certificated form, (1) complete and manually sign and deliver an irrevocable notice to the Conversion Agent in the
form on the reverse of such certificated Note (or a facsimile thereof) (Exhibit B hereto) (a “Notice of Conversion”) at the office of the Conversion Agent and shall state in writing therein the principal amount of Notes to be converted and
the name or names (with addresses) in which such holder wishes the certificate or certificates for any shares of Common Stock, if any, to be delivered upon settlement of the Conversion Obligation to be registered, (2) surrender such Notes, duly
endorsed to the Company or in blank (and accompanied by appropriate endorsement and transfer documents), at the office of the Conversion Agent, (3) if required, pay funds equal to interest (including Additional Interest, if any) payable on the
next Interest Payment Date to which such holder is not entitled as set forth in Section 15.02(j), (4) if required, furnish appropriate endorsements and transfer documents, and (5) if required, pay all transfer or similar taxes, if any
as set forth in Section 15.02(g). The Trustee (and if different, the relevant Conversion Agent) shall notify the Company of any conversion pursuant to this Article 15 on the date of such conversion. No Notice of Conversion with respect to any
Notes may be surrendered by a holder thereof if such holder has also delivered a Fundamental Change Repurchase Notice to the Company in respect of such Notes and not validly withdrawn such Fundamental Change Repurchase Notice in accordance with
Section 16.05 or if such holder has delivered a Repurchase Notice to the Company in respect of such Notes and not validly withdrawn such Repurchase Notice in accordance with Section 16.02, unless the Company defaults in the payment of the
Fundamental Change Repurchase Price or the Repurchase Price. 
 If more than one Note shall be surrendered for conversion at one time by the
same holder, the Conversion Obligation with respect to such Notes, if any, that shall be payable upon conversion shall be computed on the basis of the aggregate principal amount of the Notes (or specified portions thereof to the extent permitted
thereby) so surrendered. 
 (e) A Note shall be deemed to have been converted immediately prior to the close of business on the date (the
“Conversion Date”) that the holder has complied with the requirements set forth in clause (d) of this Section 15.02. The Company generally will pay and deliver, as the case may be, the cash and/or shares of Common Stock due in
respect of its Conversion Obligation by the third Trading Day immediately following the last Trading Day of the Cash Settlement Averaging Period; provided, however, that , if: (i) the Company elects to satisfy its Conversion
Obligation solely in shares of Common Stock; or (ii) prior to the Conversion Date for any converted Notes, the Common Stock has been replaced by Reference Property consisting solely of cash (pursuant to the provisions described in
Section 15.06), the Company will deliver such shares or cash, as applicable, on the third Trading Day immediately following the relevant Conversion Date. Notwithstanding the foregoing, if any information required in order to calculate the
conversion consideration deliverable will not be available as of the third Trading Day following the last Trading Day of the Cash Settlement Averaging Period or the relevant Conversion Date, as the case may be, the Company will deliver such
conversion consideration on the third Trading Day after the earliest Trading Day on which such calculation can be made. If any shares of Common Stock are due to converting Noteholders, the Company shall issue or cause to be issued, and deliver to
the Conversion Agent or to such Noteholder, or such Noteholder’s nominee or nominees, certificates or a book-entry transfer through the Depositary for the number of full shares of Common Stock to which such Noteholder shall be entitled in
satisfaction of such Conversion Obligation. 
  

 69 

 (f) In case any Note shall be surrendered for partial conversion, the Company shall execute and the
Trustee shall authenticate and deliver to or upon the written order of the holder of the Note so surrendered, without charge to such holder, a new Note or Notes in authorized denominations in an aggregate principal amount equal to the unconverted
portion of the surrendered Note. 
 (g) If a holder submits a Note for conversion, the Company shall pay all stamp and other duties, if any,
that may be imposed by the United States or any political subdivision thereof or taxing authority thereof or therein with respect to the issuance of shares of Common Stock, if any, upon the conversion. However, the holder shall pay any such tax that
is due because the holder requests any shares of Common Stock to be issued in a name other than the holder’s name. The Conversion Agent may refuse to deliver the certificates representing the shares of Common Stock being issued in a name other
than the holder’s name until the Trustee receives a sum sufficient to pay any tax that will be due because the shares are to be issued in a name other than the holder’s name. Nothing herein shall preclude any tax withholding required by
law or regulations. 
 (h) Upon the conversion of an interest in a Global Note, the Trustee, or the Custodian at the direction of the
Trustee, shall make a notation on such Global Note as to the reduction in the principal amount represented thereby. The Company shall notify the Trustee in writing of any conversion of Notes effected through any Conversion Agent other than the
Trustee. 
 (i) Upon conversion, a Noteholder shall not receive any additional cash payment for accrued and unpaid interest and Additional
Interest, if any, except as set forth below. The Company’s settlement of the Conversion Obligations pursuant to Section 15.02 shall be deemed to satisfy its obligation to pay the principal amount of the Note and accrued and unpaid interest
and Additional Interest, if any, to, but not including, the Conversion Date. As a result, accrued and unpaid interest and Additional Interest, if any, to, but not including, the Conversion Date shall be deemed to be paid in full rather than
cancelled, extinguished or forfeited. Notwithstanding the preceding sentences of this Section 15.02(i), if Notes are converted after the close of business on a Interest Record Date, holders of such Notes as of the close of business on the
Interest Record Date will receive the interest and Additional Interest, if any, payable on such Notes on the corresponding Interest Payment Date notwithstanding the conversion. Notes surrendered for conversion during the period from the close of
business on any Interest Record Date to the opening of business on the corresponding Interest Payment Date must be accompanied by payment of an amount equal to the interest and Additional Interest, if any, payable on the Notes so converted;
provided, however, that no such payment shall be required (1) if the Company has called the Notes for redemption in accordance with Article 3 hereof, (2) if the Company has specified a Fundamental Change Repurchase Date that
is after a Interest Record Date but on or prior to the corresponding Interest Payment Date, (3) to the extent of any Defaulted Interest, if any, existing at the time of conversion with respect to such Note or (4) if the Notes are
surrendered for conversion after the close of business on the Interest Record Date immediately preceding the Maturity Date. Except as set forth in this Section 15.02(i), no payment or adjustment will be made for accrued and unpaid interest and
Additional Interest, if any, on converted Notes. 
  

 70 

 (j) The Person in whose name the certificate for any shares of Common Stock delivered upon conversion is
registered shall be treated as a stockholder of record as of the close of business on the relevant Conversion Date; provided, however, if such Conversion Date occurs on any date when the stock transfer books of the Company shall be
closed, such occurrence shall not be effective to constitute the Person or Persons entitled to receive any such shares of Common Stock due upon conversion as the record holder or holders of such shares of Common Stock on such date, but such
occurrence shall be effective to constitute the Person or Persons entitled to receive such shares of Common Stock as the record holder or holders thereof for all purposes at the close of business on the next succeeding day on which such stock
transfer books are open. Upon conversion of Notes, such Person shall no longer be a Noteholder. 
 (k) For each Note surrendered for
conversion, if the Company has elected to deliver a combination of cash and shares of Common Stock in respect of its Conversion Obligation, the number of full shares that shall be issued upon conversion thereof shall be computed on the basis of the
aggregate Daily Settlement Amounts for the applicable Cash Settlement Averaging Period and any fractional shares remaining after such computation shall be paid in cash. If more than one Note shall be surrendered for conversion at one time by the
same holder, the number of full shares that shall be issued upon conversion thereof shall be computed on the basis of the aggregate principal amount of the Notes (or specified portions thereof) so surrendered. The Company shall not issue fractional
shares of Common Stock upon conversion of Notes. Instead, the Company shall pay cash in lieu of fractional shares based on the Daily VWAP on the relevant Conversion Date (if the Company elects to satisfy its Conversion Obligation solely in shares of
Common Stock) or based on the Daily VWAP on the last Trading Day of the relevant Cash Settlement Averaging Period (in the case of any other Settlement Method). 
 SECTION 15.03. Increased Conversion Rate Applicable to Certain Notes Surrendered in Connection with Make-Whole Fundamental Changes. 
 (a) Notwithstanding anything herein to the contrary, the Conversion Rate applicable to each Note that is surrendered for conversion, in accordance with
this Article 15, at any time from, and including, the effective date (the “Effective Date”) of a Make-Whole Fundamental Change until, and including, the close of business on the Business Day immediately preceding the related Fundamental
Change Repurchase Date corresponding to such Make-Whole Fundamental Change, or the fortieth Trading Day immediately following the Effective Date of such Make-Whole Fundamental Change (in the case of a Make-Whole Fundamental Change that does not
constitute a Fundamental Change by virtue of the parenthetical in the definition of Make-Whole Fundamental Change) (such period, the “Make-Whole Fundamental Change Period”), shall be increased to an amount equal to the Conversion
Rate that would, but for this Section 15.03, otherwise apply to such Note pursuant to this Article 15, plus an amount equal to the Make-Whole Conversion Rate Adjustment. 
 As used herein, “Make-Whole Conversion Rate Adjustment” shall mean, with respect to a Make-Whole Fundamental Change, the amount set
forth in the following table that corresponds to the Effective Date of such Make-Whole Fundamental Change and the Stock Price for such Make-Whole Fundamental Change, all as determined by the Company: 
 Make-Whole Conversion Rate Adjustment 
 (per $1,000 principal amount of Notes) 
 Stock Price 
  

																							
	 Effective Date
	  	$7.71	  	$8.25	  	$9.25	  	$10.50	  	$12.00	  	$13.50	  	$15.00	  	$17.50	  	$20.00	  	$22.50	  	$25.00
	 August 18, 2008
	  	21.6169	  	18.4486	  	14.0882	  	10.2962	  	7.2569	  	5.1893	  	3.7286	  	2.1095	  	1.1103	  	0.4815	  	0.0793
	 August 15, 2009
	  	21.6169	  	17.6122	  	13.0612	  	9.2867	  	6.3819	  	4.4782	  	3.1753	  	1.7438	  	0.8753	  	0.3325	  	0.0000
	 August 15, 2010
	  	21.6169	  	16.5940	  	11.8828	  	8.1438	  	5.4236	  	3.7301	  	2.6086	  	1.4067	  	0.6853	  	0.2505	  	0.0000
	 August 15, 2011
	  	21.6169	  	15.2486	  	10.0017	  	6.2486	  	3.8486	  	2.5375	  	1.7486	  	0.9610	  	0.4853	  	0.1838	  	0.0000
	 August 15, 2012
	  	21.6169	  	13.6244	  	7.1585	  	3.1629	  	1.2986	  	0.6338	  	0.3553	  	0.0924	  	0.0000	  	0.0000	  	0.0000
	 August 15, 2013
	  	21.6169	  	13.1274	  	0.0234	  	0.0000	  	0.0000	  	0.0000	  	0.0000	  	0.0000	  	0.0000	  	0.0000	  	0.0000

  

 71 

 provided, however, that: 
 (i) if the actual Stock Price of such Make-Whole Fundamental Change is between two Stock Prices listed in the table above under the row
titled “Stock Price,” or if the actual Effective Date of such Make-Whole Fundamental Change is between two Effective Dates listed in the table above in the column immediately below the title “Effective Date,” then the Make-Whole
Conversion Rate Adjustment for such Make-Whole Fundamental Change shall be determined by the Company by straight-line interpolation between the Make-Whole Conversion Rate Adjustment set forth for such higher and lower Stock Prices, or for such
earlier and later Effective Dates based on a 365 day year, as applicable; 
 (ii) if the actual Stock Price of such Make-Whole
Fundamental Change is greater than $25.00 per share (subject to adjustment in the same manner as the Stock Price as provided in clause (iii) below), or if the actual Stock Price of such Make-Whole Fundamental Change is less than $7.71 per share
(subject to adjustment in the same manner as the Stock Price as provided in clause (iii) below), then the Make-Whole Conversion Rate Adjustment shall be equal to zero and this Section 15.03 shall not require the Company to increase the
Conversion Rate with respect to such Make-Whole Fundamental Change; 
 (iii) if an event occurs that requires, pursuant to
this Article 15 (other than solely pursuant to this Section 15.03), an adjustment to the Conversion Rate, then, on the date and at the time such adjustment is so required to be made, each price set forth in the table above under the row titled
“Stock Price” shall be deemed to be adjusted so that such Stock Price, at and after such time, shall be equal to the product of (1) such Stock Price as in effect immediately before such adjustment to such Stock Price and (2) a
fraction whose numerator is the Conversion Rate in effect immediately before such adjustment to the Conversion Rate and whose denominator is the Conversion Rate to be in effect, in accordance with this Article 15, immediately after such adjustment
to the Conversion Rate; 
 (iv) [Reserved]; 
 (v) each Make-Whole Conversion Rate Adjustment set forth in the table above shall be adjusted in the same manner in which, at the same
time and for the same events for which, the Conversion Rate is to be adjusted pursuant to Section 15.04; and 
  

 72 

 (vi) in no event will the total number of shares of Common Stock issuable upon conversion
of the Notes exceed 129.7017 per $1,000 principal amount of Notes, subject to adjustment in the same manner as the Conversion Rate pursuant to Section 15.04. 
 (b) As soon as practicable after the Company determines the anticipated Effective Date of any proposed Make-Whole Fundamental Change, the Company shall mail to each Noteholder, the Trustee and the Conversion Agent
written notice of, and shall issue a press release indicating, and publish on the Company’s website, the anticipated Effective Date of such proposed Make-Whole Fundamental Change and shall use commercially reasonable efforts in time to give
such notice no later than fifty Business Days in advance of such anticipated Effective Date. Each such press release notice, announcement and publication shall also state that in connection with such Make-Whole Fundamental Change, the Company shall
increase, in accordance herewith, the Conversion Rate applicable to Notes entitled as provided herein to such increase (along with a description of how such increase shall be calculated and the time periods during which Notes must be surrendered in
order to be entitled to such increase). No later than five Business Days after the actual Effective Date of each Make-Whole Fundamental Change, the Company shall mail to each Noteholder, the Trustee and the Conversion Agent written notice of, and
shall issue a press release indicating, and publish on the Company’s website, such Effective Date and the amount by which the Conversion Rate has been so increased. 
 Nothing in this Section 15.03 shall prevent an adjustment to the Conversion Rate pursuant to Section 15.04 in respect of a Make-Whole Fundamental Change. 
 SECTION 15.04. Adjustment of Conversion Rate. The Conversion Rate shall be adjusted from time to time by the Company as follows: 

(a) If the Company issues solely shares of Common Stock as a dividend or distribution on all or substantially all of the shares of Common Stock, or if
the Company effects a share split or share combination of the Common Stock, the applicable Conversion Rate will be adjusted based on the following formula: 
  

							
	 CR = CR0
	 	  x  
	 	OS	 	
		 		 	OS0	 	

  

 73 

 where 
  

					
	 CR0
	  	=	  	the applicable Conversion Rate in effect immediately prior to the open of business on the Ex-Dividend Date for such dividend or distribution, or immediately prior to the open of business on
the effective date of such share split or share combination, as the case may be;
			
	 CR
	  	=	  	the applicable Conversion Rate in effect immediately after the open of business on the Ex-Dividend Date for such dividend or distribution, or immediately after the open of business on the
effective date of such share split or share combination, as the case may be;
			
	 OS0
	  	=	  	the number of shares of Common Stock outstanding immediately prior to the open of business on the Ex-Dividend Date for such dividend or distribution, or immediately prior to the open of
business on the effective date of such share split or share combination, as the case may be; and
			
	 OS
	  	=	  	the number of shares of Common Stock outstanding immediately after such dividend or distribution, or immediately after the effective date of such share split or share combination, as the case
may be.

 Such adjustment shall become effective immediately after the opening of business on the Ex-Dividend Date for such
dividend or distribution, or the effective date for such share split or share combination. If any dividend or distribution of the type described in this Section 15.04(a) is declared but not so paid or made, or the outstanding shares of Common
Stock are not split or combined, as the case may be, the Conversion Rate shall be immediately readjusted, effective as of the date the Board of Directors determines not to pay such dividend or distribution, or split or combine the outstanding shares
of Common Stock, as the case may be, to the Conversion Rate that would then be in effect if such dividend, distribution, share split or share combination had not been declared or announced. 
 (b) If the Company distributes to all or substantially all holders of its Common Stock any rights, options or warrants entitling them for a period of not
more than sixty days from the record date for such distribution to subscribe for or purchase shares of the Common Stock, at a price per share less than the average of the Last Reported Sale Prices of the Common Stock for the ten consecutive Trading
Day period ending on, and including, the Trading Day immediately preceding the declaration date for such distribution, the Conversion Rate shall be increased based on the following formula: 
  

									
	 CR =
	  	CR0	  	x	 	 OS0 + X
	  	
		  		  		 	OS0 + Y	  	

  

 74 

 where 
  

					
	 CR0
	  	=	  	the applicable Conversion Rate in effect immediately prior to the open of business on the Ex-Dividend Date for such distribution;
			
	 CR
	  	=	  	the applicable Conversion Rate in effect immediately after the open of business on the Ex-Dividend Date for such distribution;
			
	 OS0
	  	=	  	the number of shares of the Common Stock that are outstanding immediately prior to the open of business on the Ex-Dividend Date for such distribution;
			
	 X
	  	=	  	the total number of shares of the Common Stock issuable pursuant to such rights, options or warrants; and
			
	 Y
	  	=	  	the number of shares of the Common Stock equal to the aggregate price payable to exercise such rights, options or warrants, divided by the average of the Last Reported Sale Prices of Common
Stock over the ten consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the Ex-Dividend Date relating to such distribution of such rights, options or warrants.

 Such adjustment shall be successively made whenever any such rights, options or warrants are distributed and shall
become effective immediately after the opening of business on the Ex-Dividend Date for such distribution. To the extent that shares of the Common Stock are not delivered after the expiration of such rights, options or warrants, the Conversion Rate
shall be readjusted to the Conversion Rate that would then be in effect had the adjustments made upon the issuance of such rights, options or warrants been made on the basis of delivery of only the number of shares of Common Stock actually
delivered. If such rights, options or warrants are not so issued, the Conversion Rate shall again be adjusted to be the Conversion Rate that would then be in effect if such Ex-Dividend Date for such distribution had not been fixed. 
 For purposes of this Section 15.04(b), in determining whether any rights, options or warrants entitle the holders to subscribe for or purchase
shares of the Common Stock at less than the average of the Last Reported Sale Prices of the Common Stock for each Trading Day in the applicable ten-consecutive-Trading Day period, there shall be taken into account any consideration received by the
Company for such rights, options or warrants and any amount payable on exercise or conversion thereof, the value of such consideration, if other than cash, to be determined by the Board of Directors. In no event shall the Conversion Rate be
decreased pursuant to this Section 15.04(b) (other than upon a readjustment as set forth in the immediately preceding paragraph). 
 (c)
If the Company shall distribute shares of its Capital Stock, evidences of its indebtedness or other of its assets or property other than (i) dividends or distributions (including share splits) covered by Section 15.04(a) or
Section 15.04(b), (ii) dividends or distributions paid exclusively in cash and covered by Section 15.04(d), and (iii) Spin-Offs to which the provisions set forth below in this Section 15.04(c) shall apply (any of such shares
of Capital Stock, 

  

 75 

 
indebtedness, or other asset or property hereinafter in this Section 15.04(c) called the “Distributed Property”), to all or substantially all
holders of its Common Stock, then, in each such case the Conversion Rate shall be increased based on the following formula: 
  

							
	CR = CR0	 	 x  	 	SP0 	 	
		 		 	SP0 – FMV	 	

 where 
  

					
	 CR0
	  	=	  	the applicable Conversion Rate in effect immediately prior to the open of business on the Ex-Dividend Date for such distribution;
			
	 CR
	  	=	  	the applicable Conversion Rate in effect immediately after the open of business on the Ex-Dividend Date for such distribution.
			
	 SP0
	  	=	  	the average of the Last Reported Sale Prices of the Common Stock over the ten consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the Ex-Dividend
Date for such distribution; and
			
	 FMV
	  	=	  	the fair market value (as determined by the Board of Directors) of the shares of Capital Stock, evidences of indebtedness, assets or property distributed with respect to each outstanding
share of the Common Stock as of the open of business on the Ex-Dividend Date for such distribution.

 Such adjustment shall become effective immediately prior to
the opening of business on the Ex-Dividend Date for such distribution; provided that if “FMV” as set forth above is equal to or greater than “SP0” as set forth above, in lieu of the foregoing adjustment, adequate provisions shall be made so that each Noteholder shall have the right to receive on conversion in respect of each $1,000 principal amount of the
Notes held by such holder, in addition to the Settlement Amount such holder is entitled to receive, the amount and kind of Distributed Property such holder would have received had such holder owned a number of shares of Common Stock equal to the
Conversion Rate immediately prior to the Record Date for such distribution. If such distribution is not so paid or made, the Conversion Rate shall again be adjusted to be the Conversion Rate that would then be in effect if such dividend or
distribution had not been declared. If the Board of Directors determines “FMV” for purposes of this Section 15.04(c) by reference to the actual or when-issued trading market for any securities, it must in doing so consider the prices
in such market over the same period used in computing the Last Reported Sale Prices of the Common Stock over the ten consecutive Trading Day period ending on the Trading Day immediately preceding the Ex-Dividend Date for such distribution.

 With respect to an adjustment pursuant to this Section 15.04(c) where there has been a dividend or other distribution on the Common
Stock of shares of Capital Stock of any class or series, or similar equity interest, of or relating to a Subsidiary or other business unit of the Company (a “Spin-off”), the Conversion Rate will be increased based on the following formula:

  

							
	CR = CR0	 	 x  	 	FMV + MP0 	  	
		 		 	MP0	  	

  

 76 

 where 
  

					
	 CR0
	  	=	  	the applicable Conversion Rate in effect immediately prior to the open of business on the Ex-Dividend Date for the Spin-Off;
			
	 CR
	  	=	  	the applicable Conversion Rate in effect immediately after the open of business on the Ex-Dividend Date for the Spin-Off;
			
	 FMV
	  	=	  	the average of the Last Reported Sale Prices of the Capital Stock or similar equity interest distributed to holders of the Common Stock applicable to one share of the Common Stock over the
first ten consecutive Trading Day period immediately following, and including, the Ex-Dividend Date for the Spin-Off (such period, the “Valuation Period”), and
			
	 MP0
	  	=	  	the average of the Last Reported Sale Prices of the Common Stock over the Valuation Period.

 The adjustment to the Conversion Rate under the preceding paragraph of this Section 15.04(c) shall be made
immediately after the opening of business on the day after the last day of the Valuation Period, but shall become effective as of the opening of business on the Ex-Dividend Date for the Spin-Off. If the Ex-Dividend Date for the Spin-Off is less than
ten Trading Days prior to, and including, the end of the Cash Settlement Averaging Period in respect of any conversion, if applicable, references within this Section 15.04(c) to ten Trading Days shall be deemed replaced, for purposes of
calculating the affected daily Conversion Rates in respect of that conversion, with such lesser number of Trading Days as have elapsed from, and including, the Ex-Dividend Date for the Spin-Off to, and including, the last Trading Day of such Cash
Settlement Averaging Period. For purposes of determining the applicable Conversion Rate, in respect of any conversion during the ten Trading Days commencing on the Ex-Dividend Date of any Spin-Off, references in the portion of this
Section 15.04(c) related to Spin-Offs to ten Trading Days shall be deemed replaced with such lesser number of Trading Days as have elapsed from, and including, the Ex-Dividend Date for such Spin-Off to, but excluding, the Conversion Date for
such conversion. 
 Subject in all respects to Section 15.10, rights, options or warrants distributed by the Company to all holders of
its Common Stock entitling the holders thereof to subscribe for or purchase shares of the Company’s Capital Stock, including Common Stock (either initially or under certain circumstances), which rights, options or warrants, until the occurrence
of a specified event or events (“Trigger Event”): (i) are deemed to be transferred with such shares of the Common Stock; (ii) are not exercisable; and (iii) are also issued in respect of future issuances of the Common
Stock, shall be deemed not to have been distributed for purposes of this Section 15.04 (and no adjustment to the Conversion Rate under this Section 15.04 will be required) until the occurrence of the earliest Trigger Event, whereupon such
rights and warrants shall be deemed to have been distributed and an appropriate adjustment (if any is required) to the Conversion Rate shall be made under this Section 15.04(c). If any such right, option or warrant, including any such existing
rights, options or warrants distributed prior to the date of this 

  

 77 

 
Indenture, are subject to events, upon the occurrence of which such rights, options or warrants become exercisable to purchase different securities,
evidences of indebtedness or other assets, then the date of the occurrence of any and each such event shall be deemed to be the date of distribution and Ex-Dividend Date with respect to new rights, options or warrants with such rights (and a
termination or expiration of the existing rights, options or warrants without exercise by any of the holders thereof). In addition, in the event of any distribution (or deemed distribution) of rights, options or warrants, or any Trigger Event or
other event (of the type described in the preceding sentence) with respect thereto that was counted for purposes of calculating a distribution amount for which an adjustment to the Conversion Rate under this Section 15.04 was made, (1) in
the case of any such rights, options or warrants that shall all have been redeemed or repurchased without exercise by any holders thereof, the Conversion Rate shall be readjusted upon such final redemption or repurchase to give effect to such
distribution or Trigger Event, as the case may be, as though it were a cash distribution, equal to the per share redemption or repurchase price received by a holder or holders of Common Stock with respect to such rights, options or warrants
(assuming such holder had retained such rights or warrants), made to all holders of Common Stock as of the date of such redemption or repurchase, and (2) in the case of such rights, options or warrants that shall have expired or been terminated
without exercise by any holders thereof, the Conversion Rate shall be readjusted as if such rights, options and warrants had not been issued. 
 For purposes of this Section 15.04(c), Section 15.04(a), and Section 15.04(b), any dividend or distribution to which this Section 15.04(c) is applicable that also includes shares of Common Stock, or rights, options or
warrants to subscribe for or purchase shares of Common Stock to which Section 15.04(a) or Section 15.04(b) (or both) applies, shall be deemed instead to be (1) a dividend or distribution of the evidences of indebtedness, assets or
shares of capital stock other than such shares of Common Stock or rights, options or warrants to which Section 15.04(c) applies (and any Conversion Rate adjustment required by this Section 15.04(c) with respect to such dividend or
distribution shall then be made) immediately followed by (2) a dividend or distribution of such shares of Common Stock or such rights, options or warrants (and any further Conversion Rate adjustment required by Section 15.04(a) and
Section 15.04(b) with respect to such dividend or distribution shall then be made), except (A) the Ex-Dividend Date of such dividend or distribution shall be substituted as “the Ex-Dividend Date,” “the Ex-Dividend Date
relating to such distribution of such rights, options or warrants” and “the Ex-Dividend Date for such distribution” within the meaning of Section 15.04(a) and Section 15.04(b) and (B) any shares of Common Stock included
in such dividend or distribution shall not be deemed “outstanding immediately prior to the Ex-Dividend Date for such dividend or distribution, or the effective date of such share split or share combination, as the case may be” within the
meaning of Section 15.04(a) or “outstanding immediately prior to the Ex-Dividend Date for such dividend or distribution” within the meaning of Section 15.04(b). 
 In no event shall the Conversion Rate be decreased pursuant to this Section 15.04(c) (other than upon a readjustment if a distribution of
Distributed Property is not made as set forth above in this Section 15.04(c)). 
 (d) If any cash dividend or distribution is made to
all or substantially all holders of its outstanding Common Stock, the applicable Conversion Rate shall be increased based on the following formula: 
  

 78 

									
	 CR = CR0
	  	x	  		 	SP0	  	
		  		  		 	SP0 – C    	  	

 where 
  

					
	 CR0
	  	=	  	the applicable Conversion Rate in effect immediately prior to the open of business on the Ex-Dividend Date for such dividend or distribution;
			
	 CR
	  	=	  	the applicable Conversion Rate in effect immediately after the open of business on the Ex-Dividend Date for such dividend or distribution;
			
	 SP0
	  	=	  	the average of the Last Reported Sale Prices of the Common Stock over the ten consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the Ex-Dividend
Date for such dividend or distribution; and
			
	 C
	  	=	  	the amount in cash per share the Company pays or distributes to holders of its Common Stock.

 Such adjustment shall become effective immediately after
the opening of business on the Ex-Dividend Date for such dividend or distribution; provided that if “C” as set forth above is equal to or greater than “SP0” as set forth above, in lieu of the foregoing adjustment, adequate provision shall be made so that each Noteholder shall have the right to receive on the date on which the relevant cash dividend or distribution
is distributed to holders of Common Stock, for each $1,000 principal amount of Notes, the amount of cash such holder would have received had such holder owned a number of shares equal to the Conversion Rate on the Record Date for such distribution.
If such dividend or distribution is not so paid or made, the Conversion Rate shall again be adjusted to be the Conversion Rate that would then be in effect if such dividend or distribution had not been declared. 
 For the avoidance of doubt, for purposes of this Section 15.04(d), in the event of any reclassification of the Common Stock, as a result of which
the Notes become convertible into more than one class of Common Stock, if an adjustment to the Conversion Rate is required pursuant to this Section 15.04(d), references in this Section to one share of Common Stock or Last Reported Sale Price of
one share of Common Stock shall be deemed to refer to a unit or to the price of a unit consisting of the number of shares of each class of Common Stock into which the Notes are then convertible equal to the numbers of shares of such class issued in
respect of one share of Common Stock in such reclassification. The above provisions of this paragraph shall similarly apply to successive reclassifications. 
 In no event shall the Conversion Rate be decreased pursuant to this Section 15.04(d) (other than upon a readjustment if a cash dividend or distribution is not made as set forth above in this
Section 15.04(d)). 
 (e) If the Company or any of its Subsidiaries makes a payment in respect of a tender offer or exchange offer for
the Common Stock and if the cash and value of any other consideration included in the payment per share of the Common Stock exceeds the average of 

  

 79 

 
the Last Reported Sale Prices of the Common Stock over the ten consecutive Trading-Day period commencing on, and including, the Trading Day next succeeding
the last date on which tenders or exchanges may be made pursuant to such tender or exchange offer (the “Expiration Date”), the Conversion Rate shall be increased based on the following formula: 
  

					
		 	AC + (SP x OS)	 	
	 CR = CR0 x
	 	0S0 x SP	 	

 where 
  

					
	 CR0
	  	=	  	the applicable Conversion Rate in effect immediately prior to the open of business on the Trading Day next succeeding the Expiration Date;
			
	 CR
	  	=	  	the applicable Conversion Rate in effect immediately after the open of business on the Trading Day next succeeding the Expiration Date;
			
	 AC
	  	=	  	the aggregate value of all cash and any other consideration (as determined by the Board of Directors) paid or payable for shares of Common Stock purchased in such tender or exchange offer;

			
	 OS0
	  	=	  	the number of shares of Common Stock outstanding immediately prior to the time (the “Expiration Time”) such tender or exchange offer expires (prior to giving effect to such tender
offer or exchange offer);
			
	 OS
	  	=	  	the number of shares of Common Stock outstanding immediately after the Expiration Time (after giving effect to such tender offer or exchange offer); and
			
	 SP
	  	=	  	the average of the Last Reported Sale Prices of Common Stock over the ten consecutive Trading Day period commencing on, and including, the Trading Day next succeeding the Expiration Date.

 Such adjustment under this Section 15.04(e) shall become effective at the opening of business on the Trading
Day next succeeding the Expiration Date. If the Trading Day next succeeding the Expiration Date is less than ten Trading Days prior to, and including, the end of the Cash Settlement Averaging Period in respect of any conversion, references within
this Section 15.04(e) to ten Trading Days shall be deemed replaced, for purposes of calculating the affected daily Conversion Rates in respect of that conversion, with such lesser number of Trading Days as have elapsed from, and including, the
Trading Day next succeeding the Expiration Date to, and including, the last Trading Day of such Cash Settlement Averaging Period. For purposes of determining the applicable Conversion Rate, in respect of any conversion during the ten Trading Days
commencing on the Trading Day next succeeding the Expiration Date, references within this Section 15.04(e) to ten Trading Days shall be deemed replaced with such lesser number of Trading Days as have elapsed from, and including, the Trading Day
next succeeding the Expiration Date to, but excluding, the Conversion Date for such conversion. If the Company is obligated to purchase shares pursuant to any such tender or exchange offer, but the Company is 

  

 80 

 
permanently prevented by applicable law from effecting any or all or any portion of such purchases or all such purchases are rescinded, the Conversion Rate
shall again be adjusted to be the Conversion Rate that would then be in effect if such tender or exchange offer had not been made or had been made only in respect of the purchases that had been effected. In no event shall the Conversion Rate be
decreased pursuant to this Section 15.04(e) (other than upon a readjustment if a self-tender offer is not made as set forth above in this Section 15.04(e)). 
 (f) The term “Record Date” shall mean, with respect to any dividend, distribution or other transaction or event in which the holders of Common Stock (or other security) have the right to receive any
cash, securities or other property or in which the Common Stock (or other applicable security) is exchanged for or converted into any combination of cash, securities or other property, the date fixed for determination of stockholders entitled to
receive such cash, securities or other property (whether such date is fixed by the Board of Directors or by statute, contract or otherwise). 
 (g) If the Company adjusts the Conversion Rate pursuant to clauses (a), (b), (c), (d) or (e) above, the Company will issue a press release containing the relevant information (and make such press release available on the
Company’s website). 
 (h) Notwithstanding this Section 15.04 or any other provision of this Indenture or the Notes, if any
Conversion Rate adjustment becomes effective, or any Ex-Dividend Date for any issuance, dividend or distribution (relating to a required Conversion Rate adjustment) occurs, during the period beginning on, and including, the open of business on a
Conversion Date and ending on, and including, (x) the close of business on the third Trading Day immediately following the relevant Conversion Date (if the Company elects to satisfy the related Conversion Obligation solely in shares of Common
Stock or prior to the Conversion Date for any converted Notes, the Common Stock has been replaced by Reference Property consisting solely of cash pursuant to Section 15.06) or (y) the close of business on the last Trading Day of a related
Cash Settlement Averaging Period (in any other case except as described in the parenthetical immediately following (x)), the Board of Directors shall make adjustments to the Conversion Rate and the amount of cash or number of shares of Common Stock
issuable upon conversion of the Notes, as the case may be, as are necessary or appropriate to effect the intent of this Section 15.04 and the other provisions of this Article 15 and to avoid unjust or inequitable results, as determined in good
faith by the Board of Directors. Any adjustment made pursuant to this Section 15.04(h) shall apply in lieu of the adjustment or other term that would otherwise be applicable. 
 (i) In addition to those required by clauses (a), (b), (c), (d) and (e) of this Section 15.04, and to the extent permitted by applicable
law and subject to the applicable rules of The NASDAQ Global Select Market, the Company from time to time may increase the Conversion Rate by any amount for a period of at least twenty Business Days if the Board of Directors determines that such
increase would be in the Company’s best interest. In addition, the Company may also (but is not required to) increase the Conversion Rate to avoid or diminish any income tax to holders of Common Stock or rights to purchase shares of Common
Stock in connection with any dividend or distribution of shares (or rights to acquire shares) or similar event. Whenever the Conversion Rate is increased pursuant to the preceding sentence, the Company shall mail to the holder of each Note at its
last address appearing on the Note Register 

  

 81 

 
provided for in Section 2.06 a notice of the increase at least fifteen days prior to the date the increased Conversion Rate takes effect, and such
notice shall state the increased Conversion Rate and the period during which it will be in effect. 
 (j) The Company shall not take any
action that would result in adjustment of the Conversion Rate, pursuant to this Article 15, in such a manner as to result in the reduction of the Conversion Price to less than the par value per share of Common Stock. 
 (k) The applicable Conversion Rate will not be adjusted: 
 (i) upon the issuance of any shares of the Common Stock pursuant to any present or future plan providing for the reinvestment of dividends or interest payable on the Company’s securities and the investment of
additional optional amounts in shares of the Common Stock under any plan; 
 (ii) upon the issuance of any shares of the
Common Stock or options or rights to purchase those shares pursuant to any present or future employee, director or consultant benefit plan or program of, or assumed by, the Company or any of the Company’s Subsidiaries; 
 (iii) upon the issuance of any shares of the Common Stock pursuant to any option, warrant, right or exercisable, exchangeable or
convertible security not described in clause (ii) of this subsection and outstanding as of the date the Notes were first issued; 
 (iv) for a change in the par value of the Common Stock; 
 (v) for accrued and unpaid
interest, including Additional Interest, if any; or 
 (vi) for any transactions described in this Section 15.04 if
Noteholders participate (as a result of holding the Notes, and at the same time as holders of Common Stock participate) in such transactions as if such Noteholders held a number shares of Common Stock equal to the Conversion Rate at the time such
adjustment would be required, multiplied by the principal amount (expressed in thousands) of Notes held by such Noteholder, without having to convert their Notes. 
 (l) All calculations and other determinations under this Article 15 shall be made to the nearest one-ten thousandth (1/10,000) of a share. 
 (m) The Company shall not be required to make an adjustment in the Conversion Rate unless the adjustment would require a change of at least 1% in the
Conversion Rate. However, the Company shall carry forward any adjustments that are less than 1% of the Conversion Rate and make such carried forward adjustment, regardless of whether the aggregate adjustment is less than 1%, (i) the time the
Company mails a notice of redemption, (ii) upon any conversion of Notes, and (iii) on each of the forty-two Scheduled Trading Days immediately preceding the Maturity Date. 
  

 82 

 (n) Notwithstanding the foregoing, the Company will not enter into any transaction, or take any other
action, that will require an adjustment to the Conversion Rate that would exceed the number of shares of Common Stock that would require stockholder approval under the continued listing standards of the Nasdaq Global Select Market without having
obtained prior stockholder approval. 
 (o) Whenever the Conversion Rate is adjusted as herein provided, the Company shall promptly file with
the Trustee and any Conversion Agent other than the Trustee an Officers’ Certificate setting forth the Conversion Rate after such adjustment and setting forth a brief statement of the facts requiring such adjustment. Unless and until a
Responsible Officer of the Trustee shall have received such Officers’ Certificate, the Trustee shall not be deemed to have knowledge of any adjustment of the Conversion Rate and may assume without inquiry that the last Conversion Rate of which
it has knowledge is still in effect. Promptly after delivery of such certificate, the Company shall prepare a notice of such adjustment of the Conversion Rate setting forth the adjusted Conversion Rate and the date on which each adjustment becomes
effective and shall mail such notice of such adjustment of the Conversion Rate to the holder of each Note at its last address appearing on the Note Register provided for in Section 2.06 of this Indenture, within ten days of the effective date
of such adjustment. Failure to deliver such notice shall not affect the legality or validity of any such adjustment. 
 (p) If, in respect of
any Trading Day within the Cash Settlement Averaging Period for a converted Note: 
 (i) the Company elects to satisfy its
Conversion Obligation through delivery of a combination of cash and Common Stock and shares of Common Stock are deliverable with respect to the Daily Settlement Amount for such Trading Day in accordance with this Article 15; 
 (ii) any event that requires an adjustment to the Conversion Rate under any of clauses (a), (b), (c), (d) and (e) of this
Section 15.04 has not resulted in an adjustment to the Conversion Rate as of such Trading Day; and 
 (iii) the shares of
Common Stock the holder of such Note shall receive in respect of such Trading Day are not entitled to participate in the distribution or transaction giving rise to such adjustment event because, pursuant to the terms of Section 15.02(k), such
shares were not held by such holder on the record date corresponding to such distribution or transaction, 
 then the Company will adjust the number of
shares of Common Stock deliverable with respect to the Daily Settlement Amount for such Trading Day to reflect the relevant distribution or transaction. 
 (q) If: 
 (i) the Company elects to satisfy the Conversion Obligation solely in shares of
Common Stock; 
  

 83 

 (ii) any event that requires an adjustment to the Conversion Rate under any of clauses
(a), (b), (c), (d) and (e) of this Section 15.04 has not resulted in an adjustment to the Conversion Rate as of the Conversion Date; and 
 (iii) the shares of Common Stock the holder of such Note shall receive on settlement are not entitled to participate in the distribution or transaction giving rise to such adjustment event because, pursuant to the
terms of Section 15.02(j), such shares were not held by such holder on the record date corresponding to such distribution or transaction, 
 then the
Company will adjust the number of shares of Common Stock deliverable with respect to the relevant Trading Day to reflect the relevant distribution or transaction. 
 (r) For purposes of this Section 15.04, the number of shares of Common Stock at any time outstanding shall not include shares held in the treasury of the Company but shall include shares issuable in respect of
scrip certificates issued in lieu of fractions of shares of Common Stock. The Company will not pay any dividend or make any distribution on shares of Common Stock held in the treasury of the Company. 
 SECTION 15.05. Shares to Be Fully Paid. The Company shall provide, free from preemptive rights, out of its authorized but unissued shares or
shares held in treasury, sufficient shares of Common Stock to provide for conversion of the Notes from time to time as such Notes are presented for conversion. 
 SECTION 15.06. Effect of Reclassification, Consolidation, Merger or Sale. Upon the occurrence of (i) any reclassification or change of the outstanding shares of Common Stock (other than a change in
par value, or from par value to no par value, or from no par value to par value, or as a result of a split, subdivision or combination covered by Section 15.04(a)), (ii) any consolidation, merger, combination or binding share exchange
involving the Company, or (iii) any sale or conveyance of all or substantially all of the property and assets of the Company to any other Person (any such event a “Merger Event”), in each case as a result of which holders of Common
Stock shall be entitled to receive cash, securities or other property or assets with respect to or in exchange for such Common Stock (the “Reference Property”), then: 
 (a) the Company or the successor or purchasing Person, as the case may be, shall execute with the Trustee a supplemental indenture (which
shall comply with the Trust Indenture Act as in force at the date of execution of such supplemental indenture if such supplemental indenture is then required to so comply) permitted under Section 11.01(g) providing for the conversion and
settlement of the Notes as set forth in this Indenture. Such supplemental indenture shall provide for adjustments that shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article 15. If, in the case of any
Merger Event, the Reference Property includes shares of stock or other securities and assets of a corporation other than the successor or purchasing corporation, as the case may be, in such reclassification, change, consolidation, merger,
combination, binding share exchange, sale or conveyance, then such supplemental indenture shall also be executed by such other corporation and shall contain such additional provisions to protect the interests of the holders of the Notes as the Board
of 

  

 84 

 
Directors shall reasonably consider necessary by reason of the foregoing, including, to the extent required by the Board of Directors and practicable, the
provisions providing for the repurchase rights set forth in Article 16 herein. 
 In the event the Company shall execute a
supplemental indenture pursuant to this Section 15.06, the Company shall promptly file with the Trustee an Officers’ Certificate briefly stating the reasons therefor, the kind or amount of cash, securities or property or asset that will
comprise the Reference Property after any such Merger Event, any adjustment to be made with respect thereto and that all conditions precedent have been complied with, and shall promptly mail notice thereof to all Noteholders. The Company shall cause
notice of the execution of such supplemental indenture to be mailed to each Noteholder, at its address appearing on the Note Register provided for in this Indenture, within twenty days after execution thereof. Failure to deliver such notice shall
not affect the legality or validity of such supplemental indenture. 
 (b) Notwithstanding the provisions of
Section 15.02(b), and subject to the provisions of Section 15.01 and Section 15.03, at and after the effective time of such Merger Event, (i) the right to convert each $1,000 principal amount of Notes into cash, shares of Common
Stock or a combination of cash and shares of Common Stock at the Company’s election as set forth in Section 15.02 will be changed to a right to convert each $1,000 principal amount of such Note into the Reference Property and (ii) the
related Conversion Obligation shall be settled as set forth under clause (c) below, it being understood and agreed that for purposes of Section 15.01(b), references therein to “the Last Reported Sale Price of the Common Stock”
shall be deemed at and after the effective time of such Merger Event to be references to “the Last Reported Sale Price of a unit of Reference Property comprised of the kind and amount of shares of stock, securities or other property or assets
(including cash or any combination thereof) that a holder of one share of Common Stock immediately prior to such Merger Event would have owned or been entitled to receive based on the Weighted Average Consideration” and references therein to
“the Daily VWAP of the Common Stock” shall be deemed at and after the effective time of such Merger Event to be references to “the Daily VWAP of a unit of Reference Property comprised of the kind and amount of shares of stock,
securities or other property or assets (including cash or any combination thereof) that a holder of one share of Common Stock immediately prior to such Merger Event would have owned or been entitled to receive based on the Weighted Average
Consideration.” The Company shall not become a party to any Merger Event unless its terms are consistent with this Section 15.06. None of the foregoing provisions shall affect the right of a holder of Notes to convert its Notes into cash,
shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, as set forth in Section 15.01 and Section 15.02 prior to the effective date of such Merger Event. 
 (c) With respect to each $1,000 principal amount of Notes surrendered for conversion after the effective date of any such Merger Event,
the Company’s Conversion Obligation shall be settled in cash or units of Reference Property, at the Company’s election, in accordance with Section 15.02(b) as follows: 
  

 85 

 (i) (A) if the Company elects to satisfy its Conversion Obligation in respect of such
conversion by delivering solely Reference Property, the Company shall deliver to the converting Noteholder a number of units of Reference Property (each such unit comprised of the kind and amount of shares of stock, securities or other property or
assets (including cash or any combination thereof) that a holder of one share of Common Stock immediately prior to such Merger Event would have owned or been entitled to receive based on the Weighted Average Consideration) equal to (1) the
aggregate principal amount of Notes to be converted, divided by $1,000, multiplied by (2) the then-applicable Conversion Rate; (B) if the Company elects to satisfy its Conversion Obligation in respect of such conversion by paying solely
cash, the Company shall pay to the converting Noteholder cash in an amount, per $1,000 principal amount of Notes equal to the sum of the Daily Conversion Values for each of the forty consecutive Trading Days during the related Cash Settlement
Averaging Period, such Daily Conversion Values determined as if the reference to “the Daily VWAP of the Common Stock” in the definition thereof were instead a reference to “the Daily VWAP of a unit of Reference Property comprised of
the kind and amount of shares of stock, securities or other property or assets (including cash or any combination thereof) that a holder of one share of Common Stock immediately prior to such Merger Event would have owned or been entitled to receive
based on the Weighted Average Consideration”; and (C) if the Company elects to satisfy its Conversion Obligation through delivery of a combination of cash and Reference Property, the Company shall deliver in respect of each $1,000
principal amount of Notes being converted, a Settlement Amount equal to the sum of the Daily Settlement Amounts for each of the forty consecutive Trading Days during the Cash Settlement Averaging Period for such Note, such Daily Settlement Amounts
determined as if the reference to “the Daily VWAP of the Common Stock” in the definition of Daily Conversion Value and Daily Share Amount were instead a reference to “the Daily VWAP of a unit of Reference Property comprised of the
kind and amount of shares of stock, securities or other property or assets (including cash or any combination thereof) that a holder of one share of Common Stock immediately prior to such Merger Event would have owned or been entitled to receive
based on the Weighted Average Consideration”. 
 (ii) The Company will deliver the cash in lieu of fractional units of
Reference Property as set forth pursuant to Section 15.02(k), provided that the amount of such cash shall be determined as if references in such Section to “the Daily VWAP of the Common Stock” were instead a reference to
“the Daily VWAP of a unit of Reference Property composed of the kind and amount of shares of stock, securities or other property or assets (including cash or any combination thereof) that a holder of one share of Common Stock immediately prior
to such Merger Event would have owned or been entitled to receive based on the Weighted Average Consideration”. 
 (iii)
The Daily Settlement Amounts (if applicable) and Daily Conversion Values (if applicable) shall be determined by the Company promptly following the last day of the Cash Settlement Averaging Period. 
  

 86 

 (iv) For purposes of this Section 15.06, the “Weighted Average
Consideration” shall mean the weighted average of the types and amounts of consideration received by the holders of the Common Stock entitled to receive cash, securities or other property or assets with respect to or in exchange for such Common
Stock in any Merger Event who affirmatively make such an election. 
 (v) The Company shall notify the holders of the Notes of
the Weighted Average Consideration as soon as practicable after the Weighted Average Consideration is determined. 
 (vi)
Notwithstanding the foregoing, if holders of Common Stock have the opportunity to elect the form of consideration they receive in any Merger Event, then the Company will make adequate provision to give holders of the Notes, treated as a single
class, a reasonable opportunity to elect the form of such consideration for purposes of determining the composition of the consideration received. Once the election is made, it will apply to all holders of the Notes after the effective time of the
transaction. 
 (d) The above provisions of this Section shall similarly apply to successive Merger Events. 
 SECTION 15.07. Certain Covenants. 
 (a) The Company covenants that all shares of Common Stock issued upon conversion of Notes will be fully paid and non-assessable by the Company and free from all taxes, liens and charges with respect to the issue thereof. 
 (b) The Company covenants that, if any shares of Common Stock to be provided for the purpose of conversion of Notes hereunder require registration with
or approval of any governmental authority under any federal or state law before such shares may be validly issued upon conversion, the Company will, to the extent then permitted by the rules and interpretations of the Commission, secure such
registration or approval, as the case may be. 
 (c) The Company further covenants that if at any time the Common Stock shall be listed on
any national securities exchange or automated quotation system, the Company will list and keep listed, so long as the Common Stock shall be so listed on such exchange or automated quotation system, any Common Stock issuable upon conversion of the
Notes. 
 SECTION 15.08. Responsibility of Trustee. The Trustee and any other Conversion Agent shall not at any time be under any
duty or responsibility to any Noteholder to determine the Conversion Rate (or any adjustment thereto) or whether any facts exist that may require any adjustment (including any increase) of the Conversion Rate, or with respect to the nature or extent
or calculation of any such adjustment when made, or with respect to the method employed, or herein or in any supplemental indenture provided to be employed, in making the same. The Trustee and any other Conversion Agent shall not be accountable with
respect to the validity or value (or the kind or amount) of any shares of Common Stock, or of any securities, property or cash that may at any time be issued or delivered upon the conversion of any Note; and the Trustee and any other Conversion
Agent make no representations with respect thereto. 

  

 87 

 
Neither the Trustee nor any Conversion Agent shall be responsible for any failure of the Company to issue, transfer or deliver any shares of Common Stock or
stock certificates or other securities or property or cash upon the surrender of any Note for the purpose of conversion or to comply with any of the duties, responsibilities or covenants of the Company contained in this Article. Without limiting the
generality of the foregoing, neither the Trustee nor any Conversion Agent shall be under any responsibility to determine the correctness of any provisions contained in any supplemental indenture entered into pursuant to Section 15.06 relating
either to the kind or amount of shares of stock or securities or property (including cash) receivable by Noteholders upon the conversion of their Notes after any event referred to in such Section 15.06 or to any adjustment to be made with
respect thereto, but, subject to the provisions of Section 8.01, may accept (without any independent investigation) as conclusive evidence of the correctness of any such provisions, and shall be protected in relying upon, the Officers’
Certificate (which the Company shall be obligated to file with the Trustee prior to the execution of any such supplemental indenture) with respect thereto. Neither the Trustee nor the Conversion Agent shall be responsible for determining whether any
event contemplated by Section 15.01(b) has occurred that makes the Notes eligible for conversion or no longer eligible therefor until the Company has delivered to the Trustee and the Conversion Agent the notices referred to in
Section 15.01(b) with respect to the commencement or termination of such conversion rights, on which notices the Trustee and the Conversion Agent may conclusively rely, and the Company agrees to deliver such notices to the Trustee and the
Conversion Agent immediately after the occurrence of any such event or at such other times as shall be provided for in Section 15.01(b). Neither the Trustee nor any other Conversion Agent shall at any time be under any duty or responsibility to
any Noteholder to determine whether any facts exist that may require Additional Interest to be paid by the Company, or the determination of the amount thereof, if any. 
 SECTION 15.09. Notice to Noteholders Prior to Certain Actions. In case: 
 (a) the
Company shall declare a dividend (or any other distribution) on its Common Stock that would require an adjustment in the Conversion Rate pursuant to Section 15.04; or 
 (b) the Company shall authorize the granting to all of the holders of its Common Stock of rights, options or warrants to subscribe for or
purchase any share of any class or any other rights, options or warrants; or 
 (c) of any reclassification of the Common
Stock of the Company (other than a subdivision or combination of its outstanding Common Stock, or a change in par value, or from par value to no par value, or from no par value to par value), or of any consolidation or merger to which the Company is
a party and for which approval of any stockholders of the Company is required, or of the sale or transfer of all or substantially all of the assets of the Company; or 
 (d) of the voluntary or involuntary dissolution, liquidation or winding-up of the Company; 
 the Company shall cause to be filed with the Trustee and to be mailed to each Noteholder at its address appearing on the Note Register, provided for in Section 2.06
of this Indenture, as 

  

 88 

 
promptly as possible but in any event at least twenty days prior to the applicable date hereinafter specified, a notice stating (i) the date on which a
record is to be taken for the purpose of such dividend, distribution or rights, options or warrants, or, if a record is not to be taken, the date as of which the holders of Common Stock of record to be entitled to such dividend, distribution or
rights are to be determined, or (ii) the date on which such reclassification, consolidation, merger, sale, transfer, dissolution, liquidation or winding-up is expected to become effective or occur, and the date as of which it is expected that
holders of Common Stock of record shall be entitled to exchange their Common Stock for securities or other property deliverable upon such reclassification, consolidation, merger, binding share exchange, sale, transfer, dissolution, liquidation or
winding-up. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such dividend, distribution, reclassification, consolidation, merger, sale, transfer, dissolution, liquidation or winding-up. 
 SECTION 15.10. Stockholder Rights Plans. To the extent that the Company has a stockholder rights plan or other “poison pill” in
effect upon conversion of the Notes, each share of Common Stock, if any, issued upon such conversion shall be entitled to receive the appropriate number of rights, if any, and the certificates representing the Common Stock issued upon such
conversion shall bear such legends, if any, in each case as may be provided by the terms of any such stockholder rights plan or poison pill, as the same may be amended from time to time. If prior to the time of conversion, however, the rights have
separated from the shares of Common Stock in accordance with the provisions of the applicable stockholder rights agreement so that the holders of the Notes would not be entitled to receive any rights in respect of Common Stock, if any, issuable upon
conversion of the Notes, the Conversion Rate will be adjusted at the time of separation as if the Company had distributed to all holders of Common Stock, shares of Capital Stock of the Company, evidence of indebtedness or assets as provided in
Section 15.04(c), subject to readjustment in the event of the expiration, termination or redemption of such rights. 
 SECTION 15.11. Exchange in Lieu of Conversion. When a holder surrenders its Notes for conversion, the Company may, at its election, direct the Conversion Agent to surrender, on or prior to the second Business Day following the
relevant Conversion Date, such Notes to a financial institution designated by the Company (the “Designated Institution”) for exchange in lieu of conversion. In order to accept any Notes surrendered for conversion for exchange in lieu of
conversion, the Designated Institution must agree to timely deliver, in exchange for such Notes, the shares of Common Stock and/or cash that would otherwise be due upon conversion pursuant to Section 15.02 and in respect of which the Company
has notified converting Noteholders. If the Company makes the election provided for in this Section 15.11, the Company shall, by the close of business on the second Business Day following the relevant Conversion Date as part of its Settlement
Notice, notify the holder surrendering its Notes for conversion that it has made such election. In addition, the Company shall concurrently notify the Designated Institution of the Settlement Method (and, if applicable, the Specified Dollar Amount)
that Company has elected with respect to such conversion and the relevant deadline for delivery of the consideration due upon conversion. Any Notes exchanged by the Designated Institution will remain outstanding. 
 If the Designated Institution agrees to accept any Notes for exchange but does not timely deliver the related consideration due upon conversion to the
Conversion Agent, or if the 

  

 89 

 
Designated Institution does not accept such Notes for exchange, the Company shall, within the time period specified in Section 15.02(e), pay and deliver
cash and/or shares of Common Stock, as applicable in accordance with the provisions of Section 15.02 as if the Company had not made an exchange election. 
 For the avoidance of doubt, in no event will the Company’s designation of a Designated Institution pursuant to this Section 15.11 require the Designated Institution to accept any Notes for exchange.

 ARTICLE XVI 
 REPURCHASE OF NOTES AT OPTION OF HOLDERS 
 SECTION 16.01. Repurchase of Notes by the Company at Option of the
Holder. 
 (a) On each of August 15, 2013, August 15, 2018 and August 15, 2023 (each, a “Repurchase
Date”), each holder shall have the option to require the Company to repurchase Notes for which that holder has properly delivered and not withdrawn a written Repurchase Notice (as described below) at a repurchase price in cash equal to 100%
of the principal amount of those Notes, plus accrued and unpaid interest, and accrued and unpaid Additional Interest, if any, on those Notes, to, but not including, such Repurchase Date (the “Repurchase Price”); provided
that, if the Repurchase Date is on a date that is after an Interest Record Date and on or prior to the corresponding Interest Payment Date, the Repurchase Price shall be 100% of the principal amount of the Notes repurchased but shall not include
accrued and unpaid interest and Additional Interest, if any. Instead, the Company shall pay such accrued and unpaid interest and Additional Interest, if any, on the Interest Payment Date, to the holder of Record on the corresponding Interest Record
Date. Not later than twenty Business Days prior to any Repurchase Date, the Company shall mail a notice (the “Repurchase Company Notice”) by electronic transmission or first-class mail, postage prepaid, to the Trustee, the Paying
Agent and the Conversion Agent and to each holder (and to beneficial owners if required by applicable law). The Repurchase Company Notice shall include a form of Repurchase Notice to be completed by a holder and shall state: 
 (i) the Repurchase Price; 
 (ii) the Repurchase Date; 
 (iii) the name and address of the Paying Agent and the Conversion
Agent, if applicable; 
 (iv) briefly, the conversion rights, if any, that exist at the date of the Repurchase Company Notice
or as a result of the Repurchase Company Notice with respect to the Notes; 
 (v) if applicable, the applicable Conversion
Rate, any adjustments to the applicable Conversion Rate; 
  

 90 

 (vi) if applicable, that the Notes with respect to which a Repurchase Notice has been
delivered by a holder may be converted only if the holder withdraws the Repurchase Notice in accordance with the terms of the Indenture; 
 (vii) that the holder must exercise the repurchase right on or prior to the close of business on the Business Day immediately preceding the Repurchase Date (the “Repurchase Expiration Time”);

 (viii) that the Repurchase Price for any Note as to which a Repurchase Notice has been given and not withdrawn shall be
paid promptly following the later of the Business Day immediately following the Repurchase Date and the time of surrender of such Note as described in clause (xi) below; 
 (ix) the procedures the holder must follow to exercise its right to require the Company to repurchase such holder’s Notes under this
Section 16.01 and a brief description of that right; 
 (x) the procedures for withdrawing a Repurchase Notice;

 (xi) that Notes must be surrendered to the Paying Agent (by effecting book-entry transfer of the Notes or delivering Notes
in certificated form, together with necessary endorsements, as the case may be) to collect payment; 
 (xii) that, unless the
Company defaults in making payment on Notes for which a Repurchase Notice has been submitted, interest or Additional Interest, if any, on such Notes shall cease to accrue from and after the Repurchase Date; and 
 (xiii) the CUSIP, “ISIN” or other similar number(s), as the case may be, of the Notes. 
 At the Company’s request, the Trustee shall give such Repurchase Company Notice to each holder in the Company’s name and at the Company’s expense;
provided, however, that, in all cases, the text of such Repurchase Company Notice shall be prepared by the Company. 
 (b) A
holder may exercise its rights specified in Section 16.01(a) upon delivery to the Paying Agent of a duly completed notice of repurchase (a “Repurchase Notice”) in the form set forth on the reverse of the Notes as Exhibit C
during the period beginning at any time from the opening of business on the date that is 20 Business Days prior to the Repurchase Date until the Repurchase Expiration Time, stating: 
 (i) if Notes in certificated form have been issued, the certificate number(s) of the Notes which the holder shall deliver to be
repurchased; 
 (ii) the portion of the principal amount of Notes to be repurchased, which must be $1,000 or an integral
multiple thereof; and 
 (iii) that Notes are to be repurchased by the Company pursuant to the applicable provision of the
Notes and the Indenture; 
  

 91 

 provided, however, that if Notes in certificated form have not been issued for such Note, the Repurchase
Notice shall comply with the appropriate Depositary procedures for book-entry transfer. 
 The delivery of such Note (together with all
necessary endorsements) to the Paying Agent at any time after delivery of the Repurchase Notice at the offices of the Paying Agent shall be a condition to receipt by the holder of the Repurchase Price therefor; provided however, that such
Repurchase Price shall be so paid pursuant to this Section 16.01 only if the Note (together with all necessary endorsements) so delivered to the Paying Agent shall conform in all respects to the description thereof in the related Repurchase
Notice. 
 The Company shall repurchase from the holder thereof, pursuant to this Section 16.01, a portion of a Note, if the principal
amount of such portion is $1,000 or an integral multiple of $1,000. Provisions of this Indenture that apply to the repurchase of all of a Note also apply to the repurchase of such portion of such Note. 
 Any repurchase by the Company contemplated pursuant to the provisions of this Section 16.01 shall be consummated by the delivery of the
consideration to be received by the holder promptly following the later of the Repurchase Date and the time of delivery of the Note (together with all necessary endorsements or notifications of book-entry transfer). 
 Notwithstanding anything herein to the contrary, any holder delivering to the Paying Agent the Repurchase Notice contemplated by this Section 16.01
shall have the right to withdraw such Repurchase Notice by delivery of a written notice of withdrawal to the Paying Agent in accordance with Section 16.02 below at any time prior to the Repurchase Expiration Time. 
 The Paying Agent shall promptly notify the Company of the receipt by it of any Repurchase Notice or written notice of withdrawal thereof. 
 (c) Notwithstanding the foregoing, no Notes may be repurchased by the Company at the option of the holders on the Repurchase Date if the principal amount
of the Notes has been accelerated, and such acceleration has not been rescinded, on or prior to the Repurchase Date (except in the case of an acceleration resulting form a default by the Company in the payment of the Repurchase Price with respect to
such Notes). 
 (d) In connection with any repurchase, the Company shall: 
 (i) comply with the provisions of Rule 13e-4, Rule 14e-1 and other tender offer rules under the Exchange Act, if required under the
Exchange Act, 
 (ii) file a Schedule TO or any successor or similar schedule, if required under the Exchange Act, and

 (iii) otherwise comply with all federal and state securities laws in connection with any offer by the Company to purchase
the Notes. 
  

 92 

 SECTION 16.02. Withdrawal of Repurchase Notice. A Repurchase Notice may be withdrawn by means
of a written notice of withdrawal delivered to the Corporate Trust Office of the Paying Agent in accordance with this Section 16.02 at any time prior to the close of business (5:00 p.m., New York City time) on the Business Day immediately
preceding the Repurchase Date, specifying: 
 (i) the certificate number, if any, of the Note in respect of which such notice
of withdrawal is being submitted, 
 (ii) the principal amount of the Note with respect to which such notice of withdrawal is
being submitted, and 
 (iii) the principal amount, if any, of such Note that remains subject to the original Repurchase
Notice, which portion must be in principal amounts of $1,000 or an integral multiple of $1,000; 
 provided, however, that if the Notes are not in
certificated form, the notice must comply with appropriate procedures of the Depositary. 
 SECTION 16.03. Deposit of Repurchase
Price. 
 (a) The Company will deposit with the Trustee (or other Paying Agent appointed by the Company, or if the Company is acting as
its own Paying Agent, set aside, segregate and hold in trust as provided in Section 5.04) on or prior to 11:00 a.m., New York City time, on the Repurchase Date an amount of money sufficient to repurchase all of the Notes to be repurchased at
the appropriate Repurchase Price. Subject to receipt of funds and/or Notes by the Trustee (or other Paying Agent appointed by the Company), payment for Notes surrendered for repurchase (and not withdrawn prior to the Repurchase Expiration Time) will
be made promptly following the later of (i) the Repurchase Date with respect to such Note (provided the holder has satisfied the conditions in Section 16.01) and (ii) the time of book-entry transfer or the delivery of such Note to the
Trustee (or other Paying Agent appointed by the Company) by the holder thereof in the manner required by Section 16.01 by mailing checks for the amount payable to the holders of such Notes entitled thereto as they shall appear in the Note
Register; provided however, that payments to the Depositary shall be made by wire transfer of immediately available funds to the account of the Depositary or its nominee. The Trustee shall, promptly after such payment and upon written demand
by the Company, return to the Company any funds in excess of the Repurchase Price. 
 (b) If by 11:00 a.m., New York City time, on the
Repurchase Date, the Trustee (or other Paying Agent appointed by the Company) holds money sufficient to make payment on all the Notes or portions thereof that are to be repurchased pursuant to Section 16.01, then (i) such Notes will cease
to be outstanding, (ii) interest, and Additional Interest, if any, will cease to accrue on such Notes, and (iii) all other rights of the holders of such Notes will terminate (other than the right to receive the Repurchase Price, and
previously accrued but unpaid interest, and Additional Interest, if any, upon book-entry transfer or delivery of the Notes), in each case, whether or not book-entry transfer of the Notes has been made or the Notes have been delivered to the Trustee
or Paying Agent. 
  

 93 

 (c) Upon surrender of a Note that is to be repurchased in part pursuant to Section 16.01, the
Company shall execute and the Trustee shall authenticate and deliver to the holder a new Note in an authorized denomination equal in principal amount to the unrepurchased portion of the Note surrendered. 
 SECTION 16.04. Repurchase at Option of Noteholders upon a Fundamental Change. (a) If there shall occur a Fundamental Change at any time
prior to the Maturity Date, then each Noteholder shall have the right, at such holder’s option, to require the Company to repurchase for cash all of such holder’s Notes, or any portion thereof that is an integral multiple of $1,000
principal amount, on the date (the “Fundamental Change Repurchase Date”) specified by the Company that is not less than twenty Business Days and not more than thirty-five Business Days after the date of the Fundamental Change
Company Notice (as defined below) at a repurchase price equal to 100% of the principal amount thereof, together with accrued and unpaid interest, including unpaid Additional Interest, if any, thereon to, but excluding, the Fundamental Change
Repurchase Date (the “Fundamental Change Repurchase Price”), unless the Fundamental Change Repurchase Date is after an Interest Record Date and on or prior to the related Interest Payment Date, in which case interest accrued to the
Interest Payment Date will be paid to holders of the Notes as of the preceding Interest Record Date and the Fundamental Change Repurchase Price payable to the holder surrendering the Note for repurchase pursuant to this Section 16.04 shall be
equal to 100% of the principal amount of the Notes subject to repurchase and will not include any accrued and unpaid interest, including Additional Interest, if any. Repurchases of Notes under this Section 16.04 shall be made, at the option of
the holder thereof, upon: 
 (i) delivery to the Paying Agent by a holder of a duly completed notice (the “Fundamental
Change Repurchase Notice”) in the form set forth on the reverse of the Note as Exhibit D thereto on or prior to the Business Day immediately preceding the Fundamental Change Repurchase Date; and 
 (ii) delivery or book-entry transfer of the Notes to the Paying Agent at any time after delivery of the Fundamental Change Repurchase
Notice (together with all necessary endorsements) at the office of the Paying Agent, such delivery being a condition to receipt by the holder of the Fundamental Change Repurchase Price therefor; provided that such Fundamental Change
Repurchase Price shall be so paid pursuant to this Section 16.04 only if the Note so delivered to the Paying Agent shall conform in all respects to the description thereof in the related Fundamental Change Repurchase Notice. 
 The Fundamental Change Repurchase Notice shall state: 
 (A) if certificated, the certificate numbers of Notes to be delivered for repurchase; 
 (B)
the portion of the principal amount of Notes to be repurchased, which must be $1,000 or an integral multiple thereof; and 
  

 94 

 (C) that the Notes are to be repurchased by the Company pursuant to the applicable
provisions of the Notes and this Indenture; 
 provided, however, that if the Notes are not in certificated form, the Fundamental Change
Repurchase Notice must comply with appropriate Depositary procedures. 
 Any repurchase by the Company contemplated pursuant to the
provisions of this Section 16.04 shall be consummated by the payment of the Fundamental Change Repurchase Price pursuant to Section 16.06(a). 
 Notwithstanding anything herein to the contrary, any holder delivering to the Paying Agent the Fundamental Change Repurchase Notice contemplated by this Section 16.04 shall have the right to withdraw, in whole or
in part, such Fundamental Change Repurchase Notice at any time prior to the close of business on the Business Day immediately preceding the Fundamental Change Repurchase Date in accordance with Section 16.05 below. 
 The Paying Agent shall promptly notify the Company of the receipt by it of any Fundamental Change Repurchase Notice or written notice of withdrawal
thereof. 
 (b) On or before the twentieth calendar day after the occurrence of the effective date of a Fundamental Change, the Company shall
mail or cause to be mailed to all holders of record of the Notes (and to beneficial owners if required by applicable law) a notice (the “Fundamental Change Company Notice”) of, and issue a press release (and make such press release
available on the Company’s website) in respect of, the occurrence of the effective date of the Fundamental Change and of the repurchase right at the option of the holders arising as a result thereof. Such mailing shall be by first class mail.
The Company shall also deliver a copy of the Fundamental Change Company Notice to the Trustee, the Paying Agent and the Conversion Agent within five Business Days after the effective date of the Fundamental Change. Simultaneously with the providing
of such notice, the Company will also issue a press release containing the information set forth in the Fundamental Change Company Notice and make the press release available on the Company’s website. Each Fundamental Change Company Notice
shall specify: 
 (i) the events causing the Fundamental Change; 
 (ii) the effective date of the Fundamental Change, and whether the Fundamental Change is a Make-Whole Fundamental Change, in which case
the effective date of the Make-Whole Fundamental Change; 
 (iii) the last date on which a holder may exercise the repurchase
right pursuant to this Section 16.04; 
 (iv) the Fundamental Change Repurchase Price; 
 (v) the Fundamental Change Repurchase Date; 
 (vi) if applicable, the name and address of the Paying Agent and the Conversion Agent; 
  

 95 

 (vii) if applicable, the applicable Conversion Rate, and any adjustments to the
applicable Conversion Rate; 
 (viii) if applicable, that the Notes with respect to which a Fundamental Change Repurchase
Notice has been delivered by a holder may be converted only if the holder withdraws the Fundamental Change Repurchase Notice in accordance with the terms of this Indenture; 
 (ix) that the holder must exercise the repurchase right on or prior to the close of business on the Business Day immediately preceding the
Fundamental Change Repurchase Date (the “Fundamental Change Expiration Time”); 
 (x) that the holder shall
have the right to withdraw any Notes surrendered prior to the Fundamental Change Expiration Time; and 
 (xi) the procedures
that holders must follow to require the Company to repurchase their Notes. 
 No failure of the Company to give a Fundamental Change Company
Notice and no defect therein shall limit the Noteholders’ repurchase rights or affect the validity of the proceedings for the repurchase of the Notes pursuant to this Section 16.04. 
 (c) Notwithstanding the foregoing, no Notes may be repurchased by the Company at the option of the holders upon a Fundamental Change if the principal
amount of the Notes has been accelerated, and such acceleration has not been rescinded, on or prior to the Fundamental Change Repurchase Date (except in the case of an acceleration resulting from a default by the Company in the payment of the
Fundamental Change Repurchase Price with respect to such Notes). 
 (d) In connection with any purchase offer, the Company will: 

(i) comply with the provisions of Rule 13e-4, Rule 14e-1 and any other tender offer rules under the Exchange Act, if required under the
Exchange Act, 
 (ii) file a Schedule TO or any successor or similar schedule, if required under the Exchange Act, and

 (iii) otherwise comply with all federal and state securities laws in connection with any offer by the Company to purchase
the Notes. 
 Notwithstanding anything to the contrary provided in this Indenture, compliance by the Company with Rule 13e-4, Rule 14e-1 and
any other tender offer rule under the Exchange Act in accordance with clause (i) above, to the extent inconsistent with any other provision of this Indenture, will not, standing alone, constitute an Event of Default solely as a result of
compliance by the Company with such rules. 
  

 96 

 Notwithstanding the foregoing the Company shall not be required to repurchase the Notes in accordance
with this Section 16.04 if a third party makes an offer in the manner, at the times and otherwise in compliance with the requirements set forth in this Section 16.04 and purchases all Notes validly tendered and not withdrawn under such
purchase offer. 
 SECTION 16.05. Withdrawal of Fundamental Change Repurchase Notice. 
 (a) A Fundamental Change Repurchase Notice may be withdrawn by means of a written notice of withdrawal delivered to the Corporate Trust Office of the
Paying Agent in accordance with this Section 16.05 at any time prior to the close of business on the Business Day immediately preceding the Fundamental Change Repurchase Date, specifying: 
 (i) the certificate number, if any, of the Note in respect of which such notice of withdrawal is being submitted, 
 (ii) the principal amount of the Note with respect to which such notice of withdrawal is being submitted, and 
 (iii) the principal amount, if any, of such Note that remains subject to the original Fundamental Change Repurchase Notice, which portion
must be in principal amounts of $1,000 or an integral multiple of $1,000; 
 provided, however, that if the Notes are not in certificated form,
the withdrawal notice must comply with appropriate procedures of the Depositary. 
 SECTION 16.06. Deposit of Fundamental Change
Repurchase Price. 
 (a) The Company will deposit with the Trustee (or other Paying Agent appointed by the Company, or if the Company is
acting as its own Paying Agent, set aside, segregate and hold in trust as provided in Section 5.04) on or prior to 11:00 a.m., New York City time, on the Fundamental Change Repurchase Date an amount of money sufficient to repurchase all of the
Notes to be repurchased at the appropriate Fundamental Change Repurchase Price. Subject to receipt of funds and/or Notes by the Trustee (or other Paying Agent appointed by the Company), payment for Notes surrendered for repurchase (and not withdrawn
prior to the Fundamental Change Expiration Time) will be made on the later of (i) the Fundamental Change Repurchase Date with respect to such Note (provided the holder has satisfied the conditions in Section 16.04) and (ii) the time
of book-entry transfer or the delivery of such Note to the Trustee (or other Paying Agent appointed by the Company) by the holder thereof in the manner required by Section 16.04 by mailing checks for the amount payable to the holders of such
Notes entitled thereto as they shall appear in the Note Register, provided, however, that payments to the Depositary shall be made by wire transfer of immediately available funds to the account of the Depositary or its nominee. The Trustee shall,
promptly after such payment and upon written demand by the Company, return to the Company any funds in excess of the Fundamental Change Repurchase Price. 
 (b) If by 11:00 a.m. New York City time, on the Fundamental Change Repurchase Date, the Trustee (or other Paying Agent appointed by the Company) holds money sufficient to make payment on all the Notes or portions
thereof that are to be repurchased as a 

  

 97 

 
result of the corresponding Fundamental Change, then (i) such Notes will cease to be outstanding, (ii) interest, including Additional Interest, if
any, will cease to accrue on such Notes, and (iii) all other rights of the holders of such Notes will terminate (other than the right to receive the Fundamental Change Repurchase Price, and previously accrued but unpaid interest, including
Additional Interest, if any, upon book-entry transfer or delivery of the Notes), in each case, whether or not book-entry transfer of the Notes has been made or the Notes have been delivered to the Trustee or Paying Agent. 
 (c) Upon surrender of a Note that is to be repurchased in part pursuant to Section 16.04, the Company shall execute and the Trustee shall
authenticate and deliver to the holder a new Note in an authorized denomination equal in principal amount to the unrepurchased portion of the Note surrendered. 
 ARTICLE XVII 
 MISCELLANEOUS PROVISIONS 
 SECTION 17.01. Provisions Binding on Company’s Successors. All the covenants, stipulations, promises and agreements of the Company
contained in this Indenture shall bind its successors and assigns whether so expressed or not. 
 SECTION 17.02. Official Acts by
Successor Corporation. Any act or proceeding by any provision of this Indenture authorized or required to be done or performed by any board, committee or officer of the Company shall and may be done and performed with like force and effect by
the like board, committee or officer of any corporation or other entity that shall at the time be the lawful successor of the Company. 
 SECTION 17.03. Addresses for Notices, Etc. Any notice or demand that by any provision of this Indenture is required or permitted to be given or served by the Trustee or by the Noteholders on the Company shall be deemed to have
been sufficiently given or made, for all purposes if given or served by being deposited postage prepaid by registered or certified mail in a post office letter box addressed (until another address is filed by the Company with the Trustee) to Salix
Pharmaceuticals, Ltd., 1700 Perimeter Park Drive, Morrisville, North Carolina 27560, Attention: General Counsel, with a copy to the Chief Financial Officer of the Company at the same address and to Wyrick Robbins Yates & Ponton LLP, 4101
Lake Boone Trail Suite 300, Raleigh, NC 27607, Attention: Donald R. Reynolds. Any notice, direction, request or demand hereunder to or upon the Trustee shall be deemed to have been sufficiently given or made, for all purposes, if given or served by
being deposited postage prepaid by registered or certified mail in a post office letter box addressed to the Corporate Trust Office. 
 The
Trustee, by notice to the Company, may designate additional or different addresses for subsequent notices or communications. 
 Any notice or
communication mailed to a Noteholder shall be mailed to it by first class mail, postage prepaid, at its address as it appears on the Note Register and shall be deemed to have been sufficiently given to it if so mailed within the time prescribed.

 Failure to mail a notice or communication to a Noteholder or any defect in it shall not affect its sufficiency with respect to other
Noteholders. Except as otherwise provided herein, if a notice or communication is mailed in the manner provided above, it is duly given, whether or not the addressee receives it. 
  

 98 

 In case by reason of the suspension of regular mail service or by reason of any other cause it shall be
impracticable to give such notice to holders by mail, then such notification as shall be made with the approval of the Trustee shall constitute a sufficient notification for every purpose hereunder. 
 Except as otherwise provided in this Indenture or any Note, where this Indenture or any Note provides for notice of any event to a holder of a Global
Note (whether by mail or otherwise), such notice shall be sufficiently given if given to the Depositary for such Note (or its designee), pursuant to customary procedures of such Depositary. 
 SECTION 17.04. Governing Law. THIS INDENTURE AND EACH NOTE SHALL BE DEEMED TO BE A CONTRACT MADE UNDER THE LAWS OF NEW YORK, AND FOR ALL
PURPOSES SHALL BE CONSTRUED IN ACCORDANCE WITH THE LAWS OF NEW YORK (WITHOUT REGARD TO THE CONFLICTS OF LAWS PROVISIONS THEREOF). 
 SECTION 17.05. Evidence of Compliance with Conditions Precedent; Certificates and Opinions of Counsel to Trustee. 
 (a)
Upon any request or application by the Company to the Trustee to take any action under this Indenture, the Company shall furnish to the Trustee: 
 (i) an Officers’ Certificate stating that, in the opinion of the signers, all conditions precedent, if any, provided for in this Indenture relating to the proposed action have been complied with; and 

(ii) an Opinion of Counsel stating that, in the opinion of such counsel, all such conditions precedent have been complied with.

 (b) Each certificate or opinion with respect to compliance with a condition or covenant provided for in this Indenture shall include:

 (i) a statement that each person signing such certificate or opinion has read such covenant or condition and the
definitions herein relating thereto; 
 (ii) a brief statement as to the nature and scope of the examination or investigation
upon which the statement or opinion contained in such certificate or opinion is based; 
 (iii) a statement that, in the
opinion of each such person, the person has made such examination or investigation as is necessary to enable the person to express an informed opinion as to whether or not such covenant or condition has been complied with; and 
  

 99 

 (iv) a statement as to whether or not, in the opinion of each such person, such condition
or covenant has been complied with; provided, however, that, with respect to matters of fact, an Opinion of Counsel may rely on an Officers’ Certificate or certificates of public officials. 
 SECTION 17.06. Legal Holidays. In any case where any Interest Payment Date, Redemption Date, Repurchase Date, Fundamental Change Repurchase
Date, Conversion Date or Maturity Date is not a Business Day, then any action to be taken on such date need not be taken on such date, but may be taken on the next succeeding Business Day with the same force and effect as if taken on such date, and
no interest shall accrue for the period from and after such date. 
 SECTION 17.07. No Security Interest Created. Nothing in this
Indenture or in the Notes, expressed or implied, shall be construed to constitute a security interest under the Uniform Commercial Code or similar legislation, as now or hereafter enacted and in effect, in any jurisdiction. 
 SECTION 17.08. Benefits of Indenture. Nothing in this Indenture or in the Notes, expressed or implied, shall give to any Person, other than
the parties hereto, any Paying Agent, any Conversion Agent, any authenticating agent, any Note Registrar and their successors hereunder or the Noteholders, any benefit or any legal or equitable right, remedy or claim under this Indenture.

 SECTION 17.09. Table of Contents, Headings, Etc. The table of contents and the titles and headings of the articles and
sections of this Indenture have been inserted for convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof. 
 SECTION 17.10. Authenticating Agent. The Trustee may appoint an authenticating agent that shall be authorized to act on its behalf and
subject to its direction in the authentication and delivery of Notes in connection with the original issuance thereof and transfers and exchanges of Notes hereunder, including under Section 2.05, Section 2.06, Section 2.07,
Section 2.08, Section 3.05, Section 11.04, Section 15.02, Section 16.03 and Section 16.06 as fully to all intents and purposes as though the authenticating agent had been expressly authorized by this Indenture and those
Sections to authenticate and deliver Notes. For all purposes of this Indenture, the authentication and delivery of Notes by the authenticating agent shall be deemed to be authentication and delivery of such Notes “by the Trustee” and a
certificate of authentication executed on behalf of the Trustee by an authenticating agent shall be deemed to satisfy any requirement hereunder or in the Notes for the Trustee’s certificate of authentication. Such authenticating agent shall at
all times be a Person eligible to serve as trustee hereunder pursuant to Section 8.09. 
 Any corporation or other entity into which any
authenticating agent may be merged or converted or with which it may be consolidated, or any corporation or other entity resulting from any merger, consolidation or conversion to which any authenticating agent shall be a party, or any corporation or
other entity succeeding to the corporate trust business of any authenticating agent, shall be the successor of the authenticating agent hereunder, if such 

  

 100 

 
successor corporation or other entity is otherwise eligible under this section, without the execution or filing of any paper or any further act on the part
of the parties hereto or the authenticating agent or such successor corporation or other entity. 
 Any authenticating agent may at any time
resign by giving written notice of resignation to the Trustee and to the Company. The Trustee may at any time terminate the agency of any authenticating agent by giving written notice of termination to such authenticating agent and to the Company.
Upon receiving such a notice of resignation or upon such a termination, or in case at any time any authenticating agent shall cease to be eligible under this Section, the Trustee may appoint a successor authenticating agent (which may be the
Trustee), shall give written notice of such appointment to the Company and shall mail notice of such appointment to all Noteholders as the names and addresses of such holders appear on the Note Register. 
 The Company agrees to pay to the authenticating agent from time to time reasonable compensation for its services although the Company may terminate the
authenticating agent, if it determines such agent’s fees to be unreasonable. 
 The provisions of Section 8.02, Section 8.03,
Section 8.04, Section 9.03 and this Section 17.10 shall be applicable to any authenticating agent. 
 If an authenticating
agent is appointed pursuant to this Section 17.10, the Notes may have endorsed thereon, in addition to the Trustee’s certificate of authentication, an alternative certificate of authentication in the following form: 
  

							
	  
	 	,	 	
	as Authenticating Agent, certifies that this is one of the Notes described in the within-named Indenture.

  

			
		
	By:	 	  

		 	Authorized Officer

 SECTION 17.11. Execution in Counterparts. This Indenture may be executed in any number
of counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same instrument. 
 SECTION 17.12. Severability. In the event any provision of this Indenture or in the Notes shall be invalid, illegal or unenforceable, then (to the extent permitted by law) the validity, legality or enforceability of the
remaining provisions shall not in any way be affected or impaired. 
 SECTION 17.13. Waiver of Jury Trial. EACH OF THE COMPANY
AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES OR THE TRANSACTION CONTEMPLATED HEREBY.

  

 101 

 SECTION 17.14. Force Majeure. In no event shall the Trustee be responsible or liable for any
failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or
military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services; it being understood that the Trustee shall use reasonable
efforts that are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances. 
 SECTION 17.15. Calculations in Respect of the Notes. Except as otherwise provided herein, the Company shall make all calculations under this Indenture and the Notes (including, without limitation, the Last Reported Sale Price,
accrued interest payable and the Conversion Rate). All calculations under this Indenture and the Notes shall be made in good faith. In the absence of manifest error, such calculations shall be final and binding on all holders. The Company shall
provide a copy of any such calculation it has made to the Trustee and the Conversion Agent as required hereunder, and both of the Trustee and Conversion Agent shall be entitled to rely conclusively on the accuracy of any such calculation without
independent verification. The Trustee and any other Conversion Agent shall forward the Company’s calculations or any calculations by the Trustee or such other Conversion Agent, as applicable, to any Noteholder upon the written request of that
Noteholder. 
  

 102 

 IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed as of the date
first written above. 
  

			
	SALIX PHARMACEUTICALS, LTD.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	U.S. BANK NATIONAL ASSOCIATION, as Trustee
		
	By:	 	  

	Name:	 	
	Title:	 	

 [CONVERTIBLE NOTES INDENTURE] 

 IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed as of the date
first written above. 
  

			
	SALIX PHARMACEUTICALS, LTD.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	U.S. BANK NATIONAL ASSOCIATION, as Trustee
		
	By:	 	  

	Name:	 	
	Title:	 	

 [CONVERTIBLE NOTES INDENTURE] 

 EXHIBIT A 
 [FORM OF FACE OF NOTE] 
 [UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST
COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY
AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON
IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.]1 
 [THIS SECURITY AND THE COMMON STOCK, IF ANY, ISSUABLE UPON CONVERSION OF THIS SECURITY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD, PLEDGED, OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF OR OF A BENEFICIAL INTEREST HEREIN, THE ACQUIRER: 
 (1) REPRESENTS THAT IT, AND ANY ACCOUNT FOR WHICH IT IS ACTING, IS A “QUALIFIED INSTITUTIONAL BUYER” (WITHIN THE MEANING OF RULE 144A UNDER THE
SECURITIES ACT) AND THAT IT EXERCISES SOLE INVESTMENT DISCRETION WITH RESPECT TO EACH SUCH ACCOUNT; AND 
 (2) AGREES FOR THE BENEFIT OF THE
COMPANY THAT IT WILL NOT OFFER, SELL, PLEDGE, OR OTHERWISE TRANSFER THIS SECURITY OR ANY BENEFICIAL INTEREST HEREIN PRIOR TO THE RESALE RESTRICTION TERMINATION DATE (AS DEFINED IN THE NEXT PARAGRAPH), EXCEPT: 
 (A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF; OR 
 (B) PURSUANT TO A REGISTRATION STATEMENT THAT HAS BECOME EFFECTIVE UNDER THE SECURITIES ACT; OR 
 (C) TO A QUALIFIED INSTITUTIONAL
BUYER IN COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT; OR 
 (D) PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER
THE SECURITIES ACT OR ANY OTHER AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. 
  

	1	Use bracketed language for a Global Note. Such language should remain on any Global Note even after the restricted legend that follows has been removed or deemed removed.

  

 A-1 

 THE RESALE RESTRICTION TERMINATION DATE WILL BE THE DATE (1) THAT IS AT LEAST ONE YEAR AFTER THE
LAST ORIGINAL ISSUE DATE HEREOF; AND (2) ON WHICH THE COMPANY INSTRUCTS THE TRUSTEE THAT THIS LEGEND SHALL BE DEEMED REMOVED FROM THIS SECURITY, IN ACCORDANCE WITH THE PROCEDURES DESCRIBED IN THE INDENTURE RELATING TO THIS SECURITY. 

PRIOR TO THE REGISTRATION OF ANY TRANSFER IN ACCORDANCE WITH PARAGRAPH 2(D) ABOVE, THE COMPANY AND THE TRUSTEE RESERVE THE RIGHT TO REQUIRE THE DELIVERY OF SUCH LEGAL
OPINIONS, CERTIFICATIONS, OR OTHER EVIDENCE AS MAY REASONABLY BE REQUIRED IN ORDER TO DETERMINE THAT THE PROPOSED TRANSFER IS BEING MADE IN COMPLIANCE WITH THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. NO REPRESENTATION IS MADE AS TO THE
AVAILABILITY OF ANY EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.]2 
  

	2	Use bracketed language for Restricted Securities. 

  

 A-2 

 SALIX PHARMACEUTICALS, LTD. 
 5.5% Convertible Senior Note due 2028 
  

			
	No. [        ]	 	$60,000,000
		
	CUSIP No. 795435AA4*	 	

 Salix Pharmaceuticals, Ltd., a corporation duly organized and validly existing under the laws of
the State of Delaware (herein called the “Company,” which term includes any successor corporation or other entity under the Indenture referred to on the reverse hereof), for value received hereby promises to pay to [CEDE & CO., or
its registered assigns,]3 the principal sum of sixty million Dollars, [as revised by the Schedule of Increases and Decreases in Global Note attached
hereto,]4 on August 15, 2028, interest thereon as set forth below and Additional Interest in the manner, at the rates and to the Persons set
forth in Sections 5.06(d), 5.06(e) and 7.03, as applicable, of the Indenture. 
 The Company promises to pay interest on the principal amount
of this Note at the rate of 5.5% per annum (subject to increase pursuant to Sections 5.06(d), 5.06(e) and 7.03, as applicable, of the Indenture) from August 22, 2008 until August 15, 2028. The Company will pay interest semi-annually
on February 15 and August 15 of each year, commencing on February 15, 2009, to holders of record at the close of business on the preceding February 1 and August 1 (whether or not such day is a Business Day), respectively.
Interest on the Note will accrue from the most recent date to which interest has been paid, or, if no interest has been paid on the Note, from August 22, 2008. 
 Payment of the principal of and accrued and unpaid interest and Additional Interest, if any, on this Note shall be made at the office or agency of the Company maintained for that purpose in the Borough of Manhattan,
The City of New York, in such lawful money of the United States of America as at the time of payment shall be legal tender for the payment of public and private debts; provided, however, that any payment to the Depositary or its
nominee shall be paid by wire transfer in immediately available funds in accordance with the wire transfer instruction supplied by the Depositary or its nominee from time to time to the Trustee and Paying Agent (if different from Trustee).

 Reference is made to the further provisions of this Note set forth on the reverse hereof, including, without limitation, provisions giving
the holder of this Note the right to convert this Note into cash, shares of Common Stock of the Company or a combination of cash and shares of Common Stock, as applicable, on the terms and subject to the limitations set forth in the Indenture. Such
further provisions shall for all purposes have the same effect as though fully set forth at this place. 
  

	3	Use bracketed language for a Global Note. 

	4	Use bracketed language for a Global Note. 

  

 A-3 

	*	Subject to terms and conditions of the Indenture, at such time as the Company notifies the Trustee to remove the restrictive legend pursuant to Section 2.06(d) of the
Indenture, the CUSIP number for this Note shall be deemed to be CUSIP No. 795435AB2. 

 This Note shall be deemed to be a
contract made under the laws of the State of New York, and for all purposes shall be construed in accordance with and governed by the laws of said State (without regard to the conflicts of laws provisions thereof). 
 This Note shall not be valid or become obligatory for any purpose until the certificate of authentication hereon shall have been manually signed by the
Trustee or a duly authorized authenticating agent under the Indenture. 
 [Remainder of page intentionally left blank] 
  

 A-4 

 IN WITNESS WHEREOF, the Company has caused this Note to be duly executed. 
  

			
	SALIX PHARMACEUTICALS, LTD.
		
	By:	 	  

	Name:	 	
	Title:	 	

  

			
	Dated:	 	
	
	 TRUSTEE’S CERTIFICATE OF AUTHENTICATION
 U.S. BANK NATIONAL ASSOCIATION
 as Trustee, certifies that this is one of the Notes described in the within-named Indenture.

			
		
	By:	 	  

		 	Authorized Officer

  

 A-5 

 [FORM OF REVERSE OF NOTE] 
 SALIX PHARMACEUTICALS, LTD. 
 5.5% Convertible Senior Note due 2028 
 This Note is one of a duly authorized issue of Notes of the Company, designated as its 5.5% Convertible Senior Notes due 2028 (the “Notes”),
limited to the aggregate principal amount of $60,000,000 all issued or to be issued under and pursuant to an Indenture dated as of August 22, 2008 (as such may be amended from time to time, the “Indenture”), between the Company and
U.S. Bank National Association (the “Trustee”), to which Indenture and all indentures supplemental thereto reference is hereby made for a description of the rights, limitations of rights, obligations, duties and immunities thereunder of
the Trustee, the Company and the holders of the Notes. Additional Notes may be issued in an unlimited aggregate principal amount, subject to certain conditions specified in the Indenture. 
 In case an Event of Default, as defined in the Indenture, shall have occurred and be continuing, the principal of and interest, including Additional
Interest, if any, on all Notes may be declared, by either the Trustee or the holders of not less than 25% in aggregate principal amount of Notes then outstanding, and upon said declaration shall become, due and payable, in the manner, with the
effect and subject to the conditions and certain exceptions set forth in the Indenture. 
 Subject to the terms and conditions of the
Indenture, the Company will make all payments and deliveries in respect of the principal amount on the Maturity Date, as the case may be, to the holder who surrenders a Note to a Paying Agent to collect such payments in respect of the Note. The
Company will pay cash amounts in money of the United States that at the time of payment is legal tender for payment of public and private debts. 
 The Indenture contains provisions permitting the Company and the Trustee in certain circumstances, without the consent of the holders of the Notes, and in other circumstances, with the consent of the holders of not less than a majority in
aggregate principal amount of the Notes at the time outstanding, evidenced as in the Indenture provided, to execute supplemental indentures modifying the terms of the Indenture and the Notes as described therein. It is also provided in the Indenture
that, subject to certain exceptions, the holders of a majority in aggregate principal amount of the Notes at the time outstanding may on behalf of the holders of all of the Notes waive any past Default or Event of Default under the Indenture and its
consequences. 
 No reference herein to the Indenture and no provision of this Note or of the Indenture shall alter or impair the obligation
of the Company, which is absolute and unconditional, to pay the principal of and accrued and unpaid interest, and Additional Interest, if any, on this Note at the place, at the respective times, at the rate and in the lawful money herein prescribed.

 The Notes are issuable in registered form without coupons in denominations of $1,000 principal amount and integral multiples thereof. At
the office or agency of the Company referred to on the face hereof, and in the manner and subject to the limitations provided in the 

  

 A-6 

 
Indenture, Notes may be exchanged for a like aggregate principal amount of Notes of other authorized denominations, without payment of any service charge
but, if required by the Company or Trustee, with payment of a sum sufficient to cover any tax, assessments or other governmental charges that may be imposed in connection therewith as a result of the name of the holder of the new Notes issued upon
such exchange of Notes being different from the name of the holder of the old Notes surrendered for such exchange. 
 Subject to the
provisions of the Indenture, the Notes are subject to redemption at the option of the Company after August 15, 2013 at the Redemption Price. 
 Subject to the provisions of the Indenture, upon the occurrence of a Fundamental Change or on the Repurchase Dates, the holder has the right, at such holder’s option, to require the Company to repurchase for cash all of such
holder’s Notes or any portion thereof (in principal amounts of $1,000 or integral multiples thereof) on the Fundamental Change Repurchase Date or the applicable Repurchase Date, as the case may be, at a price equal to the Fundamental Change
Repurchase Price or the Repurchase Price, as the case may be. 
 Subject to the provisions of the Indenture, the holder hereof has the right,
at its option, during certain periods and upon the occurrence of certain conditions specified in the Indenture, prior to the close of business on the Business Day immediately preceding the Maturity Date, to convert any Notes, into cash, shares of
Common Stock or a combination of cash and shares of Common Stock, as applicable, at a Conversion Rate specified in the Indenture, as adjusted from time to time as provided in the Indenture. 
 Terms used in this Note and defined in the Indenture are used herein as therein defined. 
  

 A-7 

 ABBREVIATIONS 
 The following abbreviations, when used in the inscription of the face of this Note, shall be construed as though they were written out in full according to applicable laws or regulations: 
  

					
	TEN COM -as tenants in common	  	UNIF GIFT MIN ACT	  	
			
		  	  
	  	Custodian
		  	(Cust)	  	
			
	TEN ENT as tenants by the entireties	  		  	
			
		  	  
	  	
		  	(Minor)	  	
			
	JT TEN -as joint tenants with right of survivorship and not as tenants in common	  		  	
		  	Uniform Gifts to Minors Act	  	
			
		  	  
	  	(State)

 Additional abbreviations may also be used 
 though not in the above list. 
  

 A-8 

 SCHEDULE OF INCREASES AND DECREASES IN GLOBAL NOTE5 
 SALIX PHARMACEUTICALS, LTD. 
 5.5% Convertible Senior Notes due 2028 
 The
initial principal amount of this Global Note is $60,000,000. The following increases or decreases in this Global Note have been made: 
  

									
	 Date
	  	Amount of decrease in
Principal Amount of this
Global Note	  	Amount of increase in
Principal Amount of this
Global Note	  	Principal Amount of this
Global Note following
such decrease or increase	  	Signature of
authorized signatory of
Trustee or
Custodian
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	

  

	5	For Global Notes only. 

  

 A-9 

 EXHIBIT B 
 [FORM OF NOTICE OF CONVERSION] 
 To: SALIX PHARMACEUTICALS, LTD. 
 The undersigned registered owner of this Note hereby exercises the option to convert this Note, or the portion hereof (that is $1,000 principal amount or
an integral multiple thereof) below designated, into cash, shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, in accordance with the terms of the Indenture referred to in this Note, and directs that any shares
of Common Stock issuable and deliverable upon such conversion, together with any cash comprising the Daily Conversion Values or a portion of the Daily Settlement Amounts for each of the forty Trading Days during the Cash Settlement Averaging Period
and for any fractional shares, and any Notes representing any unconverted principal amount hereof, be issued and delivered to the registered holder hereof unless a different name has been indicated below. If any shares of Common Stock or any portion
of this Note not converted are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Any amount required to be paid to the undersigned on account of interest
accompanies this Note. 
  

									
	Dated:	  	  
	  		  	  
	  	
		  		  		  	  
	  	
		  		  		  	Signature(s)	  	

  

	
	Signature Guarantee
	
	Signature(s) must be guaranteed by an eligible Guarantor Institution (banks, stock brokers, savings and loan associations and credit unions) with membership in an approved signature guarantee
medallion program pursuant to Securities and Exchange Commission Rule 17Ad-15 if shares of Common Stock are to be issued, or Notes to be delivered, other than to and in the name of the registered holder.

  

 B-1 

			
	Fill in for registration of shares if to be issued, and Notes if to be delivered, other than to and in the name of the registered holder:
	  
	 	
	(Name)	 	
		
	  
	 	
	(Street Address)	 	
		
	  
	 	
	 (City, State and Zip Code)
 Please print name and address

	 	

  

	
	Principal amount to be converted (if less than all):
	$            ,000
	
	NOTICE: The above signature(s) of the holder(s) hereof must correspond with the name as written upon the face of the Note in every particular without alteration or enlargement or any change
whatever.
	
	  

	Social Security or Other Taxpayer Identification Number

  

 B-2 

 Exhibit C 
 [FORM OF REPURCHASE NOTICE] 
 To: SALIX PHARMACEUTICALS, LTD. 
 The undersigned registered owner of this Note hereby acknowledges receipt of a notice from SALIX PHARMACEUTICALS, LTD. (the “Company”) as to
the occurrence of a Repurchase Date and specifying the Repurchase Date and requests and instructs the Company to repay to the registered holder hereof in accordance with the applicable provisions of the Indenture referred to in this Note
(1) the entire principal amount of this Note, or the portion thereof (that is $1,000 principal amount or an integral multiple thereof) below designated, and (2) if such Repurchase Date does not fall during the period after an Interest
Record Date and on or prior to the corresponding Interest Payment Date, accrued and unpaid interest, including Additional Interest, if any, thereon to, but excluding, such Repurchase Date. 
 In the case of certificated Notes, the certificate numbers of the Notes to be repurchased are as set forth below: 
  

					
	Dated:                     	 	  

		
		 	  

		 	Signature(s)
		
		 	  

		 	Social Security or Other Taxpayer Identification Number
		
		 	Principal amount to be repaid (if less than all):
		 	$            ,000
			
		 	NOTICE:	 	The above signature(s) of the holder(s) hereof must correspond with the name as written upon the face of the Note in every particular without alteration or enlargement or any change whatever.

  

 C-1 

 EXHIBIT D 
 [FORM OF FUNDAMENTAL CHANGE REPURCHASE NOTICE] 
 To: SALIX PHARMACEUTICALS, LTD. 
 The undersigned registered owner of this Note hereby acknowledges receipt of a notice from Salix Pharmaceuticals, Ltd. (the “Company”) as to the occurrence of
a Fundamental Change with respect to the Company and specifying the Fundamental Change Repurchase Date and requests and instructs the Company to repay to the registered holder hereof in accordance with the applicable provisions of the Indenture
referred to in this Note (1) the entire principal amount of this Note, or the portion thereof (that is $1,000 principal amount or an integral multiple thereof) below designated, and (2) if such Fundamental Change Repurchase Date does not
fall during the period after an Interest Record Date and on or prior to the corresponding Interest Payment Date, accrued and unpaid interest, including Additional Interest, if any, thereon to, but excluding, such Fundamental Change Repurchase Date.

 In the case of certificated Notes, the certificate numbers of the Notes to be repurchased are as set forth below: 
  

			
	Dated:                     	 	
		 	  

		 	Signature(s)
		
		 	  

		 	Social Security or Other Taxpayer Identification Number
		
		 	Principal amount to be repaid (if less than all):
		 	$            ,000
		
		 	NOTICE: The above signature(s) of the holder(s) hereof must correspond with the name as written upon the face of the Note in every particular without alteration or enlargement or any change
whatever.

  

 D-1 

 EXHIBIT E 
 [FORM OF ASSIGNMENT AND TRANSFER] 
 For value received
                                 hereby sell(s), assign(s) and transfer(s) unto
                     (Please insert social security or Taxpayer Identification Number of assignee) the within Note, and hereby irrevocably
constitutes and appoints                      attorney to transfer the said Note on the books of the Company, with full power of substitution
in the premises. 
 In connection with any transfer of the within Note occurring prior to the Resale Restriction Termination Date, as defined in the
Indenture governing such Note, the undersigned confirms that such Note is being transferred: 
  

	 ̈	To Salix Pharmaceuticals, Ltd. or a subsidiary thereof; or 

  

	 ̈	Pursuant to the registration statement that has become or been declared effective under the Securities Act of 1933, as amended; or 

  

	 ̈	Pursuant to and in compliance with Rule 144A under the Securities Act of 1933, as amended; or 

  

	 ̈	Pursuant to and in compliance with Rule 144 under the Securities Act of 1933, as amended; or 

  

	 ̈	Pursuant to another available exemption from registration under the Securities Act of 1933, as amended. 

  

			
	Dated:	 	  

	
	  

	
	  

	Signature(s)
	
	  

	Signature Guarantee

  

 E-1 

	
	Signature(s) must be guaranteed by an eligible Guarantor Institution (banks, stock brokers, savings and loan associations and credit unions) with membership in an approved signature guarantee
medallion program pursuant to Securities and Exchange Commission Rule l7Ad-15 Notes are to be delivered, other than to and in the name of the registered holder.

 NOTICE: The signature on the assignment must correspond with the name as written upon the face of the Note in
every particular without alteration or enlargement or any change whatever. 
  

 E-2 

 EXHIBIT F 
 [FORM OF FREE TRANSFERABILITY CERTIFICATE] 
 CUSIP: 795435AA4 
 Dear Sir/Madam: 
 Whereas the 5.5% Convertible Senior Notes
due 2028 (the “Notes”) have become freely tradable without restrictions by non-affiliates of Salix Pharmaceuticals, Ltd. (the “Company”) pursuant to Rule 144(b)(1) under the Securities Act of 1933, as amended, in accordance with
Section 2.06 of the indenture (the “Indenture”) dated as of August 22, 2008 between the Company and U.S. Bank National Association, as Trustee, pursuant to which the Securities were issued, the Company hereby instructs you that:

 (i) the restrictive legends described in Section 2.06 of the Indenture and set forth on the Notes and Common Stock
issued upon conversion of the Notes shall be deemed removed from the Global Note, in accordance with the terms and conditions of the Securities and as provided in the Indenture, without further action on the part of holders; and 
 (ii) the restricted CUSIP number for the Securities shall be deemed removed from the Global Note and replaced with the unrestricted CUSIP
number set forth therein, in accordance with the terms and conditions of the Securities and as provided in the Indenture, without further action on the part of holders. 
 Capitalized terms used but not defined herein shall have the meanings set forth in the Indenture. 
  

			
	Very truly yours,
	
	SALIX PHARMACEUTICALS, LTD.
		
	By:	 	  

	Name:	 	
	Title*:	 	

  

	*	The signatory must be one of the officers authorized by the indenture to sign the certificate. 

  

 F-1Manufacturing and Supply Agreement - Formosa Laboratories, Inc.

 Exhibit 10.1 
  

	[***]	CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 MANUFACTURING AND SUPPLY AGREEMENT 
 This MANUFACTURING AND SUPPLY AGREEMENT (this “Agreement”), effective as of August 19, 2008 (the “Effective
Date”), is made by and between NeurogesX Inc., a Delaware California corporation having a principal place of business at 2215 Bridgepointe Parkway, Suite 200, San Mateo, California 94404 U.S.A. (“NeurogesX”), and
Formosa Laboratories, Inc., a Taiwanese corporation having a principal place of business at 36-1 Hoping Street, Louchu County, Tauyuan, Taiwan 338 (“Supplier”). NeurogesX and Supplier may be referred to herein each,
individually, as a “Party” or, collectively, as the “Parties”. 
 BACKGROUND 
 A. NeurogesX has developed and is currently in the process of seeking marketing approval for a product which incorporates trans-capsaicin (the
“API” as further defined below) for the treatment of neuropathic pain. 
 B. Supplier has developed methods for and has experience
and know how in manufacturing API under GMP conditions. 
 C. NeurogesX desires to engage Supplier, and Supplier desires to perform, the
manufacturing and supply of such API in bulk form for NeurogesX, all on the terms and conditions set forth herein. 
 NOW THEREFORE, for and
in consideration of the covenants, conditions, and undertakings hereinafter set forth, it is agreed by and between the Parties as follows: 
 ARTICLE 1 
 DEFINITIONS 
 As used in this Agreement, the following capitalized terms shall have the meanings indicated below: 
 1.1
“Act” shall mean the United States Federal Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.) and the regulations promulgated thereunder, as such may be amended from time to time. 
 1.2 “API” shall mean the Active Pharmaceutical Ingredient as set forth in the Specifications. An API is any component that is intended
to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to affect the structure or any function of the body of humans or other animals. The term includes those components
that may undergo chemical change in the manufacture of the drug product and be present in the drug product in a modified form intended to furnish the specified activity or effect. 

 1.3 “Approval” shall have the meaning as set forth in Section 7.1 below.

 1.4 “Batch Log Records” shall mean all documentation and records related to the manufacturing process for each batch of
API. 
 1.5 “Confidential Information” shall have the meaning as set forth in Section 10.1 below. 
 1.6 “Deliverables” shall mean the test results, reports and other items that Supplier is obligated to provide to NeurogesX pursuant to a
Proposal. 
 1.7 “Documentation” shall mean all written materials generated in connection with the Services, including the
Batch Log Records, Master Production Record, test results, Certificate of Analysis (“CoA”), analytical test methods, reports, protocols and any other documents related to the manufacturing process for the API, as well as such other
documents reasonably necessary for NeurogesX to complete its regulatory filings. 
 1.8 “Facility” shall mean
Supplier’s GMP manufacturing facility located at [***]. 
 1.9 “FDA” shall mean the United States Food and Drug
Administration, or any successor agency thereto. 
 1.10 “GLP” shall mean good laboratory practice. 
 1.11 “GMP” shall mean current good manufacturing practice and standards as provided for (and as amended from time to time) in the
Current Good Manufacturing Practice Regulations of the U.S. Code of Federal Regulations Title 21 (21 CFR § 11, § 210 and § 211) and in European Community Directive 2004/27/EC and 2004/28/EC (Principle and guidelines of good
manufacturing practice for medicinal products) in relation to the production of pharmaceutical products, as interpreted by the ICH Harmonized Tripartite Guideline, any U.S., European, or other applicable laws, regulations or respective guidance
documents subsequently established in the Territory, and any arrangements, additions or clarifications agreed from time to time between the Parties. 
 1.12 “LTS” shall mean Loehmann Therapie-Systeme AG and its subsidiaries. 
 1.13
“Master Production Record” shall mean the certain documents approved by NeurogesX that define the manufacturing methods and procedures, test methods, specifications, materials, and other procedures, directions and controls
associated with the manufacture and testing of API. 
 1.14 “NeurogesX Property” shall have the meaning set forth in
Section 6.2 below. 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 -2- 

 1.15 “Quality Agreement” shall mean that certain Commercial Quality Assurance Agreement
between the Parties dated June 7, 2006, which is attached hereto as Exhibit A and as such may be modified pursuant to the terms set forth therein. 
 1.16 “Raw Materials” shall mean all raw materials, supplies, components and packaging necessary to manufacture the API in accordance with the Specifications and Master Production Record. 

1.17 “Regulatory Requirements” shall mean (i) compliance with all applicable laws, rules, guidelines, regulations and standards
of governmental authorities, including GMP, and (ii) obtaining and maintaining all licenses and other authorizations required by regulatory authorities, that in each case are applicable to the manufacturing, processing, and supply activities
hereunder, the Facility, or any other facilities at which any of the manufacturing or process activities hereunder may be performed or are applicable in the Territory. 
 1.18 “Services” shall mean the development, validation, and/or other services performed by Supplier pursuant to a Proposal. 
 1.19 “Specifications” shall mean with respect to API, the specifications set forth on Exhibit B hereto, as such may be modified pursuant
to Section 3.5 below. 
 1.20 “Supplier Background Technology” shall mean all patent rights, know-how and other
intellectual property rights developed by Supplier outside the scope of this Agreement (including outside the scope of any Services) without use of or reference to NeurogesX’ Confidential Information, or otherwise acquired or licensed by
Supplier, in each case to the extent controlled by Supplier as of the Effective Date or at any time during the term of this Agreement. 
 1.21 “Proposal(s)” shall have the meaning set forth in Section 4.1 below, as such may be modified pursuant to Section 4.3 below. 
 1.22 “Territory” shall mean [***]. 
 1.23 “$” shall mean the lawful
currency of the United States of America. 
 ARTICLE 2 
 SUPPLY 
 2.1 API Supply. Subject to the terms and conditions of this
Agreement, Supplier shall supply to NeurogesX all quantities of the API ordered by NeurogesX under this Agreement. Supplier shall supply to NeurogesX the API in kilogram orders, but shall not supply the API by aggregating the excess API of batches
manufactured by Supplier for third party clients. In addition, NeurogesX has the exclusive right to purchase any full batch manufactured solely for NeurogesX by submitting an Order pursuant to Section 2.4 below. In addition, Supplier shall use
its best efforts to fulfill the Orders using as few manufacturing runs as possible. 
 2.2 Raw Materials. Supplier shall be
responsible, at its expense, for procuring, inspecting and releasing adequate amounts of Raw Materials from vendors approved by NeurogesX, to meet NeurogesX’ purchase orders, unless otherwise agreed to by the Parties in 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 -3- 

 
writing. NeurogesX approval of vendors shall not be unreasonably withheld or delayed. NeurogesX reserves the right to require the Supplier to purchase Raw
Materials from a particular vendor at a reasonable price upon prior written notice of twelve (12) weeks. If the required change of vendor results in a cost increase of Raw Materials and as a consequence causes the Batch Prices of API, as stated
in Exhibit D attached hereto, to increase more than [***], NeurogesX shall be responsible for that equivalent increase in the Batch Prices of API. Further, Supplier shall conduct tests on each Raw Material and shall provide NeurogesX with the
results of such tests. Such tests include, but are not limited to quality tests to determine the purity, impurity, presence of any heavy metals and tests to identify the raw materials of the API. 
 2.3 Forecasts. At least [***] before the commercial launch of the API or a product incorporating the API (such product a
“Product”), NeurogesX shall provide Supplier with an initial forecast of the quantities of API estimated to be required from Supplier during the four (4) calendar quarter periods following such launch. Thereafter, at least
ninety (90) days prior to each calendar quarter (“Q1”), NeurogesX will provide Supplier with a rolling forecast of the quantities of API estimated to be required during Q1 and the next three (3) calendar quarters
(“Q2”, “Q3” and “Q4”, respectively). For clarity, all forecasts provided to Supplier under this Section 2.3 are for advisory purposes, with the exception of Q1 demand which will be binding.

 2.4 Orders. NeurogesX’ orders for API shall be made pursuant to a written purchase order on its standard form specifying the
desired quantity of API (each an “Order”), and will provide for shipment in accordance with reasonable delivery schedules and lead times as may be agreed upon from time to time by Supplier and NeurogesX so long as the minimum lead
time shall be at least [***] and a maximum lead time of [***] unless otherwise agreed to by the Parties. In the event that the actual quantity of Raw Materials required to fulfill NeurogesX’s purchase order falls short of the quantity of Raw
Materials ordered by the Supplier pursuant to written purchase order, [***] shall bear the difference between Raw Material payments for the actual purchase order quantities. Such payment can be credited against the next Order for API as prepayment
from [***]. NeurogesX shall exercise its ability, if desired, to purchase full batches at the time the Order is made. ANY ADDITIONAL OR INCONSISTENT TERMS OR CONDITIONS OF ANY PURCHASE ORDER, ACKNOWLEDGMENT OR SIMILAR STANDARDIZED FORM GIVEN OR
RECEIVED PURSUANT TO THIS AGREEMENT WILL HAVE NO EFFECT AND SUCH TERMS AND CONDITIONS ARE HEREBY EXCLUDED UNLESS THE PARTIES SPECIFICALLY AGREE IN WRITING FOR SUCH TERMS OR CONDITIONS TO SUPPLEMENT OR SUPERCEDE THE TERMS AND CONDITIONS OF THIS
AGREEMENT. 
 2.5 Packaging. API shall be shipped packaged in containers in accordance with the applicable Specifications or as
otherwise agreed by the Parties in writing. Each such container will be individually labeled in accordance with any regulatory requirements which may include a description of its contents, including the manufacturer lot number, quantity of API, and
expiration date and/or retest date. 
 2.6 Delivery. Supplier shall deliver the quantities of API ordered by NeurogesX on the dates
specified in NeurogesX’ purchase orders submitted in accordance with Section 2.4 above. All API shall be delivered C.I.P. (Incoterms 2000) to named place of destination. Upon Supplier’s delivery of the API, C.I.P. place of
destination, NeurogesX will bear all risk of loss, 

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 -4- 

 
delay, or damage. [***] shall select the carrier. All API delivered hereunder shall be suitably packed for shipment by Supplier in accordance with good
commercial practice, and instructions provided to Supplier by NeurogesX, with respect to protection of such API during transportation and marked for shipment to NeurogesX’ specified receiving point. 
 2.7 Cost Reduction. The Parties will participate in cost reduction projects pertaining, but not limited to, the manufacture and supply of API for
NeurogesX. If a Party identifies a potential cost reduction measure, the identifying Party shall disclose the details to the other Party so that both Parties can evaluate whether such measure should be implemented and agree upon the costs of
implementing such measure and the resulting cost savings. In the event the Parties agree on implementing a cost saving measure, the Parties agree to come together and discuss who will pay for the cost implementation and negotiate how to share the
cost savings and the Parties shall adjust the price of the API and revise Exhibit D accordingly. 
 2.8 Shortage of Supply of API.
Supplier shall promptly notify NeurogesX if Supplier has any reason to believe that it may be unable to deliver API in accordance with NeurogesX’ purchase orders to the extent that Supplier is obligated to supply API hereunder, including if
Supplier is experiencing manufacturing difficulties that it believes create a reasonable possibility of disrupting supply in the future. In such event, the Parties shall meet and cooperate reasonably in order to formulate a plan in an effort to
avoid any such disruption, such plan may include Supplier or NeurogesX identifying potential backup suppliers of API (each, an “Alternate Supplier”) or NeurogesX manufacturing the API. 
 ARTICLE 3 
 QUALITY

 3.1 Quality. All API supplied by Supplier shall meet the Specifications (as may be amended) and shall be manufactured,
packaged, tested and stored at the Facility in accordance with the Quality Agreement, all applicable Approvals and Regulatory Requirements, including GMP manufacturing and record keeping procedures. 
 3.2 Quality Control. Prior to each shipment of API, Supplier shall perform quality control testing procedures and inspections to verify that the
API to be shipped conforms fully to the Specifications, as set forth in the Quality Agreement. Each shipment of API shall be accompanied by a Certificate of Analysis (“CoA”) issued by the Supplier, in a form agreed upon with NeurogesX,
describing all current requirements of the Specifications, results of test performed certifying that the API supplied have been manufactured, controlled and released at the Facility in accordance with the Specifications, all Approvals and applicable
Regulatory Requirements. In the event of a dispute between the parties over a GMP issue(s), NeurogesX and Supplier agree to submit the issue to a mutually agreed upon independent consultant, and the consultant’s opinion shall be binding upon
the both parties in regards to that GMP issue(s). The expense of obtaining the independent consultant’s binding opinion shall be borne by the losing Party. 
 3.3 Acceptance. Acceptance by NeurogesX of API manufactured by Supplier shall be subject to inspection and applicable testing, by NeurogesX or its designee as set forth in the Quality Agreement and Exhibit E.
If on such inspection or testing, NeurogesX or its designee 

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 -5- 

 
discovers that any API fails to conform with the Specifications, any GMP requirements, any Regulatory requirements, or otherwise fails to conform to the
warranties given by Supplier in Section 8.1 below, NeurogesX or such designee may reject such API, which rejection will be accomplished by giving written notice to Supplier that specifies the manner in which the API fails to meet the foregoing
requirements. Upon request from Supplier, NeurogesX shall return the rejected API in accordance with Supplier’s reasonable instructions at Supplier’s expense, provided that such instructions comply with all applicable laws, regulations and
Regulatory Requirements. [***]. Supplier shall [***] replace rejected API within the shortest possible time within [***] after Supplier’s receipt of notice thereof provided materials are available, and in any event within [***]. The replacement
of rejected API shall have priority over the supply of API ordered for shipment not more than [***] before, or any time after, the rejection of such nonconforming API. If an API shipment or part thereof is rejected before the date on which payment
is due therefor, NeurogesX may withhold payment for such shipment or the rejected portion thereof. If an API shipment or portion thereof is rejected after payment, NeurogesX may credit the amount paid therefor against other amounts due to Supplier
hereunder. [***]. The warranties given by Supplier in Section 8.1 below shall survive any failure to reject by NeurogesX under this Section 3.3. 
 3.4 Latent Defects. As soon as either Party becomes aware of any defect in any API that is not discoverable upon a reasonable inspection or quality control testing as set forth in the Specifications
(“Latent Defect”), but in no case later than thirty (30) days after reaching such awareness, it shall immediately notify the other Party, and both parties shall determine as to the responsibility of such Latent Defect pursuant to
Section 3.3. Supplier will only be responsible for Latent Defects resulting from any deviation from the manufacturing process on the part of Supplier including any deviation from the terms, conditions and/or specification(s) outlined in the
Quality Assurance Agreement, reasonably demonstrated, relative to its manufacturing, packaging, and testing services responsibilities according to this Agreement. Any Latent Defect solely related to compatibility issues will not be the financial
responsibility of Supplier. The term “compatibility issues” as used in this Section 3.4 shall mean a previously unknown chemical reaction between the API or Product’s chemical components and packaging. 
 3.5 Changes to the Specifications. Any changes to the Specifications will be made in accordance with the Quality Agreement. 
 3.6 Lot Records; Samples. Supplier shall maintain lot records in accordance with the Quality Agreement. Subject to the foregoing, Supplier shall
notify NeurogesX before disposing of any of the foregoing, and NeurogesX shall have the option of having such records and samples delivered to NeurogesX or its designee. Upon the request of NeurogesX, Supplier shall provide NeurogesX reasonable
access to and copies of such records and samples at NeurogesX’ expense. 
 ARTICLE 4 
 SERVICES 
 4.1 Scope of
Services. From time to time during the term of this Agreement, NeurogesX may request and Supplier may agree to perform certain services for NeurogesX relating to the API or its manufacture (the “Services”), all as described in one or
more mutually 

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 -6- 

 
agreed proposals which shall be attached hereto as Exhibit C (each, a “Proposal”). Such services may include, but are not limited to
on-going batch stability studies for NeurogesX and future product development. Each Proposal shall be numbered consecutively (for example, the initial Proposal would be Proposal #1 and set forth in detail the Services to be performed by Supplier,
including without limitation, the timeline for delivery of reports and other Deliverables, the fees to be charged, and the like). The Parties may modify Exhibit C hereto to revise an existing Proposal pursuant to Section 4.3 below or otherwise
add a new Proposal, provided, that no Proposal, or any modification thereto, shall be attached to or made a part of this Agreement without first being executed by the Parties hereto in writing which specifically references this Agreement.

 4.2 Standards of Performance. Supplier will use [***] to perform Services and deliver to NeurogesX the completed Deliverables, all
in accordance with the respective Proposal, including without limitation, the specifications and the timelines set forth therein. All Services shall be conducted in a good, scientific manner in compliance with all applicable Regulatory Requirements,
GLP, laws and regulations. 
 4.3 Changes to Proposals. NeurogesX may, at any time, submit to Supplier a request for changes to any
Proposal. NeurogesX agrees to pay Supplier the reasonable costs associated with such change, as [***] in advance [***] in writing. Supplier shall use its [***] to make all changes requested by NeurogesX, and to minimize the time and additional
charges required as a result of such changes. Without limiting the foregoing, if Supplier can implement the requested changes without resulting in increases in Supplier’s time or cost, and without affecting Supplier’s ability to meet the
Services timeline as set forth in such Proposal, Supplier shall implement such changes in accordance with such timeline at no additional cost to NeurogesX. 
 4.4 Acceptance of Deliverables under a Proposal. Supplier shall timely deliver to NeurogesX or its designee each Deliverable resulting from the Services. Acceptance by NeurogesX of such Deliverables shall be
subject to inspection and other testing by NeurogesX or its designee. If on such inspection or testing NeurogesX or its designee discovers that the Deliverable fails to conform to the applicable specifications, NeurogesX or such designee may reject
such Deliverable upon written notice. Upon request from Supplier, NeurogesX shall return the rejected Deliverable in accordance with [***], provided that such instructions comply with applicable laws, regulations and Regulatory Requirements. If
NeurogesX rejects a Deliverable, Supplier shall promptly correct the failure(s) specified in the rejection notice and re-deliver to NeurogesX, at Supplier’s cost and expense (including re-delivery costs), a replacement Deliverable that meets
the applicable specifications, for acceptance testing under this Section 4.4. If Supplier disagrees with NeurogesX’ determination, the Parties agree to proceed according to Section 3.3 above. 
  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 -7- 

 4.5 Reporting/Transfer of Results. 
 (a) In connection with the Services and as applicable, Supplier will provide NeurogesX with regular written reports, as part of the
Deliverables or as requested by NeurogesX, and a final written report upon completion of each Service, of all results and NeurogesX IP developed or generated during the course of the Services. Supplier shall provide reasonable assistance to
NeurogesX in NeurogesX’ efforts to understand and use the information contained in such reports. Supplier agrees that the first time Supplier provides any information in such reports that Supplier believes to be Supplier Background Technology
or Supplier Improvements, such information shall be fully described in a separate section in such report. 
 (b) Supplier will
also respond to NeurogesX’ reasonable inquiries, at Supplier’s expense, regarding the status of the Services on an ongoing basis, and Supplier will endeavor to keep NeurogesX reasonably informed of interim results on an informal basis,
including, if requested, periodic meetings at Supplier’s facility to discuss results and progress of the Services, and Supplier will follow any reasonable instructions or direction of NeurogesX with regard to the Services. 
 ARTICLE 5 
 PAYMENTS

 5.1 API Orders. 
 (a) Price. The price to be paid by NeurogesX per kilogram (kg) of API ordered by NeurogesX shall be as set forth on Exhibit D hereto. The parties agree [***] may be made by [***] during the term of this
Agreement based on [***]; provided, however [***] measured at the beginning of such [***]. Further adjustments may be made to price to account for changes in the quantity of API to be supplied or applicable run sizes, provided that such increases
are agreed by NeurogesX in advance. Also, price adjustments may occur upon modifications to the Specifications requested by either Party to the extent of any [***] resulting from such changes in Specifications, consistent with Sections 2.7 and 3.5.

 (b) [***] 
 (c) Invoicing; Payment. In accordance with the flow chart in Exhibit E attached hereto, Supplier shall submit the first invoice to NeurogesX for [***] of the Order cost after completing the manufacturing run,
generating the CoA and Certificate of Compliance and submitting Batch Documentation to NeurogesX. Supplier shall submit the second invoice to NeurogesX for [***] of the Order cost upon NeurogesX approval of manufacturing release. In addition, if
NeurogesX is unable to approve the release for shipping within 60 days of approval of manufacturing release, NeurogesX shall be responsible for any and all storage fees pursuant to GMP. Supplier shall submit a third invoice to NeurogesX for [***] of
the Order cost upon NeurogesX confirmation that the Order meets the specifications based on a NeurogesX approved third party’s documentation and CoA. All invoices will be sent to the address specified in the applicable Order, and each invoice
will state the aggregate and unit price for API in a given shipment, plus any taxes, or other costs incident to the purchase by NeurogesX under this Agreement. All payments pursuant to this Agreement, or an Order shall be made by wire transfer in
U.S. dollars within [***] of NeurogesX’ receipt of the invoice. 
 (d) Currency Fluctuation. The currency exchange
rate between the US dollar and Taiwan dollar shall be set at the market rate at the end of the trading day on the Effective Date of this Agreement. In the event that the exchange rate between the two currencies 

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 -8- 

 
fluctuates more than [***] between the Effective Date and the date an Order is submitted to Supplier, NeurogesX and Supplier agree that the percentage change
in the currency exchange shall be equally split between the Parties. Solely for clarity and example purposes, if the US dollar [***] in value relative to the Taiwan dollar between the Effective Date and an Order date, NeurogesX would agree to pay
the contract amount [***] of the contract amount to account for the US dollar value decrease. 
 5.2 Services. In consideration for
the Services performed by Supplier, NeurogesX agrees to pay to Supplier in U.S. dollars by wire transfer the amounts set forth in the applicable Proposal in accordance with the terms and conditions set forth therein. 
 ARTICLE 6 
 OWNERSHIP AND
LICENSES 
 6.1 Background IP. Each Party shall retain all right, title and interest in and to all inventions (whether or not
patentable), discoveries, technology and know-how (collectively, “Inventions”) that are owned or controlled by such Party as of the Effective Date or developed and/or acquired by such Party entirely independently and outside of this
Agreement after the Effective Date. 
 6.2 NeurogesX Property. NeurogesX shall own all data, documents, protocols, and materials
created, reduced to practice or compiled by Supplier in the course of performing Services that are based on NeurogesX’ Confidential Information (collectively, the “NeurogesX Property”). 
 6.3 Supplier Technology. Pursuant to Section 6.1, Supplier shall own all right, title and interest in and to the Supplier Background
Technology and all improvements and modifications thereto, which improvements are of a general nature, performed independently, without use of or reference to NeurogesX’ Confidential Information, including for example, standard operating
procedures, software or laboratory methodologies (the “Supplier Improvements”). 
 ARTICLE 7 
 REGULATORY MATTERS 
 7.1 Regulatory
Approvals. NeurogesX, itself or through its agents, shall have the right to correspond with and submit regulatory applications and other filings to the FDA or other regulatory authorities to obtain approvals to import, export, sell, or otherwise
commercialize the API alone or with other products (each, an “Approval” and collectively, “Approvals”) as NeurogesX deems useful or necessary, however, NeurogesX agrees that it shall not, sell or otherwise
commercialize the API other than as a component of a product. Except as otherwise required by law, Supplier shall not correspond directly with the FDA or any other regulatory agency relating to the process of obtaining Approvals or any obtained
Approval for the API without NeurogesX’ prior consent. [***]. Not withstanding the foregoing, Supplier may maintain its own Drug Master File (DMF) with the FDA. Supplier agrees to allow NeurogesX, its affiliates and sublicensees to reference
any DMF filed with the FDA related to the API and/or NeurogesX’s commercialization efforts. 
  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 -9- 

 Information. Without limiting Section 7.1 above, Supplier shall promptly
provide NeurogesX all written and other information, other than information developed for other Supplier clients and subject to a confidentiality obligation, in Supplier’s possession or control that is necessary or useful for NeurogesX to apply
for, obtain, and maintain Approvals for a product, which incorporates the API, including without limitation, Documentation, information relating to the Facility, process, methodology, or components used in the manufacture, processing, or packaging
of the API or other information required to be submitted to the FDA or other regulatory authorities in the form of a marketing application or to support a post-approval change. In addition, Supplier shall immediately inform NeurogesX when any such
information is no longer current and reflective of current manufacturing practices, procedures, or the Specifications and provide updated information to NeurogesX through agreed channels for managing change according to the Quality Agreement.

 Inspections. Supplier shall permit the FDA and other regulatory authorities to conduct inspections of the Facility
as the FDA or other regulatory authorities may request, and shall cooperate with the FDA or other regulatory authorities with respect to the inspections and any related matters, in each case relating to the API. Supplier shall give NeurogesX prior
notice, to the extent practicable, of any such inspections, and keep NeurogesX informed about the results and conclusions of each regulatory inspection, including actions taken by Supplier to remedy conditions cited in the inspections. Responses to
any 483 observations (or equivalent observations from other Regulatory Authorities) that directly relate to API have to be approved by NeurogesX before they are submitted. In addition, Supplier shall allow NeurogesX or its representative to assist
in the preparation for and be present at the inspections to participate in discussion directly related to the API or its manufacture. Supplier will provide NeurogesX with copies of any written inspection reports issued by the regulatory agency and
all correspondence between Supplier and the regulatory agency, including, but not limited to, FDA Form 483, Notice of Observation, and all related correspondence, in each case relating to the API or general manufacturing concerns (i.e., facility
compliance or the like). NeurogesX and its regulatory consultants, agents, marketing partners, and other third parties, under reasonable confidentiality requirements, shall have access to all regulatory and quality assurance GMP audits of Supplier
to assess regulatory compliance and to the buildings, records, and areas of the Facility or other facilities involved in the manufacture, testing, storage, and shipment of the API. 
 7.2 Maintenance of Approvals. Notwithstanding anything in the Agreement to the contrary, Supplier shall not undertake any modifications to the API
manufacturing or testing processes or use any subcontractors or vendors in any way that could delay or otherwise impact the Approvals or other regulatory submissions, including without limitation, regulatory product reviews, Investigational New Drug
applications (INDs), New Drug Applications (NDAs), or any other compliance status without the prior written agreement of NeurogesX. 
 7.3
Reporting. Pursuant to the FDA’s and other applicable regulatory agency’s regulations and policies, NeurogesX may be required to report information that reasonably suggests that an API may have caused or contributed to the death or
serious injury. Accordingly, Supplier shall inform NeurogesX of any such information promptly after becoming aware of it so that NeurogesX can comply with such reporting requirements. 
  

 -10- 

 7.4 Records. Supplier shall maintain adequate and accurate records covering the manufacture,
stability programs, quality control testing, storage and release of API supplied hereunder and all other Services provided hereunder, in accordance with GMPs and all Regulatory Requirements, for as long as required under applicable laws and
regulations, and then for a period of [***] thereafter. Supplier will make such records available to NeurogesX, its designees and regulatory agencies as requested by NeurogesX, at no additional cost to NeurogesX. Subject to the foregoing maintenance
requirement, Supplier shall notify NeurogesX before destroying any such records, and NeurogesX shall have the option of having such records delivered to NeurogesX or its designee at NeurogesX’ cost. 
 ARTICLE 8 
 PRODUCT WARRANTIES

 8.1 Supplier Product Warranties. Supplier represents and warrants that: 
 (a) Specifications. All API supplied hereunder shall comply with the Specifications shown on the CoA provided for the particular
shipment pursuant to Section 3.2 above; 
 (b) Regulatory Requirements. The Facility, the manufacturing and supply
activities contemplated herein and all API supplied hereunder shall comply with the Regulatory Requirements and the Quality Agreement, and all Raw Materials used in the manufacture of API hereunder shall comply with the applicable specifications,
Regulatory Requirements, and the Quality Agreement; 
 (c) Compliance with FFDCA. None of the API supplied to NeurogesX
under this Agreement shall be adulterated or misbranded within the meaning of the Act; and 
 (d) No Encumbrance. Title
to all API supplied under this Agreement shall pass as provided in this Agreement, free and clear of any security interest, lien, or other encumbrance. 
 (e) As of the Effective Date, to its knowledge, Supplier’s method of manufacturing the API does not infringe any patent, trademark, trade secret, or other proprietary rights of third parties to the API.

 8.2 NeurogesX Product Warranties. NeurogesX represents and warrants that: 
 (a) upon marketing authorization NeurogesX is responsible for ensuring that any product incorporating the API conforms to all applicable
regulatory and legal requirements and Approvals, and will continue to so conform during the term of this Agreement. 
 8.3 Recalls. If
NeurogesX is required by any regulatory agency to recall the API or if NeurogesX voluntarily initiates a recall of the API and, in either case, if such recall is a result of a breach of any of the warranties set forth in Sections 8.1(a) through
8.1(d) above, Supplier shall bear the out-of-pocket costs of such recall. 
  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 -11- 

 ARTICLE 9 
 TERM AND TERMINATION 
 9.1 Term. The
term of this Agreement shall commence on the Effective Date and continue in full force until the tenth (10th) anniversary of the Effective
Date, unless terminated earlier in accordance with this Article 9 of this Agreement. This Agreement may be extended for additional two (2)-year periods at NeurogesX’ sole option upon written notice to Supplier at least six (6) months prior
to expiration of the then-current term. 
 9.2 Termination for Breach. Either Party may terminate this Agreement upon written notice
in the event that the other Party shall have materially breached this Agreement, and such breach is not cured within [***] after receiving written notice of such breach. Notwithstanding the foregoing, if during such [***] period, the allegedly
breaching Party disputes that it has materially breached this Agreement, then the other Party shall not have the right to terminate this Agreement until it has been finally determined in accordance with Section 13.2 below that the allegedly
breaching Party has materially breached this Agreement, and such Party fails to comply herewith within [***] thereafter. 
 9.3 Permissive
Termination 
 (a) Services. [***]. 
 (b) Agreement. NeurogesX may terminate this Agreement upon [***] prior written notice to Supplier. In the event of a termination by
NeurogesX, NeurogesX will continue to be obligated under this Agreement for all open purchase orders and continue to be obligated under Section 2.3 for any residual inventory. 
 (c) Supplier may terminate this agreement upon [***] prior written notice to NeurogesX. 
 9.4 Effect of Expiration or Termination. 
 (a) Rights and Obligations. Termination or expiration of this Agreement shall not relieve a Party from any liability that, at the time of such termination or expiration, has already accrued to the other Party.
Upon expiration or termination of this Agreement: Supplier shall, as promptly as practicable (i) cease all work on the Services, and (ii) turn over to NeurogesX all Deliverables, Documentation and NeurogesX Property (whether in written or
electronic form, including any work in progress) which are then in Supplier’s possession or control. Supplier shall have the right to retain a copy of all Documentation for legal purposes. 
 (b) Survival. The provisions of Sections 1, 2.8, 6, 7.2, 7.3, 7.5, 7.6, 8, 9, 10, 11, 12, and 13 of this Agreement shall survive
the termination or expiration of this Agreement for any reason. Section 3.3, 3.4, 4.4, 4.5 shall survive any termination or expiration of this Agreement with respect to APIs or Deliverables delivered pursuant to this Agreement. 
  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 -12- 

 ARTICLE 10 
 CONFIDENTIALITY 
 10.1 Confidential Information. The Parties may from time to time disclose to
each other Confidential Information. “Confidential Information” means any information disclosed by one Party to the other Party. For avoidance of doubt, all executed Batch Log Records for NeurogesX, Specifications and NeurogesX IP
shall be deemed the Confidential Information of NeurogesX. However, for any API batches not entirely purchased by NeurogesX, and where a portion of the remaining quantity is purchased by a third party, Supplier shall be allowed to disclose to that
third party, pursuant to a non-disclosure agreement between Supplier and such third party, the Certificate of Analysis and Batch Log Records for that specific API batch. Notwithstanding the foregoing or anything herein to the contrary, Confidential
Information shall not include any information that, in each case as demonstrated by written documentation: (a) was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure; (b) was
generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party; (c) became generally available to the public or otherwise part of the public domain after its disclosure and other
than through any act or omission of the receiving Party in breach of this Agreement; or (d) was subsequently lawfully disclosed to the receiving Party by a person other than the disclosing Party. 
 10.2 Confidentiality. Each Party shall hold and maintain in strict confidence all Confidential Information of the other Party disclosed under this
Agreement. All prior disclosures between the parties shall also be held in confidence according to the terms of this Agreement . Without limiting the foregoing, neither Party shall use or disclose the Confidential Information of the other Party,
except as otherwise permitted by this Agreement or as may be necessary or useful to exercise its rights (including in the case of NeurogesX, its rights to NeurogesX Property) or perform its obligations under this Agreement. Nothing contained in this
Article 10 of this Agreement shall prevent either Party from disclosing any Confidential Information of the other Party to the extent reasonable necessary in prosecuting or defending litigation, complying with applicable governmental laws,
regulations, such as SEC regulations, or court order or otherwise submitting information to tax or other governmental authorities, in submissions to regulatory authorities, or as a part of patent applications filed on inventions made under this
Agreement; provided that if a Party is required by law to make any such disclosure, other than pursuant to a confidentiality agreement, it will give reasonable advance notice to the other Party of such disclosure and, save to the extent
inappropriate in the case of patent applications or the like, will use its reasonable efforts to secure confidential treatment of such information. 
 10.3 Confidential Terms. Each Party shall treat the terms of this Agreement as the Confidential Information of the other Party. Notwithstanding anything to the contrary, however, each Party may disclose the terms of this Agreement
(a) to advisors, actual or potential investors, lenders and potential lenders, acquisition partners, sublicensees, and others on a need to know basis under circumstances that reasonably ensure the confidentiality thereof, or (b) as
required by securities or other applicable laws or regulations, such as SEC regulations. 
  

 -13- 

 ARTICLE 11 
 REPRESENTATIONS AND WARRANTIES 
 11.1 Supplier. Supplier represents and warrants that:
(a) it has full power to enter into this Agreement; (b) it has the corporate authority to enter into and execute the Agreement; (c) Supplier shall fully comply with the requirements of any and all applicable federal, state, local and
foreign laws, regulations, rules, and orders of any governmental body having jurisdiction over the activities contemplated by this Agreement or having jurisdiction over the Territory and to the extent applicable to Supplier, including all Regulatory
Requirements; (d) it shall perform all Services in a professional manner in accordance with industry standards; (e) the manufacture and supply of API hereunder will not infringe or misappropriate any intellectual property right of any
third party and (f) it has not been debarred under the Generic Drug Enforcement Act of 1992 and that it will not employ any person or entity that has been so debarred to perform any activities under this Agreement. 
 11.2 NeurogesX. NeurogesX represents and warrants that: (a) it has full power to enter into the Agreement; (b) it has obtained all
necessary corporate approvals to enter and execute into this Agreement; and (c) NeurogesX shall fully comply with the requirements of any and all applicable federal, state, local and foreign laws, regulations, rules and orders of any
governmental body having jurisdiction over the activities contemplated by this Agreement and to the extent applicable to NeurogesX. 
 11.3
Disclaimer. EXCEPT AS PROVIDED IN THIS ARTICLE 11, SECTION 8.1 AND 8.2 ABOVE, NEITHER PARTY MAKES ANY REPRESENTATIONS, WARRANTIES OR CONDITIONS (EXPRESS, IMPLIED, STATUTORY OR OTHERWISE) WITH RESPECT TO THE SUBJECT MATTER HEREOF AND EACH
PARTY EXPRESSLY DISCLAIMS ANY SUCH ADDITIONAL REPRESENTATIONS, WARRANTIES OR CONDITIONS. 
 ARTICLE 12 
 INDEMNIFICATION 
 12.1
NeurogesX. NeurogesX shall indemnify, defend, and hold harmless Supplier, its directors, officers, employees, agents, successors and assigns from and against any liabilities, expenses, or costs (including reasonable attorneys’ fees and
court costs) arising out of any claim, complaint, suit, proceeding, or cause of action brought against any of them by a third party resulting from: [***], in each case subject to the requirements set forth in Section 12.3 below. Notwithstanding
the foregoing, NeurogesX shall have no obligations under this Section 12.1 for any liabilities, expenses, or costs to the extent arising out of or relating to claims covered under Section 12.2 below. NeurogesX shall indemnify and hold
harmless Supplier from any third party claims, actions, proceedings alleging the [***]. 
 12.2 Supplier. Supplier shall indemnify,
defend, and hold harmless NeurogesX, its directors, officers, employees, agents, successors and assigns from and against all liabilities, expenses, and costs (including reasonable attorneys’ fees and court costs) arising out of any claim,
complaint, suit, proceeding, or cause of action brought against any of them by a third party resulting from: (a) the negligent or intentionally wrongful acts or omissions of Supplier; and (b) breach by Supplier of any of its
representations and warranties under this Agreement, in each case 

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 -14- 

 
subject to the requirements set forth in Section 12.3. Notwithstanding the foregoing, Supplier shall have no obligations under this Section 12.2
for any liabilities, expenses, or costs to the extent arising out of or relating to claims covered under Section 12.1 above. Supplier shall indemnify and hold harmless NeurogesX from any IP Claims arising from the manufacture, sale and use of
the API under this Agreement by or for NeurogesX, which IP Claims are caused by use of any technology or intellectual property owned or supplied by Supplier. 
 12.3 Indemnification Procedure. A Party that intends to claim indemnification (“Indemnitee”) under this Article 12 shall promptly notify the indemnifying Party (“Indemnitor”)
in writing of any third party claim, suit, or proceeding included within the indemnification described in this Article 12 (each a “Claim”) with respect to which the Indemnitee intends to claim such indemnification, and the
Indemnitor shall have sole control of the defense and settlement of the Claim. The Indemnitee shall have the right to participate, at its own expense, with counsel of its own choosing in the defense or settlement of the Claim. The indemnification
obligations under this Article 12 shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the consent of the Indemnitor. The Indemnitee and its employees, at the Indemnitor’s request and expense, shall
provide full information and reasonable assistance to Indemnitor and its legal representatives with respect to Claims. 
 ARTICLE 13

 GENERAL 
 13.1
Governing Law. This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the United States and the State of California, including the Uniform Commercial Code as adopted by California, without reference
to conflict of laws principles and excluding the 1980 U.N. Convention on Contracts for the International Sale of Goods. 
 13.2
Disputes. In the event of any dispute or claim arising out of or in connection with this Agreement, or the performance, breach or termination thereof, either Supplier or NeurogesX may, by written notice to the other Party, have such dispute
referred to the Chief Executive Officers (or equivalent) of Supplier and NeurogesX, for attempted resolution by good faith negotiations within [***] after such notice is received by such other Party. 
 13.3 English Language. This Agreement shall be made in the English language, which language shall be controlling in all respects, and all versions
hereof in any other language shall not be binding upon the Parties. All communications and notices to be made pursuant to this Agreement shall be in the English language. 
 13.4 Implied Obligations. This Agreement sets forth all of the rights and obligations of the Parties with respect to the subject matter hereof. 
 13.5 Force Majeure. Nonperformance of any Party shall be excused to the extent that performance is rendered impossible by strike, fire,
earthquake, terrorism, blackout, flood, governmental acts, orders, or restrictions or failure of suppliers. 
  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 -15- 

 13.6 Assignment. The rights and obligations of each Party under this Agreement may not be assigned
or otherwise transferred to a third party without the prior written consent of the other Party. Any assignment in violation of this Section 13.6 shall be null and void. Notwithstanding the foregoing, either Party may transfer or assign its
rights and obligations under this Agreement, without the consent of the other Party, to a successor to all or substantially all of its business or assets relating to this Agreement whether by sale, merger, operation of law or otherwise if the
assignee or transferee has agreed to be bound by the terms and conditions of this Agreement. 
 13.7 Subcontractors. Supplier agrees
not to subcontract its performance of any activities under this Agreement, including the Services and the supply of API to NeurogesX pursuant to Article 2, without NeurogesX’ prior written approval, such approval not to be unreasonably withheld
or delayed. 
 13.8 Notices. Any notice or report required or permitted to be given or made under this Agreement by either Party shall
be in writing and delivered to the other Party at its address indicated in this Agreement (or to such other address as a Party may specify by notice under this Agreement) by courier or by registered or certified airmail, postage prepaid, courier
service, or by facsimile, which facsimile is promptly confirmed, in writing, by registered or certified airmail, postage prepaid. All notices shall be effective as of the date received by the addressee. 
  

			
	 If to Supplier:
	 	 Formosa Laboratories, Inc.
 No.36-1, Hoping Street,
Louchu County
 Taoyuan, Taiwan
 Attn: [***]
 Fax: +[***]

  

			
	If to NeurogesX:	 	 2215 Bridgepointe Parkway
 San Mateo, California,
94404
 U.S.A.
 Attn: [***]
 Fax: [***]

		
		 	With copy to [***]

 13.9 Limitation of Liability. EXCEPT TO THE EXTENT SUCH PARTY MAY BE REQUIRED TO INDEMNIFY
THE OTHER PARTY UNDER ARTICLE 12 ABOVE OR IN THE CASE OF WILLFUL BREACH OF THIS AGREEMENT, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY OR ANY THIRD PARTY FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY, OR INCIDENTAL DAMAGES (INCLUDING LOST OR
ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME), ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE), OR OTHERWISE, EVEN IF AN AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS
ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME. 
 13.10 Headings. Headings included herein are for convenience only, do not form a
part of this Agreement, and shall not be used in any way to construe or interpret this Agreement. 
  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 -16- 

 13.11 Non-Waiver. Any waiver of the terms and conditions hereof must be explicitly in writing. The
waiver by either of the Parties of any breach of any provision hereof by the other shall not be construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself. 
 13.12 Severability. Should any section, or portion thereof, of this Agreement be held invalid by reason of any law, statute, or regulation
existing now or in the future in any jurisdiction by any court of competent authority or by a legally enforceable directive of any governmental body, such section or portion thereof will be validly reformed so as to approximate the intent of the
Parties as nearly as possible and, if unreformable, will be deemed divisible and deleted with respect to such jurisdiction, but the Agreement will not otherwise be affected. 
 13.13 Independent Contractors. The relationship of NeurogesX and Supplier established by this Agreement is that of independent contractors.
Nothing in this Agreement shall be construed to create any other relationship between NeurogesX and Supplier. Neither Party shall have any right, power, or authority to assume, create or incur any expense, liability, or obligation, express or
implied, on behalf of the other. 
 13.14 Entire Agreement. This Agreement, together with the Exhibits hereto, constitutes and
contains the entire understanding and agreement of the Parties respecting the subject matter hereof and cancels and supersedes any and all prior and contemporaneous negotiations, correspondence, understandings and agreements between the Parties,
whether oral or written, regarding such subject matter. Notwithstanding the foregoing, to the extent the terms and conditions of the body of this Agreement conflict with the terms and conditions of any Exhibit hereto (including without limitation,
the Quality Agreement and any Proposal), the terms and conditions of the body of this Agreement shall govern. No agreement or understanding varying or extending this Agreement shall be binding upon either Party, unless set forth in a writing which
specifically refers to the Agreement that is signed by duly authorized officers or representatives of the respective Parties, and the provisions of the Agreement not specifically amended thereby shall remain in full force and effect. 
 13.15 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but which together shall constitute
one and the same instrument. 
 IN WITNESS WHEREOF, the Parties have caused their duly authorized representatives to execute this Agreement.

  

									
	NEUROGESX INC.	 		 	FORMOSA LABORATORIES, INC.
					
	By:	 	/s/ Stephen F. Ghiglieri	 		 	By:	 	/s/ Chen-Yu Cheng

									
					
	Name:	 	Stephen F. Ghiglieri	 		 	Name:	 	Chen-Yu Cheng, Ph.D.

									
					
	Title:	 	Chief Financial Officer	 		 	Title:	 	Chief Executive Officer

  

 -17- 

 EXHIBIT A 
 QUALITY ASSURANCE AGREEMENT 
 [Following this Page] 

 Commercial Quality Assurance Agreement 
 Between 
 NeurogesX, Inc. 
 And 
 Formosa Laboratories, Inc.

	1.	INTRODUCTION AND SCOPE 

  

	 	1.1	The purpose of this Quality Agreement is to define and establish the obligations and responsibilities of Formosa Laboratories, Inc. (Formosa) and NeurogesX, Inc. (NGX) as they
relate to the development, manufacture and supply of Active Pharmaceutical Ingredients (API) to NGX by Formosa for clinical studies and commercial supply. All manufacture and supply of API will be performed in accordance with current Good
Manufacturing Practices and the International Conference on Harmonization (ICH) Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. 

  

	 	1.2	NGX and Formosa are responsible for the steps involved in manufacture, control, packaging and final release of API as specified in this agreement. 

  

	 	1.3	This Agreement and appendices will be accessible to competent Regulatory Agencies as required. 

  

	 	1.4	Both the NGX and Formosa Quality Assurance Units are responsible for keeping this document current, and changes as such will be submitted through the NGX Quality Assurance Unit, who
shall be responsible for maintaining this Quality Agreement and its revision control. Modifications will be agreed between the parties and reflected in written revisions. 

  

	2.	DEFINITIONS 

  

	 	2.1	Active Pharmaceutical Ingredient (API) – any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation,
treatment or prevention of disease, or to affect the structure or any function of the body of humans or other animals. The term includes those components that may undergo chemical change in the manufacture of the drug product and be present in the
drug product in a modified form intended to furnish the specified activity or effect. 

  

	 	2.2	Batch (or Lot) – a specific quantity of drug substance or other material that is intended to have uniform character and quality, within specified limits, and is produced
according to a single manufacture order during the same cycle of manufacture 

  

	 	2.3	C of A – Certificate of Analysis, list of all tests required to adequately characterize a material including all test results for each test, acceptance criteria and
reference of the test methods used with an approval of the appropriate QC and QA departments. 

  

	 	2.4	Certificate of Compliance – The Certificate of Compliance certifies that the API has been produced according to all applicable cGMP regulations as defined above, [***]
internal procedures and batch records, and all relevant NGX regulatory submissions. 

  

	 	2.5	Change Control: a documented and controlled process by which changes to facilities, equipment and processes are documented, reviewed and approved before they are implemented.
Change control procedures apply to changes of facilities, utilities, design, components, software and computerized systems, manufacturing equipment, labeling, packaging materials, as well as standard operating procedures, specifications,
manufacturing instructions and other product specific documentation. Change control procedures need to include as a minimum: 

 [***] 
 Changes to facilities, utilities, systems, processes or methods that potentially affect an approved market application may
need to be submitted to Regulatory Authorities for notification or prior approval. NGX Regulatory Affairs department will determine the level of change required and the impact to 
  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 
regulatory filings. (see 21 CFR 211.100, 211.160; FDA Guidance for Industry, BACPAC I, Feb.2001, PAC-ATLS, Apr.1998, Changes to an Approved NDA or ANDA, Apr.
2004, Changes to an Approved NDA or ANDA – Questions and Answers, Jan.2001; see also for reference: Scale-up and Postapproval Changes: Chemistry, Manufacturing and Controls; Semisolid Dosage Forms) 
  

	 	2.6	cGMP – current Good Manufacturing Practices, which shall include all applicable standards relating to manufacturing practices for Active Pharmaceutical Ingredients,
starting materials and intermediates (i) in the form of laws or regulations, or (ii) in the form of guidance documents (including, but not limited to, advisory opinions, compliance policy guides and guidelines) which are being implemented
within the pharmaceutical manufacturing industry for like products; in each case, which are promulgated by the FDA. This includes but is not limited to FDA regulations 21CFR parts 11, 210, and 211 as well as EU Directives 2004/27/EC and 2004/28/EC,
and the EC Guide to Good Manufacturing Practice for Medicinal Drug Products, Part II, as well as the International Conference of Harmonization Guidance Q7A. 

  

	 	2.7	Developer – Any third party who provides the service of developing formulas, processes, test methods, software or systems for use in manufacturing drug substance,
intermediates, bulk drug product, or finished drug product 

  

	 	2.8	FDA – United States Food and Drug Administration, or any successor agency 

  

	 	2.9	Final Drug Substance Specification – the combination of physical, chemical, biological, and microbiological tests and acceptance criteria that an API should meet
throughout its shelf life. 

  

	 	2.10	Final Release – The release of the API by NGX QA Unit for further processing of finished product for clinical trials or commercial use. Final release signifies that the
material has been produced using approved processes and meets the established specifications and regulatory submissions as determined by NGX QA review of all relevant documentation. 

  

	 	2.11	Manufacturer’s Release – The release of the API by Formosa’s Quality Assurance Unit. Release signifies that the material has been produced using approved
processes, in compliance with cGMP regulations and meets the established specifications as determined by Formosa QA’s review of all relevant documentation. 

  

	 	2.12	Master Production Record – a set of specific and detailed instructions required to manufacture a batch of intermediates or API. 

  

	 	2.13	Material Violation – a regulatory violation of a magnitude requiring a Significant Change in order to correct the violation . 

  

	 	2.14	Notification – means an e-mail, fax or phone call, unless “notification in writing” is specified, which means an e-mail or fax. 

  

	 	2.15	OOS – out-of-specification result, a test result that is outside of the preestablished specification and is investigated and documented per Standard Operating Procedures
for such results. 

  

	 	2.16	Product – any API manufactured by Formosa for NGX under this Quality Agreement 

  

	 	2.17	Quality Assurance Unit – an independent unit within the organization responsible for duties associated with assuring the quality of the API and its intermediates.

  

	 	2.18	 Significant Change – a proposed change to a raw material, packaging or labeling component, equipment, manufacturing method or procedure, product or
material specification or requirements, sampling method, test method or release requirement or procedure of any kind known to or reasonably likely to 

	 	 
affect the quality, stability, shelf life or other characteristics of the API or any of its starting materials or intermediates, or that would require the
parties to make additional regulatory filings, including to the Investigational New Drug (IND) Application, New Drug Application (NDA) or other applicable market application. 

  

	 	2.19	Significant Deviation – a planned or unplanned deviation from written procedures, including the specifications, quality control procedures or manufacturing processes
known to, or reasonably likely to have an impact on the quality, stability, shelf life or other characteristics of the API or any of its starting materials or intermediates, or that would require the parties to make additional regulatory filings,
including to the Investigational New Drug (IND) Application, New Drug Application (NDA), or equivalent Regulatory filings. 

  

	 	2.20	Stability – the ability of the API to remain within its established specifications throughout its retest or expiration period, as appropriate. 

 

	 	2.21	Starting Material – The Regulatory starting materials defining the beginning of the GMP portion of an API synthesis. 

  

	 	2.22	SOP – Standard Operating Procedures 

  

	 	2.23	Supplier – any third party who provides materials that will be used in manufacture of the API or as primary packaging or labeling components for NeurogesX products

  

	 	2.24	Third Party Service Provider – an independent service contracted for any aspect of manufacturing or testing (TPSP) 

	3.	Overview of Functions and Responsibilities 

  

					
	NeurogesX, Inc.	 	Formosa Laboratories, Inc.	 	Third Party
	San Carlos Business Park	 	No. 36-1 Hoping Street	 	NA
	981F Industrial Road	 	Louchu County	 	
	San Carlos, CA 94070-4117	 	Taoyuan, Taiwan 338	 	
	USA	 		 	

  

							
	Responsibilities:	 	NeurogesX	 	Formosa	 	 Third
 Party

	 SPONSOR
	 	        [***]        	 	        [***]        	 	        [***]        
	 STARTING MATERIALS
	 	[***]	 	[***]	 	[***]
	 Purchasing
	 	[***]	 	[***]	 	[***]
	 Quality Control testing
	 	[***]	 	[***]	 	[***]
	 Specifications + methods
	 	[***]	 	[***]	 	[***]
	 Reserve samples
	 	[***]	 	[***]	 	[***]
	 	 	[***]	 	[***]	 	[***]
	 RAW MATERIALS
	 	[***]	 	[***]	 	[***]
	 Purchasing
	 	[***]	 	[***]	 	[***]
	 Quality Control Testing
	 	[***]	 	[***]	 	[***]
	 Specifications and methods
	 	[***]	 	[***]	 	[***]
	 Reserve samples
	 	[***]	 	[***]	 	[***]
	 	 	[***]	 	[***]	 	[***]
	 PACKAGING MATERIALS
	 	[***]	 	[***]	 	[***]
	 Purchasing
	 	[***]	 	[***]	 	[***]
	 Quality Control Testing
	 	[***]	 	[***]	 	[***]
	 Specifications + methods
	 	[***]	 	[***]	 	[***]
	 Reserve samples
	 	[***]	 	[***]	 	[***]
	 	 	[***]	 	[***]	 	[***]
	 PRODUCTION
	 	[***]	 	[***]	 	[***]
	 Current production formula
	 	[***]	 	[***]	 	[***]
	 –Manufacturing of the API and its intermediates
and in-process controls
	 	[***]	 	[***]	 	[***]
	 –Primary packaging (incl. in-process-controls)

	 	[***]	 	[***]	 	[***]
	 –Cleaning Confirmation
	 	[***]	 	[***]	 	[***]
	 –Secondary packaging (incl. in-process-controls)

	 	[***]	 	[***]	 	[***]
	 Labeling for clinical supplies
	 	[***]	 	[***]	 	[***]
	 Labeling of commercial supplies
	 	[***]	 	[***]	 	[***]
	 	 	[***]	 	[***]	 	[***]
	 QUALITY CONTROL
	 	[***]	 	[***]	 	[***]
	 Testing of the intermediates and API
	 	[***]	 	[***]	 	[***]
	 Testing and tracking of reference
standard
	 	[***]	 	[***]	 	[***]
	 Characterization of reference
standard
	 	[***]	 	[***]	 	[***]
	 Tracking API impurity profile
	 	[***]	 	[***]	 	[***]

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

							
	Responsibilities:	 	NeurogesX	 	Formosa	 	 Third
 Party

	 Stability protocol development
	 	        [***]        	 	        [***]        	 	        [***]        
	 Stability protocol review and
approval
	 	[***]	 	[***]	 	[***]
	 Stability testing of API used in NGX clinical and
commercial lots
	 	[***]	 	[***]	 	[***]
	 Stability report generation
	 	[***]	 	[***]	 	[***]
	 Stability report review and approval
	 	[***]	 	[***]	 	[***]
	 Establishing retest / expiration date
	 	[***]	 	[***]	 	[***]
	 Analytical method development
	 	[***]	 	[***]	 	[***]
	 	 	[***]	 	[***]	 	[***]
	 QUALITY ASSURANCE
	 	[***]	 	[***]	 	[***]
	 Release of the starting materials and raw materials

	 	[***]	 	[***]	 	[***]
	 Manufacturer’s release of API for use in NGX
clinical or commercial supplies
	 	[***]	 	[***]	 	[***]
	 Final release of API for use in NGX clinical or
commercial supply
	 	[***]	 	[***]	 	[***]
	 Tracking and inspection of API reserve
samples
	 	[***]	 	[***]	 	[***]
	 	 	[***]	 	[***]	 	[***]
	 VENDOR QUALIFICATIONS
	 	[***]	 	[***]	 	[***]
	 Third party manufacturers
qualification
	 	[***]	 	[***]	 	[***]
	 	 	[***]	 	[***]	 	[***]
	 INVESTIGATIONS
	 	[***]	 	[***]	 	[***]
	 Deviation investigation
	 	[***]	 	[***]	 	[***]
	 Deviation approval (significant)
	 	[***]	 	[***]	 	[***]
	 Out of specification results
investigations
	 	[***]	 	[***]	 	[***]
	 Out-of-Specification report approval
	 	[***]	 	[***]	 	[***]
	 Review and approval of any other significant quality
incident or non-conformance
	 	[***]	 	[***]	 	[***]
	 	 	[***]	 	[***]	 	[***]
	 VALIDATION
	 	[***]	 	[***]	 	[***]
	 Facility/utility/equipment validation
	 	[***]	 	[***]	 	[***]
	 Cleaning validation
	 	[***]	 	[***]	 	[***]
	 Computer validation
	 	[***]	 	[***]	 	[***]
	 Analytical method validation protocol
approval
	 	[***]	 	[***]	 	[***]
	 Analytical method validation
execution
	 	[***]	 	[***]	 	[***]
	 Analytical method validation report
approval
	 	[***]	 	[***]	 	[***]
	 Process validation plan and protocol
approval
	 	[***]	 	[***]	 	[***]
	 Process validation execution
	 	[***]	 	[***]	 	[***]
	 Process validation report approval
	 	[***]	 	[***]	 	[***]
	 Development reports
	 	[***]	 	[***]	 	[***]
	 Analytical methods
	 	[***]	 	[***]	 	[***]
	 Production processes
	 	[***]	 	[***]	 	[***]
	 	 	[***]	 	[***]	 	[***]
	 CHANGE CONTROL
	 	[***]	 	[***]	 	[***]
	 Process and Formulation
	 	[***]	 	[***]	 	[***]
	 Equipment (except like-for-like
changes)
	 	[***]	 	[***]	 	[***]

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

							
	Responsibilities:	 	NeurogesX	 	Formosa	 	 Third
 Party

	 Test Methods
	 	        [***]        	 	        [***]        	 	        [***]        
	 Specifications
	 	[***]	 	[***]	 	[***]
	 Computer systems directly impacting the quality of
NGX products
	 	[***]	 	[***]	 	[***]
	 Impact to Regulatory Filings and level of
change
	 	[***]	 	[***]	 	[***]
	 	 	[***]	 	[***]	 	[***]
	 COMPLAINTS AND RECALLS
	 	[***]	 	[***]	 	[***]
	 Complaints and Recalls
	 	[***]	 	[***]	 	[***]
	 	 	[***]	 	[***]	 	[***]
	 	 	[***]	 	[***]	 	[***]
	 SHIPPING of API
	 	[***]	 	[***]	 	[***]
	 Definition of shipping procedures
	 	[***]	 	[***]	 	[***]
	 Authorization of API shipments for clinical or
commercial manufacture
	 	[***]	 	[***]	 	[***]
	 Shipping of the API
	 	[***]	 	[***]	 	[***]

 X in both columns – to be approved by both parties 
 X* – to be available for review by NGX prior to finalization 
  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	4.	Description of Functions and Responsibilities 

  

	 	4.1	Production of Product – Formosa shall manufacture and test NGX’s starting materials, intermediates and APIs in accordance with [***] SOPs, cGMPs, applicable laws
and regulations, including all applicable FDA regulations, any applicable local laws and regulations in the place of manufacture, and any Investigational New Drug (IND), New Drug Application (NDA), Medicinal Application Authorization (MAA), and
other regulatory filings or approvals for the Drug Product manufactured from the API (collectively, the “Regulatory Requirements”), and applicable contracts between Formosa and NGX. The manufactured material shall adhere to the
specification supplied by NGX and be in compliance with all cGMPs and any other applicable Regulatory Requirements. Formosa will prepare for each batch of Product manufactured for NGX, the complete production record documentation (see Appendix 1,
Batch Accompanying Documentation). The documentation will be readily accessible for review and inspection by NGX and regulatory authorities, and true and complete copies of these records will be sent to NGX by Formosa for each batch of Product
produced (see Appendix I). 

  

	 	4.2	Control of Suppliers – Formosa shall maintain an approved supplier’s list in accordance with Formosa’s procedures. NGX’s approval will be required for any
supplier change for starting materials used in NGX’s products. Formosa shall notify NGX of intended change in suppliers at least [***] in advance of implementing the change whenever possible. Formosa will provide the [***] to NGX upon request.
Changes in suppliers of solvents will require a notification to NGX. The initial approved supplier’s list shall be subject to NGX’s written approval. 

 Formosa is responsible for auditing and qualification of starting material and raw material suppliers according to cGMP regulations for all starting
materials, raw materials, intermediates and processing aids used in the GMP steps of the manufacturing process. 
 Formosa’s audit logs,
audit reports and qualification status of suppliers will be available for review by NGX during NGX audits. 
  

	 	4.3	Third Party Service Providers – Should Formosa employ a third party service provider (TPSP) for any manufacture, testing, storage or shipping of NGX’s product, NGX
and Formosa and the TPSP will agree on the following: 

  

	 	1.	Formosa will not use any TPSP without a written consent by NGX. 

  

	 	2.	Formosa will be the primary contact with the TPSP. 

  

	 	3.	Formosa will adequately qualify the supplier according to Formosa policies and procedures (including on-site audits) and this Quality Assurance Agreement. 

 

	 	4.	Formosa will be responsible for release and review of any one part or all parts of the process performed by the TPSP, and shall be responsible for any actions performed by the TPSP
with respect to NGX’s product as if performed by Formosa itself. 

  

	 	5.	Formosa will perform appropriate process transfer according to their internal procedures and applicable regulations. 

  

	 	6.	NGX retains the right to review or obtain copies of documents created by TPSPs and retained by Formosa. 

  

	 	7.	The TPSP shall comply with a Quality Assurance Agreement substantially similar to this agreement and any other agreements between Formosa and NGX applicable to Product.

  

	 	8.	NGX reserves the right to audit the TSPS if desired and to review audit reports generated by Formosa. 

  

	 	4.4	Printed Materials – The API supplied to NGX hereunder shall be packaged, labeled and stored in accordance with instructions from NGX. 

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	 	4.5	API Specifications – The referenced API(s) must be manufactured, packaged, labeled (if necessary) and handled according to the written specifications and procedures as
outlined in this agreement. Changes to the specifications shall be mutually agreed upon and approved in writing by both parties. 

 In testing starting materials, intermediates and API(s) [***] the analytical methods requiring validation. Methods which appear in the current compendia or other recognized standard references should be written in sufficient detail to
describe specific equipment and analytical parameter ranges. Product aspect methods such as appearance, color and clarity of solution shall also be written. For those analytical methods developed by Formosa, documentation supporting the development
and validation of the analytical method shall be supplied upon request to NGX. 
 Each lot of API will be sampled and tested in accordance
with the agreed upon [***] procedures, Regulatory Requirements, and must meet the specifications as outlined in this agreement. 
  

	 	4.6	Manufacturing Documentation – Formosa is responsible for the preparation and revision of Master Batch Records, Test Methods and Shipping Instructions for the Product.
Formosa will provide these documents to NGX for review and approval before they are used in any manufacturing, testing or shipping operations. Editorial changes or changes in formatting that do not change the content of the document do not require
NGX prior approval, however, copies of the revised documents will be provided to NGX immediately after the change has been implemented. 

  

	 	4.7	Reserve samples – Formosa shall keep retention samples of raw materials as required by [***] SOPs and Regulatory Requirements under the recommended storage conditions or
better. Formosa shall keep retention samples of regulatory starting materials, intermediates (where applicable) and drug substance as required by Regulatory Requirements, for each batch of API produced. The quantity of starting materials and
intermediates should be [***] the amount required to perform all physical and chemical tests according to the specification. Intermediate samples need to be held until the final API has been released by NGX. 

 The quantity of API retained should be at least [***] the amount to be able to perform all physical and chemical tests according to the Certificate of
Analysis. Formosa will visually inspect all retain samples annually and inform NGX within [***] if any unusual observations are made during the inspections. 
  

	 	4.8	Reprocessing and Reworking – Reprocessing or reworking of the API or any other intermediates in the GMP stages of the manufacturing process is not allowed under this
Quality Agreement. 

  

	 	4.9	Deviations 

  

	 	4.9.1.	Planned Deviations – Any planned deviations will be fully documented in accordance with [***] procedures. Formosa will inform NGX QA in advance of any manufacturing run
or testing activity that requires a significant planned deviation. NGX will review and approve the deviation before beginning of the manufacturing run or testing activity. 

  

	 	4.9.2.	Unplanned Deviations – Any unplanned deviations from approved procedures, batch records, specifications or test methods will be immediately investigated, evaluated,
documented and approved by Formosa’s QA unit. Formosa QA will notify NGX QA of any significant unplanned deviation occurring during a manufacturing run within [***] and of any other significant deviation within [***]. NGX QA unit will review
and approve the investigation plan. NGX reserves the right to request additional or more in-depth investigation by Formosa. The documentation of the deviation, the investigation and any necessary actions required for resolution will be retained as
part of the batch document for the batch(es) affected. A copy thereof will be provided 

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	 	 
to NGX no later than [***] after completion of the investigation by Formosa for NGX review and approval. 

  

	 	4.10	OOS Results and other Non-Conformances – Formosa QA will inform NGX QA within [***] of any OOS result obtained during release or stability testing of the API or of any
other non-conformance that occurred during the receiving, manufacturing or testing of NGX products. The OOS and non-conformance investigation will be conducted in accordance to [***] procedures. NGX will review and approve all investigation plans
before they are executed. NGX reserves the right to request additional or more in-depth investigation by Formosa. The investigation will be completed within [***], or, if that is not possible, a justification will be included with the investigation
documentation. The documentation of the incident, the investigation and any necessary actions required for resolution will be retained as part of the batch document for the batch(es) affected. A copy thereof will be provided to NGX no later than
[***] after completion of the investigation by Formosa for NGX review and approval. All actions investigating non-conformances and justifying the release of the batch of material must be fully documented. Formosa will inform NGX of completion of the
corrective actions and provide supporting documentation. 

  

	 	4.11	Product Complaints, Recalls – NGX will inform Formosa of any product complaint it receives that is potentially related to API quality. Formosa will promptly investigate
the potential quality issue as described under non-conformances above. Formosa will provide copies of all relevant information to NGX for review and approval as described above. In addition, NGX will investigate and document the product complaint
according to its internal procedures and include copies of all relevant Formosa information. NGX is responsible for any correspondence with Regulatory Authorities and the originators of complaints. 

 Formosa will inform NGX within [***] of any product complaint it receives that is potentially related to Product. [***]. In addition, NGX will also
investigate the incident according to [***] procedures. Formosa will inform NGX of any field alerts or recalls of products produced by other manufacturers from lots of Formosa’s capsaicin API within [***]. 
 Formosa will maintain clear traceability of all materials used in the manufacture of the API. It will assist NGX with the highest priority if a situation
arises that potentially requires recall of Product. 
  

	 	4.12	Release of Product – Formosa QA will review all applicable test results and batch records for each isolated intermediate during a manufacturing run and perform
manufacturer’s release before the intermediate can be used in the next production step. 

 Formosa will perform the
manufacturer’s release of each batch of API. Formosa will provide copies to NGX of all documentation outlined in Section “Batch Accompanying Documentation”, for each batch produced, no later than [***] from completion of manufacture
of the batch. 
 NGX will perform a comprehensive review of the documentation and inform Formosa of any quality or regulatory issues
identified during the review. [***] 
 NGX QA will perform the final release of the API batch for further manufacturing for clinical or
commercial use. NGX will inform Formosa of acceptance or rejection of the batch. 
  

	 	4.13	Shipment of Product – Formosa will not ship any API to any destination on behalf of NGX until NGX has released the API and authorized shipment or unless prior approval
has been received from NGX to perform such shipments. Formosa will ship the API according to procedures defined by NGX. 

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

	 	4.14	Solvents – Formosa will use recycled solvents only for the same synthesis step of the same product. Recylced solvents have to be tested and meet an approved
specification before they can be reused. They will be clearly labeled as such, including the product name and step number for which it can be used. 

  

	 	4.15	Change Control – Changes to raw materials, packaging materials, equipment, utilities, facilities, computer systems, manufacturing methods and procedures, product and
material specifications and requirements, sampling, test methods, and release requirements that potentially affect the quality, purity, strength or identity of the API or any of its starting materials or intermediates or that potentially affect a
regulatory filing, require prior written approval from NGX. 

 Formosa will inform NGX of any changes that potentially affect
an approved market application or the validation status of the manufacturing process [***]. NGX reserves the right to reject any changes that significantly affect an approved market application. NGX Regulatory Affairs department will determine the
impact of the change on the filing and the level of change (i.e. prior-approval, changes-being-effected supplement, or [***] update) according to applicable regulations prior to approval and implementation of the change. [***]. 
 Depending on the level of the change (i.e. prior-approval changes, or changes-being-affected) and the revalidation requirements, implementation of a
major change may take a considerable time. It is the responsibility of Formosa to inform NGX of a change early enough prior to implementation so that sufficient time is available for required regulatory filings and revalidation, as applicable. NGX
reserves the right to reject any changes if a sufficient timeframe for regulatory filings and revalidation is not provided. 
 Changes that
potentially impact the quality, purity, strength or identity of the product or the validated state of equipment, systems or processes include, but are not limited to: 
 [***]. 
 Changes to the approved Master Production Records and Final Product Specifications will always
require Formosa’s and NGX’s written approvals. 
 All changes will be implemented according to [***] change control procedures.
These procedures will satisfy the minimum requirements outlined in the Definition section. Notification of a proposed change to NGX and review and approval by NGX will be handled according to [***] written procedures. 
  

	 	4.16	Audits and Inspections of Facilities and Products – Formosa and TPSP’s will notify NGX within [***] of any inspections or actions by regulatory agencies or other
enforcement bodies, of Formosa’s or any TPSP’s facilities and/or processes relating to NGX’s Product, or which could potentially impact NGX’s Product. Where reasonably possible, Formosa and TPSP’s shall afford NGX the
opportunity to be present at such inspections directly related to NGX Product. Formosa will provide NGX with the results of all such inspections, as they relate to Neurogesx’s Product or Quality Systems impacting NGX Product, no more than [***]
from the completion of that inspection, as time is of the essence. 

 Formosa will provide NGX any correspondence or notices
from any regulatory authority, including the FDA or local governmental agencies, relating to [***] no later than [***] following such receipt. Formosa will provide NGX with concurrent copies of any responses to any such correspondence or notices
(e.g., FDA 483 notice). NGX will review and approve any written response to any such inspections, notices and/or correspondences applicable to NeurogesX Product prior to submission. 
  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 NGX reserves the right to audit Formosa’s facilities, systems, documents and processes under the
accompaniment of Formosa personnel, (including validation, investigation and qualification processes) as they relate to the manufacture and control of NGX’s Product or otherwise relating to Formosa’s performance of this Agreement. These
audits may be performed on an annual basis or as mutually agreed upon by Formosa and NGX and at times convenient to NGX and Formosa. In addition to an annual audit, NGX reserves the right to perform for-cause audits as needed. Formosa will respond
to in writing, and forward all responses to observations, generated during NGX’s audit within [***] of issuance of the final audit report. 
 NGX also reserves the right to audit TPSPs (e.g. contract laboratories, third party manufacturers, etc) if utilized by Formosa in the manufacture or testing of API in any capacity. 
 NGX reserves the right to be on site at Formosa during manufacture and testing of starting materials, intermediates or APIs, including presence in the
manufacturing suites and/or during regulatory inspections specific to NGX’s Product including presence in the inspection room with adequate notice to Formosa. 
  

	 	4.17	[***] Product Reviews – Formosa will track the manufacturing history of the API, including test results, impurity profiles, changes, deviations, OOSs and investigations
and perform trending analysis on parameters agreed upon between Formosa and NGX. Formosa will provide NGX with [***] summary of this information. [***] on a procedure for conducting of [***] Product Reviews. 

 [***] determine any corrective actions resulting from the review of the trending results or any other information in the [***] Report. 
 NGX is responsible for compiling [***] Product Reviews and for their submission to Regulatory Authorities. 
  

	 	4.18	Storage of Product – Formosa agrees to store bulk and / or released API under appropriate product label storage conditions and in a secured area, to ensure it complies
with all the quality specifications, attributes and in compliance with all applicable regulations. If special storage conditions are necessary for special purposes, the conditions, timeframes and material requirements will be supplied in writing by
NGX. 

  

	 	4.19	Stability Activities – Formosa is responsible for writing of stability protocols, stability testing, data interpretation and reporting. Stability studies will be
conducted in accordance with ICH guidelines. Stability protocols will be approved by NGX prior to initiation of the stability study. Stability samples will be placed in qualified chambers with continuous temperature monitoring. For each batch on
stability, Formosa will provide NGX with an updated summary table of all stability results for all time points up to the current time point and no later than [***] after the completion of testing for each time point. [***], as part of the [***]
report, Formosa will compile a report discussing and trending all available results for all batches on stability. NGX will review and approve the report. After completion of a stability study, Formosa will generate a final report for NGX review and
approval. 

 NGX is responsible for updating stability information with Regulatory Authorities and for establishing retest /
expiration dates. 
 All stability related activities under the responsibility of Formosa will be completed in a timely manner according to
Formosa’s internal procedures, the agreed-upon stability protocols and applicable regulations. NGX will notify Formosa to terminate stability programs 1) at the conclusion of a 
  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 
clinical trial, 2) when a stability protocol is cancelled or 3) when the lot on stability is no longer relevant due to product or clinical program decisions
made by NGX. 
  

	 	4.20	Validation and Qualification – Formosa is responsible to ensure that all equipment, facilities, utilities and computer systems used for the production of the GMP steps
of the API are qualified or validated in accordance with all applicable GMP regulations and guidance documents and are maintained in a validated state. 

  

	 	4.21	Process and Analytical Method Validation – Formosa will generate process and method validation protocols in accordance with all applicable cGMP regulations, guidances
and ICH guidances. [***]. Formosa is responsible for the execution of the validation activities and generation of final reports. NGX will review and approve the final reports. Any problems encountered during the execution of the protocol must be
documented by Formosa and notifications must be sent to NGX within [***]. 

  

	 	4.22	Retention of Records – Formosa will retain all original manufacturing and testing records as part of the batch history record for a period of no less than [***] past the
expiration date of the API batch, including cleaning verification results. Process, cleaning and method validation records, as well as batch history records and testing records associated with process validation or cleaning validation will be
retained for the life of the market application. Alternatively, Formosa may provide the original records to NGX for retention over the required time period. 

 Formosa will retain all equipment, utility, facility or computer system validation / qualification records for a period of no less than [***] after the decommissioning of the equipment, utility, facility or computer
system. 
 Formosa will inform NGX before destruction of any original records related to manufacturing or testing activities for NGX and give
NGX the right to obtain these records before they are destroyed. 
 NGX and Formosa will meet periodically to review quality issues related
to the obligations and responsibilities as described in this Quality Agreement. During this review the quality issues related to the past production by Formosa will be reviewed. The information discussed will be documented by [***]. 
  

									
	 Approved by:
	  		    		  		  	
					
	/s/ Claudia Hartke	  	May 19, 2006	    		  	/s/ Chen-Yu Cheng	  	6/17/06
	Dr. C. Hartke (Sr. Director, Quality Assurance)	    		  	Dr. Chen-Yu Cheng (President)
					
	/s/ Karen Harder	  	19 May 2006	    		  	/s/ Lino Tsai	  	June 6, 2006
	Ms. K. Harder (Sr. VP, Regulatory Affairs and Technical Operations)	    		  	Ms. Lino Tsai (VP Regulatory Affairs)
					
	 	  	 	    		  	 	  	 

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 Appendix 1 
 Batch Accompanying Documentation 
 Formosa will provide an authentic copy of the batch records to NeurogesX for
clinical and commercial batches in compliance with Formosa’s API release procedure (current version). 
 The following documents shall be provided to
NeurogesX with each delivery of the API to the NGX specified recipient: 
 [***] 
  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 Appendix 2 
 Persons to Contact 
 NeurogesX, Inc. (NGX) 
 [***] 
 [***] 
 Formosa
Laboratories, Inc. (Formosa) 
 [***] 
 [***] 
 [***] 
  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 EXHIBIT B 
 [***] 
  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 EXHIBIT C 
 [***] 
  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 EXHIBIT D 
 BATCH PRICES 
 [***] 
  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 EXHIBIT E 
 [***] 
  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}]]